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Abstract in English 
Introduction 
It has been estimated that breastfeeding is a healthier alternative than replacement feeding 
because of its nutritional and immunological values. If optimally implemented it has the 
potential to save children’s lives. Despite the HIV infection context, breastfeeding is 
recommended for infants born to HIV-infected women in low-income settings as the best 
feeding option when formula feeding is unsafe. However, both breastfeeding and HIV-infection 
are energy demanding. There are concerns about the effects of lactation on post-partum weight 
changes among HIV-infected women because low weight could increase the risk of HIV 
progression and worsen biological parameters, such as the CD4 cell count and HIV viral load 
of HIV-positive mothers. 
Our objectives were i) to examine the feeding practices and the determinants of exclusive/ 
predominant or any breastfeeding among the trial’s participants (paper 1); ii) to explore if 
exclusive or predominant breastfeeding is associated with a change of the body mass index 
(BMI) among breastfeeding HIV-1-positive women (paper 2); iii) to assess the mothers’ HIV-
1 disease progression in relation to the exclusive/predominant or any breastfeeding duration 
during the infant first 6 months of life and until week 50 post-partum (paper 3). 
Methods 
Our data were collected in the context of the ANRS 12174 phase 3 clinical trial (clinical trial 
no NCT0064026) between November 2009 and March 2013. The trial compared the efficacy 
of lamivudine with lopinavir/ritonavir in preventing postnatal HIV-1 transmission during 
lactation to infants born to HIV-1 positive mothers. Mothers infected with HIV-1 with CD4 cell 
count of >350 cell/µl and their uninfected offspring were followed from day 7 after birth for 50 
weeks, keeping monthly records of their self-reported feeding patterns. Feeding was classified 
into 3 categories: 1) exclusive breastfeeding during the first 6 months, only breast-milk being 
given to infant for 6 months, 2) predominant breastfeeding, breast-milk with liquid-based items 
being given, and 3) mixed feeding, other non-breast milk or solid food being given in addition 
to breast milk with or without liquid-based items. The categories were merged into 2 groups: 
exclusive or predominant breastfeeding (EPBF) applying to infants aged <6 months and mixed 
feeding applying to infants of any age.  
In paper 1 the feeding patterns are shown using Kaplan-Meier curves. A flexible parametric 
multiple regression model was used to identify the determinants of the mothers’ feeding 
behaviour. In paper 2, we ran a linear mixed-effect model with BMI as the dependent variable 
and exclusive or predominant breastfeeding duration as the key explanatory variable. In paper 
3 we ran a multiple logistic regression model with the HIV-1 disease progression as the 
dependent composite endpoint combining decrease in mothers’ weight (<10% of initial weight), 
decrease in CD4 cell count (<350 cell/µl) and HIV-1 clinical stage, as per the world health 
organization (WHO) classification (above stage 2).  
Results 
In paper 1, a total of 1,225 mother-infant dyads provided feeding data from Burkina Faso (N = 
204), South Africa (N = 213), Uganda (N = 274) and Zambia (N = 534). N=1 216 mother-infant 
dyads were included in paper 2 and 3 from Burkina Faso (203), South Africa (212), Uganda 
(272) and Zambia (529). The mean maternal age was 27.4 years, the mean BMI was 24.5 kg/m². 
Breastfeeding was initiated by 57.7% within the first hour and 93.9% within the first day. 
Overall, the median durations of any form of breastfeeding and EPBF were 40.6, and 20.9 
weeks, respectively. No major change in mean BMI was seen in this cohort over a 50 weeks of 
lactation. The mean change between 26 and 50 weeks after birth was 0.7 kg/m². Baseline mean 
BMI (measured on day 7 post-partum) and CD4 cell count were positively associated with 
maternal BMI change, with a mean increase of 1.0 kg/m² (95% CI:0.9; 1.0) per each additional 
baseline-BMI kilogram and 0.3 kg/m² (95% CI:0.2; 0.5) for each additional CD4 cell/μl, 
respectively. In the adjusted model, there was no significant correlation between EPBF duration 
and HIV-1 disease progression. 
Conclusion: 
Better breastfeeding practice, as per WHO’s recommendations, has been achieved in the ANRS 
12174 clinical trial for the majority of the children. Breastfeeding did not affect the BMI or the 
HIV-1 disease progression in HIV-1 infected Sub-Saharan African mothers when their CD4 
cell counts were >350 cells/μl. Considering the benefits of breast milk for infants, and the 
recurrent results from different studies that breastfeeding does not harm HIV-1-infected 
mothers, this study also supports the WHO 2016 guidelines on infant feeding, which indicates 
that mothers living with HIV should breastfeed for at least 12 months and to 24 or more, 
provided that the right treatment or prophylaxis for the infection is given where formula feeding 
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is unsafe. Thus, there is a need to improve breastfeeding and complementary feeding practices 
of children, particularly those exposed to HIV and antiretroviral treatment, taking into account 
context and socio-demographic factors. 
Abstract in French 
Introduction 
L’allaitement est perçu comme une alternative plus saine que le lait artificiel à cause de ses 
qualités nutritionnelles et immunologiques. En dépit du contexte marqué par l’infection à VIH, 
le lait maternel est recommandé comme la meilleure option alimentaire pour les enfants nés de 
mères séropositives dans les pays à faibles revenus, chaque fois que le lait artificiel présente 
des risques. Cependant, l’allaitement maternel comme l’infection à VIH entraîne des dépenses 
énergétiques plus importantes au niveau de l’organisme. Ces constats ont suscité des 
inquiétudes par rapport à l’influence de l’allaitement sur les variations de poids chez la femme 
séropositive, car une perte de poids pourrait être à l’origine d’un risque de progression plus 
rapide de l’infection à VIH dont une détérioration de paramètres biologiques tels que la 
numération CD4 et la charge virale. 
Notre objectif était de i) décrire les pratiques d’allaitement et les déterminants de l’option 
alimentaire (allaitement maternel exclusif ou prédominant ou allaitement mixte) par les 
participants à l’essai clinique ANRS 12174 (publication 1) ; ii) définir la relation entre 
l’allaitement maternel exclusif ou prédominant et la variation de l’indice de masse corporelle 
parmi les femmes allaitantes et séropositives à l’infection à VIH-1 (publication 2) ; iii) identifier 
la relation entre la progression de l’infection à VIH-1 et la durée de l’allaitement par la mère en 
fonction du mode (exclusif, prédominant ou mixte) pendant les 6 premiers mois ou jusqu’à 50 
semaines après la naissance de l’enfant (publication 3). 
Méthodes 
Nos données ont été collectées entre Novembre 2009 et Mars 2013 dans le contexte de l’essai 
clinique de phase 3 ANRS 12174 (numéro d’enregistrement NCT0064026). L’objectif de 
l’essai ANRS 12174 était de comparer l’efficacité de deux médicaments (lamivudine et 
lopinavir/ritonavir) à prévenir la transmission postnatale du VIH-1 aux enfants allaitant. Les 
mères séropositives au VIH-1 avec des taux de CD4>350 cell/µl et leurs nouveau-nés non 
infectés ont été suivis du septième jour à la 50ème semaine après la naissance avec une collecte 
mensuelle des données d’alimentation telles que rapportées par les mères. Le mode 
d’alimentation a été classé en trois catégories : 1) allaitement maternel exclusif pendant les six 
premiers mois ; uniquement le lait maternel est donné à l’enfant ; 2) l’allaitement maternel 
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prédominant ; le lait maternel est associé à des aliments essentiellement liquides ; 3) et 
l’alimentation mixte où autres laits non maternels ou aliments solides ont été servis à l’enfant 
en plus de lait maternel avec ou sans autre aliment liquide. Les deux premières catégories ont 
été fusionnées en un groupe pour obtenir deux grandes catégories : l’allaitement maternel 
exclusif ou prédominant pour les enfants âgés de moins de six mois et l’alimentation mixte quel 
que soit l’âge de l’enfant. 
Dans la première publication, les modes d’alimentation ont été décrits en utilisant les courbes 
de survie de Kaplan-Meier. Un modèle de régression multiple paramétrique flexible a été utilisé 
pour identifier les déterminants des pratiques d’alimentation par les mères. Dans la deuxième 
publication, nous avons mis en œuvre un modèle linéaire mixte avec l’indice de masse 
corporelle comme variable dépendante et la durée de l’allaitement maternel exclusif ou 
prédominant comme principale variable indépendante. Dans la troisième publication un modèle 
de régression logistique a été utilisé avec la progression de l’infection à VIH-1 comme critère 
de jugement composite combinant la perte de poids maternel (au-dessous de 10% du poids 
initial), la baisse du taux de CD4 (<350 cell/µl) et le stade clinique de l’infection à VIH selon 
la classification de l’OMS (au-dessus du stade 2). 
Resultats  
Au total, les données de 1225 couples mères-enfants ont été utilisées du Burkina Faso (N=204), 
de l’Afrique du Sud (N=213), de l’Ouganda (N=274) et de la Zambie (N=534) pour la première 
publication. Dans les deuxième et troisième publications nous avons inclus 1216 couples mères-
enfants dont 203, 212, 272 et 529 couples du Burkina Faso, de l’Afrique du Sud, de l’Ouganda 
et de la Zambie respectivement. L’âge moyen des mères était de 27.4 ans et l’indice de masse 
corporelle moyen de 24.5 kg/m² de surface corporelle. L’allaitement maternel a été initié par 
57.7% des mères dans la première heure après la naissance et 93.9% dans la première journée. 
Au total les durées médianes de l’allaitement tout type confondu et de l’allaitement maternel 
exclusif ou prédominant étaient de 40.6 et 20.9 semaines respectivement. Aucune variation 
majeure n’a été constatée au niveau de l’indice de masse corporelle dans notre cohorte durant 
tout le suivi de 50 semaines. Une diminution moyenne de 0.7 kg/m² entre 26 et 50 semaines a 
été notée au niveau de l’indice de masse corporelle. L’indice de masse corporelle moyen initial 
et le taux de CD4 de base (mesuré à J7 postpartum) étaient positivement associés avec la 
variation de l’indice de masse corporelle maternel avec une augmentation moyenne de 1.0 
kg/m² (IC à 95% : 0,9 ; 1,0) pour chaque kilogramme additionnel d’IMC de base et 0.3 kg/m² 
(IC à 95% : 0.2; 0.5) pour chaque unité additionnelle de CD4 respectivement. Dans l’analyse 
ajustée, l’association entre la durée de l’allaitement maternel exclusif ou prédominant et la 
progression de l’infection à VIH-1 n’était pas significative. 
Conclusion  
Les meilleures pratiques d’allaitement maternel selon les recommandations de l’OMS ont été 
mises en œuvre au cours de l’essai clinique ANRS 12174 pour la plupart des enfants. 
L’allaitement maternel n’a influencé ni l’indice de masse corporelle, ni la progression de la 
maladie chez les mères séropositives au VIH-1 et vivant en Afrique au Sud du Sahara, lorsque 
leur taux de CD4 était >350 cells/μl. Considérant les multiples avantages du lait maternel pour 
les enfants et les résultats répétés de différentes études prouvant que l’allaitement maternel ne 
détériore pas la santé des mères infectées par le VIH-1, notre étude abonde dans le sens des 
recommandations 2016 de l’OMS  sur l’alimentation de l’enfant. Ces recommandations 
soulignent que les mères vivant avec le VIH doivent allaiter pendant au moins 12 mois et 
jusqu’à 24 mois ou au-delà, à condition que le traitement ou la prophylaxie adaptée soit 
administré contre l’infection, et cela, chaque fois que la pratique de l’allaitement artificiel n’est 
pas sans risque. Par conséquent, il y a aussi un besoin d’améliorer la pratique de l’allaitement 
y compris l’introduction de l’alimentation complémentaire, particulièrement chez les enfants 
exposés au VIH et à une prophylaxie antirétrovirale, tout en prenant en compte le contexte et 
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The definitions regarding the infant feeding patterns have been taken from WHO and UNICEF 
2016 updates on HIV and infant feeding guidelines (1) and other WHO online tools. 
 
Exclusive breastfeeding (EBF): only breast milk (including breast milk that has been 
expressed, or coming from a wet nurse) is given to the infant without any other kind of food or 
liquid, except medically prescribed drugs, mineral supplements or vitamins. WHO recommends 
that EBF starts within 1 h after birth and continues until the infant is 6 months of age. 
 
Predominant breastfeeding (PBF): infant is fed with breast milk and incidentally with some 
liquid-based food such as juice, tea, sugar-water and salt-water including glucose without any 
kind of formula or animal milk. 
 
Exclusive or predominant breastfeeding (EPBF): infant is either exclusively or 
predominantly fed with breast milk. This group is the result of the merging of both EBF and 
PBF groups in this thesis work. 
 
Complementary feeding: is when breastmilk and other solid, semi-solid or liquid-based food 
is given to the infant because breastmilk alone is no longer sufficient to meet the infant’s need. 
WHO recommends that complementary feeding starts from 6 months after birth and onward for 
24 months or more. 
 
Prelacteal feeding: any food given to the infant before the initiation of breastfeeding.  
 
Formula or replacement feeding: breastmilk is completely stopped. An infant is given 
breastmilk substitutes in the form of commercial formula. Exclusive replacement feeding is 
when infant has never taken breastmilk. 
 
Mixed feeding (MF): infant is fed with breast milk and other solid or liquid-based food, 
including other kinds of formula and non-human milks. This feeding mode is different from 
complementary feeding since it could start at any time in the infant feeding process regardless 
of WHO’s breastfeeding recommendations. 
 
Option A: a pregnant, HIV-positive and immunocompetent (CD4 cell count >350 cells/µl) 
woman is offered a prophylactic antiretroviral therapy (ART) regimen during antenatal and 
intrapartum period to prevent the vertical transmission of HIV to a child in-utero and during 
labor and delivery. An antiretroviral prophylaxis is also given to the mother postpartum (“tail” 
regimen) for a short period, to reduce the risk of drug resistance while an infant receives 
postpartum antiretroviral prophylaxis throughout the breastfeeding period (2).  
 
Option B: a pregnant or breastfeeding, HIV-positive woman is offered ART to prevent the 
vertical transmission of HIV-infection to her child during pregnancy and postpartum throughout 
the breastfeeding period. After breastfeeding cessation, ART is stopped if the mother has CD4 
cell count >350 cells/µl and will be resumed when the mother would need it for herself (2). 
 
Option B+ or universal treatment program: a pregnant or breastfeeding woman is offered 
ART for life immediately after she is diagnosed as HIV-infected, regardless of her CD4 cell 
count. This ART aims to prevent the vertical transmission of HIV to her child, while benefitting 
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The following germane questions were posed. How was breastfeeding practiced by 
participating women in the ANRS 12174 phase 3 clinical trial? What were the determinants 
that influenced the compliance of these women to the world health organization (WHO) 
breastfeeding recommendations for mothers infected with the human immunodeficiency virus 
(HIV) in resources constrained settings? Has breastfeeding a negative impact on HIV-infected 
mothers’ nutritional status and on their HIV disease progression?  
Throughout the introduction, I will present salient information on HIV and its modes of 
transmission. Thereafter I will discuss its association with women’s and children’s health 
relevant for placing the research findings in a biological and historical context. The prevention 
methods focusing on the prevention of mother to child transmission of HIV and the evolvement 
of the guidelines on feeding a child born to a HIV positive woman from early 2000 up to current 
challenges will be summarized. Further, I provide epidemiological patterns and current 
nutritional knowledge of breastfeeding. I will next elaborate on the ANRS 12174 clinical trial, 
its relevance for this thesis, and in the context of today’s universal treatment program strategy 
and the possible use of the other options B, A or Pre-exposure prophylaxis (PreP). Lastly, the 
question of why it is important to provide scientific evidence that contribute to answer the above 
research questions will be explained. 
1.1 HIV-1 transmission  
The Human Immunodeficiency Virus type 1 (HIV-1, Figure 1) is an RNA virus that is 
transmitted through body fluids, including blood, semen, vaginal fluid, rectal fluid and breast 
milk. There is an increased risk of HIV-1 transmission when the body fluid of an HIV-1-
infected person is in contact with vulnerable body parts of an HIV-uninfected person through, 
for instance, a rupture of the skin or a mucous membrane (3). In the case of an infection through, 
e.g., sexual contact, the virus has to pass through the different layers of cells of the mucous 
membrane (4). HIV-1 can cross these cell layers and enter the body on its own but some factors 
facilitate penetration. This is the case with sexually transmitted infections (herpes, syphilis; (5, 
6), the micro-lesions occurring during sexual intercourse, the use of enemas, vaginal washing, 
brushing teeth, flossing, dental work and surgery. Other risk factors of HIV-1 infection include 
the surface area of the mucosa in contact with the infectious fluid, the amount of virus (viral 
load), the infectiousness of the viruses in the fluid (more infectious during primary infection) 
or onsite inflammation attracting T-cells that are the main target for the virus (3, 7).  
 
Figure 1:  Human immunodeficiency virus (source: AIDSinfo; material in the public 
domain). 
HIV-1 cannot multiply on its own. Typically it attacks a lymphocyte called T-helper cell or 
CD4 cell, fuses with it, takes control of it, replicates itself inside the cell, and then releases new 
HIV-1 virions into the blood. This life cycle include binding and fusion, reverse transcription 
and integration, replication, assembly, budding and maturation (8). These are all stages targeted 
by the anti-retroviral (ARV) drugs. Figure 2 is a reprint of the HIV life cycle and the 




Figure 2: HIV life cycle (source: AIDSinfo; material in the public domain). 
                                                                                                 
The rate of HIV transmission from male to female is 2-3 times higher than it is from female to 
male (6, 9). The specific risk factors for female acquisition of HIV infection include a higher 
affinity of some HIV serotypes for the Langerhans’ cells of the cervix, vulval and vaginal 
inflammation or ulceration, and other sexually transmitted infections (10). In addition to these 
biological and clinical risk factors, socio-cultural factors also play a role in putting female 
partners more at risk for HIV infection. Gender inequality, poverty, less access to education, 
lack of employment opportunities, traditional practices and practices, such as vaginal washing, 
female circumcision, low use of female and male condoms, and the societal pressure to produce 
children, make women highly vulnerable to HIV acquisition (10). 
1.1.1 HIV-1 during pregnancy, birth and lactation  
During pregnancy, the woman’s body experiences unique and complex changes that include 
the immune system. Both the humoral and cell-mediated immunity are involved in these 
changes (11, 12). Reports from resource-limited settings tend to show that HIV-1 disease is 
associated with poorer pregnancy outcomes, including complications both in early and late 
pregnancy (13-16). A pooled analysis on sub-Saharan African community data from 2013 
found higher rates of spontaneous abortions, ectopic pregnancies, preterm labour, preterm 
rupture of membranes, placental abruption, low birth weight and stillbirths (16). In the same 
review, the postpartum period was also associated with more infectious morbidity in HIV-1-
infected women. Women with more advanced HIV-1 disease had a higher risk of pregnancy 
loss and perinatal mortality. HIV-1 is the predominant underlying risk factors for maternal 
deaths, even when antiretroviral therapy (ART) is universally provided (17). Advanced 
maternal HIV-1 disease affects infant health and survival indirectly due to low birth weight and 
prematurity, and directly through the risk of HIV-1 transmission (18).  
1.1.2 Mother-to-child transmission of HIV-1 
Early HIV research on mother-to-child transmission (MTCT) of HIV-1 showed that, in the 
absence of any intervention, transmission ranged from 15 to 40%, with higher rates in Africa 
and Asia (19-21). The mode of delivery influenced the transmission rate; Caesarean section 
decreased the rate while vaginal delivery, prolonged rupture of membranes, intrapartum 
hemorrhage and invasive fetal monitoring increased the rates (20). More recent analyses 
showed that maternal immunological, nutritional and clinical status, maternal viral load and 
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resistance in plasma and breastmilk, viral phenotype and genotype, and breast conditions also 
affect the HIV-1 transmission to the fetus/child (22). Behavioural factors such as smoking, drug 
use and unprotected sexual intercourse during pregnancy increase the rate of HIV-1 
transmission to the fetus (20, 21).  
Untreated HIV-1 infection can be transmitted to the fetus in-utero during pregnancy (5-10%), 
labour and delivery (10-15%) and the breastfeeding period (5-20%) (21). During pregnancy, 
transmission can occur by direct contamination of maternal infected blood through the placenta 
to the fetal circulation. Such contamination increases with the age of the placenta, with in-utero 
infection more commonly occurring towards the end of pregnancy.  
During labour and delivery, infection occurs through muco-cutaneous contact of the baby with 
maternal fluids, mainly blood and cervico-vaginal secretions. The transfer of fluids and viruses 
from the mother to the child is facilitated by uterine contractions during labour and delivery, 
the passage through the birth canal, or the ingestion and absorption of liquids through the fetal-
neonatal digestive tract (23, 24). According to the classification of the timing of transmission 
based on the time of detection of HIV-1 in the infant, an infant is considered infected in-utero 
when virus is detectable within 48 h of birth. Later detection after an initial negative test 
indicates intrapartum or breast milk transmission. By definition, the infection occurred 
intrapartum if the tests are negative during the first week of life before turning positive between 
7 and 90 days (10). When a woman is breastfeeding, it is impossible to find any difference 
between intrapartum and early postpartum transmission of HIV because the existence of a 
(window) period after HIV infection during which current technologies cannot detect the virus. 
However, late postnatal transmission can be documented and is defined as an infant HIV-
infection 3-6 months after birth, where previous polymerase chain reaction (PCR) testing was 
negative before becoming positive between 2 and 6 months of an infant’s age (25). This timing 
of HIV diagnosis in infants has been greatly reduced with the implementation of nucleic acid 
technologies (NAT) using HIV DNA or RNA PCR or even ultrasensitive P24 antigen detection. 
These technologies are used in PMTCT programmes to test HIV exposed infants at their sixth 
week of life. Earlier diagnosis of in-utero infection is possible, but is not yet recommended in 
routine practice (26). 
Transmission of HIV-1 through breastfeeding was first reported by Philippe Van de Perre and 
colleagues (27). In the absence of maternal ART, it can occur at any time-point as long as the 
child is breastfed and the risk seems constant per day of breastfeeding. Three clinical factors, 
including the rate of viral replication in the mother, the duration and mode of breastfeeding, 
and the inflammation of the mammary gland, increase the risk of MTCT of HIV (28). In 
mothers taking ART with a suppressed HIV viral load, the residual HIV transmission rate has 
been estimated at 0.2% per month of breastfeeding (29).  
Some fetal and infant factors modulate the HIV-1 transmission from mother-to-child. Among 
them, prematurity, multiple pregnancy, mode of infant feeding (breast milk, formula or 
replacement feeding or mixed breast milk and formula/replacement feeding), child 
gastrointestinal tract factors (integrity of mucous membranes), immature immune system would 
be associated with higher risk of transmission (10, 30). Extensive research is focusing on 
whether the HIV transmission through lactation is cell-free and cell-associated; this has 
implications for pharmacological preventive strategies for the mother and child. 
1.1.3 The dilemma of infant feeding and HIV transmission 
With optimal viral suppression at delivery, postnatal infant prophylaxis and avoidance of 
breastfeeding, the risk of perinatal HIV-1 transmission is 0.1% (31). The global plan to 
eliminate MTCT (eMTCT) by 2020 set the motto that “children everywhere can be born free 
of HIV-1 and their mothers remain alive”. The impact criteria required by WHO for validating 
eMTCT included 50 or fewer new pediatric HIV infections per 100,000 live births and a 
transmission rate of either 5% or less in breastfeeding populations, or 2% or less in non-
breastfeeding populations (32). However, implementation of optimal prevention strategies were 
incomplete and still about 160,000 new HIV infections among children aged 0-14 years 
occurred in 2016. This was less than 300,000 in 2010 (33). In 2015, adolescent girls and young 
women accounted for 25% of new HIV-1 infections among adults, and women accounted for 
56% of new infections in sub-Saharan Africa (34).  
In many high income countries, including the United States, United Kingdom and Canada (35), 
the guidelines to prevent the MTCT of HIV have been very clear - HIV-infected mothers should 
not breastfeed. In resource-limited settings, avoidance of breastfeeding in HIV-1 contexts has 
remained a challenge. The feeding option relied primarily on the mothers’ decision after 
nutrition counselling on the feeding context by a healthcare worker. The way a HIV positive 
mother decided to feed her baby affected the infant’s risk of either becoming infected with HIV 
or dying from other infections (36). Other studies also found that replacement feeding is not 
safe in very poor contexts, even with maximum support (37). Before the 2010 guidelines, the 
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healthcare workers put emphasis on the WHO’s main criteria for exclusive replacement 
feeding: “when replacement feeding is acceptable, feasible, affordable, sustainable and safe, 
avoidance of all breastfeeding by HIV-infected mothers is recommended. Otherwise, exclusive 
breastfeeding is recommended during the first months of life” (38). These criteria have been 
heavily criticized as unethical and difficult, putting women in an impossible situation to make 
a decision (39-42).  
The current guidelines have uniform feeding recommendations for all women in resource-
limited settings, irrespective of HIV-1 or socio-economic status (1). Mothers living with HIV-
1 should breastfeed for at least 12 months and continue breastfeeding for at least 24 months 
(similar to the general population), while being fully supported for ART adherence (43-45). 
This harmonisation has been made possible, thanks to ART.  
A dichotomized approach remains since WHO includes HIV infection of mothers as an absolute 
contra-indication of breastfeeding, but only in high-resource countries. Supported breastfeeding 
is widely practiced in resource-limited settings by HIV-positive mothers and occasionally by 
individual women in high income countries where formula-feeding is expected. WHO 2016 
guidelines seems then tailored for resource-limited settings, while at the same time the world is 
committed to zero tolerance for any infant HIV-1 acquisition (35, 46, 47).  
1.2 Breastfeeding 
1.2.1 Breastfeeding advantages 
Breastfeeding has several advantages for both babies and breastfeeding mothers. However, an 
important community trial in Burkina Faso, South Africa and Uganda promoting exclusive 
breastfeeding for 6 months (the PROMISE-EBF trial) was unable to reconfirm these advantages 
of breastfeeding promotion on diarrhoeal diseases prevention (48), growth of children under-6 
months old (49), and on neuropsychological outcomes in 5-8 year old children (50). This was 
probably due to the uniform breastfeeding practices in the study areas. Other studies have found 
that universal coverage with general nutritional interventions, including exclusive breastfeeding 
(EBF), could prevent 8% and 11.6% of under-3 and under-5-year old child mortality, 
respectively, as well as 10-15% of child stunting (51-54). Mortality risk for infants of <6 months 
old and not breastfed is 3.5 times higher than in any breastfed boys and 4.1 times higher in girls 
(53). In children aged 6-23 months, 50, 36 and 58% reductions in deaths, sudden infant death 
and necrotizing enterocolitis were noted, respectively. For children, 823 000 (13.8%) annual 
deaths could have been averted in 75 high-mortality low-and-middle-income countries 
(LMICs) in 2015 if breastfeeding had been scaled up to near universal levels (53). About half 
of all diarrhoeal episodes and a third of respiratory infections could have been avoided by 
universal breastfeeding. Besides, breastfeeding could prevent 72 and 57% of admissions for 
diarrhoea and respiratory infections, respectively, and 68% reduction in malocclusions. 
Exclusive breastfeeding could prevent infant growth deficit (55, 56). Therefore, it is assumed 
globally that breastfed children are healthier than non-breastfed children, in which better health 
status results from reduced incidence and severity of communicable diseases, including 
diarrhoea, and improved feeding during illness. Other expected benefits are lower risk of auto-
immune diseases and potential long-term effects on cardiovascular diseases and cognition (52). 
Positive effects of breastfeeding on the mother include lactation amenorrhoea and birth spacing, 
protection against breast and ovarian cancer, type 2 diabetes and osteoporosis. Current global 
rates of breastfeeding seemingly avert ~19,500 annual breast cancer deaths compared with a 
scenario in which no woman breastfeeds (53). 
1.2.2 Breastfeeding practices  
Meta-analysis (53) showed that, worldwide over a 20-year period, exclusive breastfeeding rates 
increased from 24.9% in 1993 to 35.7% in 2013. In general, early initiation of and exclusive 
breastfeeding are still low in all settings. In children <6 months, 53, 61 and 63% are not 
exclusively breastfed in low-income, lower-middle-income and upper-middle-income 
countries, respectively. In children aged 6-23 months, 18, 34 and 55% were not receiving any 
breastmilk in low-income, lower-middle-income and upper-middle-income countries, 
respectively. The same meta-analysis indicated that breastfeeding prevalence was highest in 
Sub-Saharan Africa, South Asia and parts of Latin America. It was ~37% for children of <6 
months. Continued breastfeeding was higher in West and Central Africa than in Eastern and 
Southern Africa. To the contrary, exclusive breastfeeding rate was higher in Eastern and 
Southern Africa, highest in Rwanda and lowest in Gabon. The feeling that breast milk is not 
enough to cover the child’s needs was the main reason explaining why mothers stopped EBF 
early in Sub-Saharan Africa (53).  
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The main explanatory factors associated with increased EBF rates were mothers’ of age 25-35 
years, who had completed secondary school or above, had completed at least 4 antenatal care 
(ANC) visits, resided in rural area, belonged to the wealthiest quantile, delivered female or a 
singleton baby at a health facility or initiated breastfeeding early. Mothers’ knowledge on EBF, 
mainly through counselling sessions during pregnancy and after delivery, was also an important 
factor in promoting EBF. At the country level, higher gross national income per capita was 
associated with lower EBF rate (57-59).  
1.3 HIV and infant feeding recommendations 
WHO recommends early initiation of breastfeeding, which means putting the baby on the breast 
within one hour of delivery. Early initiation of breastfeeding is associated with exclusive, as 
well as an extended duration, of breastfeeding. It helps keep the baby warm and helps mother-
child bonding (59, 60). Early initiation of breastfeeding would reduce neonatal and early infant 
mortality through both EBF and other mechanisms (61, 62). EBF is recommended for the first 
6 months.  
From 6 until 23 months of age, WHO recommends continued frequent on-demand 
breastfeeding, since breastfeeding benefits children older than 6 months. The 12-23-month aged 
breastfed child’s energy intake comes 35-40% from breastmilk and the remainder from 
complementary foods (62). The importance of breastfeeding is emphasized during a child’s 
illness, when appetite for other foods decreases but breast-milk intake is maintained. 
Complementary food usually starts at 6 months of age, which implies that the infant is receiving 
breast or formula milk in addition to solid or semi-solid food. According to WHO, it is when 
breast milk or infant formula alone is no longer sufficient to meet infants nutritional 
requirements. Breastfeeding protection and promotion is needed to achieve successful practices 
(48). 
HIV-1 infected mothers must use highly active antiretroviral therapy (HAART) or antiretroviral 
(ARV) prophylaxis to reduce HIV transmission through breastfeeding. The main objective is 
to reduce the HIV viral load in the mother. In countries where health authorities have opted for 
breastfeeding and ARV prophylaxis as strategies to increase HIV-free survival among children 
born to HIV-infected mothers, WHO recommends EBF during the first 6 months, the 
introduction of complementary food from 6 months and onwards, while going on with 
breastfeeding until 24+ months or until a safe breastmilk substitute can be provided (1). 
1.3.1 Interventions to prevent mother-to-child transmission of HIV-1   
WHO recommends HIV testing for all pregnant or breastfeeding women in every setting during 
antenatal and postnatal care visits to tailor care provisions (prevention or treatment) according 
to their HIV status. For HIV-positive women, the assisted partner notification service should 
be provided. ART should be started directly and continued for life regardless of CD4 count 
(universal treatment program) (45). HIV testing should also be offered to all sexual and drug-
injecting partners. For HIV-negative pregnant or breastfeeding women, living in settings where 
HIV burden is high, or living within populations with HIV incidence greater than 3 per 100 
person-years (substantial and increased risk of HIV acquisition during pregnancy and 
breastfeeding), pre-exposure prophylaxis (PreP) is recommended (63). However PreP is always 
optional and its initiation relies purely on the decision of the woman after being counselled by 
a qualified healthcare worker. Figure 4 gives an algorithm to assist in the decision making 




VMMC: Voluntary medical male circumcision 
STI: sexually transmitted infection 
Figure 3: A suggested prioritization framework for offering PrEP to pregnant and 
breastfeeding women (63)WHO Technical brief: Preventing HIV during pregnancy 
and breastfeeding in the context of pre-exposure prophylaxis (PrEP). Geneva: World 
Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO) 
 
 
1.3.2 Historical overview of HIV and infant feeding recommendations 
In high income settings, formula feeding became the only feeding option offered to HIV-
infected mothers once the transmission paths of HIV-1 (including the mother-to-child 
transmission) had been well understood (35, 64, 65). In low and middle-income countries, the 
history of infant feeding in the context of maternal HIV-1 infection started with the 
recommendation of formula feeding for all babies in 1985 (66, 67). However, the problem of 
increased mortality among HIV-1 exposed and formula-fed infants was identified. These infant 
deaths were associated with multiple factors, including lack of hygiene in preparation of the 
formula, non-sustainability of the formula by families, and infant malnutrition. These factors 
contributed to the increase in the prevalence of infectious diseases, including pneumonia and 
diarrhoea, leading to increased mortality among the infants (66). In 1998, WHO recommended 
EBF for 4 months, followed by abrupt weaning to address the morbidity and mortality issues. 
In 2007, it became evident that abrupt weaning was not a good solution to increase HIV-free 
survival of infants born to HIV-infected mothers (68-70). At this point, the WHO’s 
recommendation was EBF during 6 months, then a progressive weaning over a 2-month period. 
Thereafter in 2010, mothers were allowed to breastfeed exclusively for 6 months, to add 
complementary food from 6 months and onwards, and to wean within 12 months of infant life. 
Further, WHO’s 2016 guidelines for HIV-exposed children extended the period of continued 
breastfeeding to 2 years or beyond, as in the general population. Table 1 (summarized from 
Sinning, 66) explains the evolvement of feeding recommendations and ARV regimens since 
the early years after the discovery of HIV infection. While infants were being fed breast milk, 
prophylactic ARV was administered either to the mother or the child (1, 66). 
Option A is the administration of ARV prophylaxis to an HIV-infected and immunocompetent 
pregnant or breastfeeding woman and to her HIV-exposed child in the postpartum period to 
prevent mother-to-child transmission. Option B is when an HIV infected mother is given ARV 
as mono- or dual-therapy or as a highly active antiretroviral therapy (HAART) that tries to 
achieve a level of viral suppression that reduces the transmission rate of HIV to the offspring 
either in-utero or during the lactation period. Option B+ or universal treatment program is the 
provision of HAART both as an HIV treatment for the mother and prevention to the child. This 
is lifelong therapy for the mother that starts with the diagnosis of HIV infection (2).  
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The provision of ART at higher CD4 counts is justifiable for medical, public health and human 
rights reasons. Therefore, the need to take a CD4 count as a condition to start ART was removed 
(71). The cost-effectiveness of this option includes reduced laboratory costs, reduced cost 
related to the management of ARV therapy by less trained health professionals because of a 
simplified protocol, and reduced mortality among women because they can access ARV therapy 
more quickly and earlier in disease progression (71). However, the MTCT rates remain much 
higher than expected under the B+ approach. The issues that need to be addressed include the 
acceptability of lifelong antiretroviral treatment, and adherence to and retention on treatment. 
Other biological explanations are discussed in the last chapter of the introduction. 
In resource-limited settings, mostly in Sub-Saharan Africa, the national health guidelines 
including those on PMTCT used to be inspired by WHO guidelines. However, it is claimed that 
since the early 1990’s, the WHO guidelines on PMTCT have slipped dangerously away from 
evidence-based to opinion-based recommendations of experts. The implementation of non-
tested policies has exposed targeted populations to non-assessed risks, such as those associated 
with the abrupt weaning recommendation (72). Besides, the rapid succession of these guidelines 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.4 Current implementation and limitations of the B+ option  
Despite the momentum and invested effort, the global pace towards the elimination of mother-
to-child transmission (e-MTCT) of HIV and the 2020 target will be slowing, according to 
UNICEF. If the trend is maintained, ~100,000 instead of 20,000 new paediatric infections are 
expected in 2020. Using data from WHO (73), it is possible to estimate the overall mean 
mother-to-child transmission rate including breastfeeding period at 12.8% in 2016 for the 
African region of WHO spanning Eastern and southern Africa and Madagascar (mean 
transmission rate=11.4%) and Western and Central Africa (mean transmission rate 14.3%). The 
overall estimated mean percentage of ART coverage was 47.9%, including Eastern and 
southern Africa and Madagascar (56.2%) and Western and Central Africa (39.5%). The overall 
estimated mean percentage of HIV-positive women receiving ART for PMTCT was 70.1%, i.e. 
71.6 and 68.5% for Eastern and southern Africa and Western and Central Africa, respectively. 
1.4.1 Adherence  
In a MITRA plus ancillary study published in 2015 (74), a sub-cohort of women with ≤200 
CD4 cells/µl at enrolment was followed up for 24 months after delivery to determine virological 
and immunological responses, drug resistance and mortality. About 95% (64/68), 85% (56/66), 
74% (39/53) and 65% (30/46) of participants reported drug adherence at 3, 6, 12 and 24 months, 
respectively. Response failures were more likely to occur among women who reported breach 
of adherence to ART 24 months postpartum (74). In a Cameroonian cohort, 88% of women 
were still in care at 6 months and 81.1% at 12 months. At 18 and 24 months, the retention rates 
were 74.2 and 73.3%, respectively. Women visiting small facilities with high staff turnover 
were more at risk of discontinuing Option B+ procedures [HR (95% CI) = 2.0 (1.2–3.4), P = 
0.012] (75). In Malawi, a survey was conducted to explore the levels and determinants of the 
loss to follow-up under option B+ therapy. About 20% of women who tested HIV-positive in 
antenatal and postpartum clinics dropped out without initiating ART. Of the women who started 
ART under Option B+ (n=21 939), 17% appeared to be loss to follow-up 6 months after start. 
Most loss occurred in the first 3 months of therapy. Option B+ patients who started therapy 
during pregnancy were 5 times more likely than women who started ART at WHO HIV stage 
3/4 or with a CD4 cell count ≤350 cells/µl, to never return after their initial clinic visit (odds 
ratio 5.0, 95% CI 4.2-6.1). Option B+ patients who started therapy while breastfeeding were 
twice as likely to miss their first follow-up visit (odds ratio 2.2, 95% CI 1.8-2.8). Loss to follow-
up and no follow-up were highest in pregnant Option B+ patients (29%), mostly among those 
who began ART at large clinics on the day they were diagnosed with HIV. Among non-pregnant 
women starting on ART for medical indication (low CD4 cell count or WHO clinical stage 3 
or 4) in ART clinics, the no follow-up and loss to follow-up rate was 10% at 6 months. The 
higher retention rates among these women were explained by better adherence counselling 
including more time to prepare to start ART, longer experience and training of staff, and the 
motivation induced by a symptomatic HIV infection. In the same study, pregnant women 
reported being “scared” and “traumatized” by the seriousness of the commitment to lifelong 
ART. They felt pressured by their HIV-positive test, the need to disclose this new HIV status 
to their partner and initiate lifelong ART on the same day (76-78). In South Africa, 32% of 
women initiating ART during pregnancy were loss by 6 months postpartum. Later gestational 
age at initiation and being newly diagnosed with HIV were risk factors for disengagement from 
ART (79). Other factors associated with loss to follow-up among pregnant women include 
younger age (80), initiating treatment at higher CD4 counts (76, 81), timing of presentation to 
ANC (82), and receiving a new HIV diagnosis during pregnancy. The strongest predictors of 
loss to follow-up were primiparity, WHO clinical stage 1 or 2, and receiving only 1 to 4 weeks 
of ART before delivery (83, 84).  
1.4.2 Coverage  
The universal treatment program strategy was first initiated in Malawi. Its underlying rationale 
was to provide a highly effective ART intervention during pregnancy and the 24-months 
prolonged breastfeeding period, in a setting of high fertility with limited testing for CD4 cell 
count (71). The early results of this strategy rapidly achieved a 6-fold increase in the number 
of pregnant or breastfeeding HIV-infected women starting ART (77) and a PMTCT 
antiretroviral coverage of >60% nationwide. Following the experience of Malawi, WHO 
recommended in 2015 that all HIV-positive pregnant women be provided with lifelong ART. 
From 2010 to 2015, a progressive switch occurred from ARV prophylaxis to lifelong ART. By 
2015, the global roll-out of the universal treatment program could cover 91% of 1.1 million 
women receiving ART to prevent MTCT (85). By mid-2016, the universal treatment program 
was the ARV regimen recommended nationally in almost all countries of the world. 
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1.5 Options A, B/B+ and pre-exposure prophylaxis are not 
exclusive to each other: findings from the ANRS 12174 trial   
A good counselling or a worse health status can be significant determinants of strong adherence 
to the universal ART coverage. Although the universal treatment program is currently globally 
accepted and its implementation is being scaled up, it has been deemed “not good enough” (86). 
Therefore, option A improved with a PreP strategy can still have some indications mainly in 
eliminating mother-to-child transmission. It is well established that mothers antiretroviral 
therapy alone, though reducing tremendously the HIV transmission risks to the child, does not 
put the child at zero risk of being infected. The main reason in addition to low coverage and 
adherence is that the viral reservoirs in breast are hardly reached by mothers’ ART (28). In this 
scenario, infant ARV prophylaxis as currently implemented (ARV drug to infants in B+ option 
for 6 weeks to cover the risk of HIV related to delivery), prolonged with a PreP scheme 
(meaning infants take ARV drug to cover the whole period of breastfeeding duration), can add 
to the child’s protection by reducing HIV-1 residual transmission during maternal ART. When 
mothers are not ready to start lifelong ART or their viral load remains still detectable despite 
ART, when countries are unable to achieve full implementation of universal maternal ART, 
option A with PreP offers an efficacious and cost-effective alternative (87). Currently PreP is 
targeted only to uninfected pregnant or breastfeeding women in high incidence areas, to men 
who have sex with men, transgender women, injecting drug users, serodiscordant heterosexual 
couples, and commercial sex workers. HIV-exposed children are excluded, meaning they are 
not specifically targeted by these preventive health measures (86). 
1.6 Breastfeeding, mothers’ HIV infection and BMI  
Weight loss and low BMI are markers of HIV disease progression. Body weight was previously 
used to make a clinical diagnosis of AIDS. A 10% weight loss without any other evident cause 
was a clinical criterion in the diagnosis of AIDS disease in remote areas without laboratories 
(88-91). Individuals with asymptomatic HIV-1 infection need to increase their energy intake by 
10% to maintain their body weight; this increase is assessed to up to 20-30% among those who 
are already at a symptomatic HIV-1 stage (92, 93). 
Besides, during pregnancy and breastfeeding, in a physiological context, women’s bodies 
undergo important energy trade-off translated externally into weight variations. Put in a simple 
way, this is seen as a weight gain during pregnancy, followed by a return to the pre-pregnancy 
weight during the lactation period (94, 95). Studies have been inconsistent in their conclusion 
with respect to the effects of breastfeeding on the weight and health of HIV-1 infected mothers. 
For instance, the Vertical Transmission Study in South Africa comparing women practicing 
EBF to those opting for replacement or mixed feeding found that HIV-infected and uninfected 
mothers experienced similar weight loss over 24 months (92). The Kesho Bora study showed 
that 6 months of breastfeeding was not detrimental to the weight of well-nourished HIV-1 
infected mothers (96). A study in Zambia randomized women into a short-duration (4 months 
EBF and abrupt weaning) and a long-duration (mean duration of 16 months including 6 months 
of EBF) breastfeeding period. It showed a net weight gain in HIV-1 infected women 
breastfeeding from 4 to 24 months postpartum. Effects of lactation in women with low CD4 
counts were similar to those in women with higher CD4 counts (97). In Uganda, a report also 
concluded that food insecurity rather than breastfeeding is associated with changes in maternal 
body composition (98). In contrast, 2 Kenyan studies (99, 100) found weight loss among HIV-
infected breastfeeding mothers compared to mothers using formula feeding.  Additional studies, 
including our work, may help consolidate the body of knowledge and evidence on whether 
breastfeeding could be advised without any fear for the lactating mothers’ health, mostly when 




Exclusive Breastfeeding, including early initiation of breastfeeding, provides a better protection 
compared to mixed or unsafe formula feeding with regard to the mother-to-child transmission 
of HIV and the other common childhood infections in LMICS contexts (101). However, global 
breastfeeding prevalence is currently ~37%. Nevertheless, breastfeeding is traditional practice 
in Sub-Saharan Africa. It is implemented diversely by mothers and only a few women actually 
follow the WHO guidelines for breastfeeding, including EBF (57, 102). The breastfeeding 
modality (exclusive or not) is closely related to postnatal HIV-1 transmission (103-105). 
Because breastfeeding is often the only pragmatic way to feed infants born to HIV-positive 
mothers, the risk of mothers passing the virus on to their child is never nil in resources-limited 
settings. Strategies to lower the probability of HIV vertical transmission have proven efficient 
among the breastfeeding population. In this thesis, we will start with a description of 
breastfeeding patterns among the mother-infant pairs participating in the ANRS 12174 clinical 
trial, since the way mothers implement breastfeeding influence the risk of HIV-1 transmission. 
The breastmilk quality depends on the mother’s nutritional status; breastfeeding could be 
detrimental to the mother with a poor nutritional status (106). In the case of moderate 
malnutrition, the breast milk quality is a little or marginally affected. When it comes to severe 
malnutrition (deprivation of >1500 calories per day), breast production diminishes and the milk 
concentration in some nutrients may be seriously affected. These nutrients include vitamins A, 
B, C and D (107). 
Food and nutrition are among the root causes of the epidemic of HIV and AIDS in Sub Saharan 
Africa. In a body infected with HIV, good nutritional status is paramount in maintaining the 
immune system, managing opportunistic infections, boosting the treatments and slowing the 
progression of the disease (108). Most Sub-Saharan African countries are areas of endemic 
chronic malnutrition mainly among women and children (109, 110). These factors combined 
with the HIV-1 infection-associated metabolic burden may contribute to a detrimental impact 
of breastfeeding on maternal nutritional status and HIV-1 disease progression. The ANRS 
12174 clinical trial was to assess if infant prophylaxis to HIV-1 exposed uninfected infants 
during the whole breastfeeding period could prevent postnatal HIV-1 transmission through 
breastfeeding (111). In this phase III randomized trial, we nested an assessment of the 
correlation between breastfeeding and HIV-1 infected mothers’ disease progression. 
3. STUDY AIM AND OBJECTIVES 
1. Aim of the study 
The aim of this thesis was to assess infant feeding practices, nutritional status and HIV-1 disease 
progression of lactating HIV-1-positive mothers in relation to the feeding patterns of their 
infants. 
2. Specific objectives 
The specific objectives were:  
- to describe the different feeding patterns implemented by the ANRS 12174 trial 
participants (paper 1) 
- to assess the changes in BMI and hemoglobin concentration in breastfeeding women 
living with HIV-1 in relation to a CD4 count of >350 cells per microliter (paper 2) 
- to assess the HIV-1 disease progression (measured by the change in weight, CD4 cell 









4.1 Study designs 
The study design was a cohort of mother-infant pairs included in the ANRS 12174 phase 3 
randomized controlled PMTCT clinical trial. This trial compared the efficacy of infant peri-
exposure prophylaxis with lopinavir/ritonavir (LPV/r) versus lamivudine to prevent HIV-1 
transmission during breastfeeding (trial registration number: www.clinicaltrials.gov  
registration # NCT00640263). The rationale behind the trial was to administer the prophylaxis 
to the infant and by doing so, to spare mothers from using HAART only to prevent child’s 
infection, and thus avoid HAART side effects and selection of resistant strains later for the 
mothers. It was also to fill the gaps left by countries which are not ready to implement universal 
ART coverage. Infant PreP may be an efficacious route to prevent residual MTCT when 
mothers are already on ART with detectable viral load. The ANRS 12174 study protocol has 
been published (111).  
The participants were recruited progressively in 2 steps, initially at the antenatal care visits and 
after the occurrence of births on the different sites. Screening was done before the child birth; 
the pregnant women were contacted while attending an ANC visit between 28th and 40th week 
of pregnancy. They were offered a voluntary counselling and testing for HIV with the 
possibility of receiving the result the same day. If positive for HIV-1 they were briefed on the 
ANRS 12174 trial and invited to participate during the post-test counselling session. They were 
also advised about the different feeding options for their child. Only women willing to 
breastfeed or those not yet clear about the feeding option they intend to implement were referred 
to the research clinic for further assessment regarding their HIV-1 stage, the level of CD4 count 
and the other inclusion/exclusion criteria listed below. Those who clearly did not want to 
breastfeed were excluded.  
At the screening 2 or postnatal screening that took place within the first 6 days after delivery, 
the women who passed the screening 1 were re-assessed with their new-borns with regard to 
the inclusion/exclusion criteria (see below) before the final inclusion decision. Once included, 
the participants were distributed to the study arms (boosted lopinavir or lamivudine group) and 
followed up over 50 weeks. We described and analysed data extracted from this database, 
considering feeding modes as an exposure variable and different outcomes, including 
mothers’BMI, Hemoglobin concentration, CD4 cell count, HIV-1 viral load and status, as well 
as HIV-1 disease progression in general. The overview of the different papers included in this 
study is summarized in Table 2. 
 Table 2: Summary of the methods for the papers included in the thesis 
Paper title Objective  Exposure  Outcome  Analytical 
techniques 
1. Breastfeeding 
patterns and its 
determinants among 
mothers living with 
Human 
Immunodeficiency 
Virus-1 in 4 African 
countries 
participating in the 
ANRS 12174 trial 
To study feeding 





practices of the 
participants in the 






















living with HIV-1 
with a CD4 count 
>350: Results from 4 
African countries 
(The ANRS 12174 
trial) 
To study the effect 
of breastfeeding 




other risk factors 

























participating in the 
ANRS 12174 clinical 
trial in Burkina Faso, 
South Africa, Uganda 
and Zambia: a cohort 
design. 
To assess mothers’ 
HIV-1 disease 
progression 
(measured by the 
change in weight, 
CD4 cell count 
and HIV-1 disease 






















during the infant’s 
first 6 months of 
life and until week 
50 post-partum. 
4.2 Study population  
4.2.1 Study sites  
The study sites were Ouagadougou (Burkina Faso), Mbale (Uganda), East London (South 
Africa) and Lusaka (Zambia). Ouagadougou is the capital of Burkina Faso in West Africa. The 
city is located in the central part of the country on flat land covering 274, 200 km2. At the time 
of the ANRS 12174 trial, Ouagadougou had 1.2 million inhabitants (112). According to the 
region’s health authority’s statistics, the frequency of ANC visits and assisted delivery were 95 
and 85%, respectively. The HIV prevalence among ANC-attendees was 5.9%. The participants 
were recruited from peripheral antenatal clinics and referred to the research clinic based at the 
paediatric university teaching hospital Charles De Gaulle in the eastern part of Ouagadougou. 
The data on 204 mother-infants pairs were included and analysed from Burkina Faso. 
In South Africa, the ANRS 12174 study was conducted in East London, located on the southeast 
coast in Eastern Cape Province. The HIV prevalence among pregnant women was estimated at 
23% and 213 participants were included from the East London site. The HIV voluntary 
counselling and testing (VCT) uptake among new antenatal visit attendees was 80%. About 
50% of HIV-infected women would choose exclusive breastfeeding. 
Mbale is located in eastern Uganda ~200 km from Kampala, the capital, with a total population 
of 720, 000, of which 274 participated in the study. The general HIV prevalence was 10% 
among pregnant women. HIV VCT was accepted by 70% of pregnant women, 80% of those 
accepting the test returned for results, and 80 to 90% intended to breastfeed.. 
Lusaka, the capital of Zambia, was the 4th study site. Its population was estimated at 2 million, 
of which 534 participants were included. HIV prevalence among females aged 15-49 years was 
estimated at 25%; 98% of pregnant women would attend at least one ANC visit and exclusive 
breastfeeding rate countrywide was 26% for children aged <4 months. The characteristics of 
















Population size of 
catchment area 
1 200 000* 267000 720 000* 2 000 000* 
Population density 
(persons per km2) 
51.8** (2006) 39.9 (113)  124 (114) 15 (115) 
Percentage of HIV in 
the general population 
(%) 
2* 9 (116) 6.2 (117) 27 (118) 
Percentage of HIV 
among ANC attending 
women 
(%) 
5.9* 23* 10* 25* 
ANC attendance (%) 95* 92 (119) 97 (120) 98* 
Number of included 
cases 
204 213 274 534 
* source: ANRS 12174 trial protocol 
**source: INSD (http://www.insd.bf/n/contenu/Tableaux/T0316.htm [accessed on 12/06/2018] 
                                                                                                                                    
4.2.2 Study participants 
o Eligibility criteria 
HIV-1 positive, immune-competent women, delivering HIV-1-negative infants as per DNA 
PCR assessment on day 7 (+/- 2 days) postpartum and opting to exclusively breastfeed during 
6 months after delivery were eligible to participate in the study. Further inclusion and exclusion 




Table 4: ANRS 12174 trial eligibility criteria (87) 
 Inclusion criteria Exclusion criteria 
Baby 
is a singleton 
Presents clinical symptoms 
and/or biological 
abnormalities equal to or 
greater than grade II of the 
ANRS classification for 
adverse event on the day of 
enrolment, with exceptions 
for hemoglobin (baby 
excluded if Hb <12 g/dL) 
and absolute neutrophil 
count (baby excluded if 
neutrophils <1200 cells/µL) 
 
is breastfed at day 7 by 
her/his mother and her/his 
mother intends to continue 
breastfeeding for at least 6 
months  
presents with serious 
congenital malformation(s) 
 
has a post-partum blood 
sample with a negative HIV-
1 DNA PCR test result on 
day 7 (+/- 2 days) 
birth weight is <2.0 kg 
 
has received some 
antiretroviral prophylaxis at 
birth or during the first week 
is participating in another 





has reached the local legal 
age for participating in 
medical research studies 
has participated in the ANRS 
12174 trial for a previous 
pregnancy 
 
is HIV-1 infected (with or 
without HIV-2 infection) 
and is not eligible for 
HAART 
 
is participating in another 
clinical trial on the day of 
enrolment 
 
has received antiretroviral 
prophylaxis during 
pregnancy or  delivery 
 
has an antenatal lymphocyte 
CD4 count above the 
threshold for HAART 
initiation in pregnant women 
according to the national 
recommendation in each site 
 
resides within the study area 
and is not intending to move 
out of the area in the next 
year 
 
gives assent for the infant to 







o Sample size 
 
The ANRS 12174 clinical trial sample size has been calculated taking into account its primary 
objective, which was to compare the efficacy of infant LPV/r (80/20 mg twice a day) vs. 
lamivudine (12 mg twice daily if <6 kg, 24 mg per day if 6.0 to 9.0 kg, and 36 mg per day if 
≥9.0 kg) from day 7 until one week after cessation of breastfeeding (maximum recommended 
duration of prophylaxis: 50 weeks for a maximum duration of breastfeeding of 49 weeks) to 
prevent postnatal HIV-1 acquisition between 7 days and 50 weeks of age. The derived primary 
outcome measures were acquisition of HIV-1 (as assessed by HIV-1 DNA PCR) between day 
7 and 50 weeks of age. The trial planned to include 1500 infants to cover most scenarios under 
the study hypotheses. However, only 1267 infants were finally included due to field constraints 
including lower prevalence at the time of the protocol implementation which started in 
November 2009. Our cohort study was a planned ancillary study of the ANRS 12174 clinical 
trial. 
4.3 Data management and analysis 
Data were collected on paper case report form or directly entered online using the Electronic 
Data capture system, ®OpenClinica (https://www.openclinica.com). Twenty-four hours and 
one-week recalls of breastfeeding practice were collected during the enrolment visit on day 7 
and the following visits on weeks 2, 6 and every 4 weeks (±2) until the end of the study at week 
50. In all papers, we have defined the feeding categories: 1) exclusive breastfeeding (EBF - 
only breast milk is given to the infant without any other kind of food or liquid except medically 
prescribed drugs or vitamins); 2) predominant breastfeeding (PBF - breast milk with some 
liquid-based food such as juice, tea, sugar-water and salt-water including glucose without any 
kind of formula or animal milk) and 3) mixed feeding (MF - breast milk with other solid or 
liquid-based food including other kind of milks). EBF and PBF were further combined into 
“Exclusive or predominant breastfeeding group” (EPBF) as PBF presented few cases and was 
assessed to present the same risk as EBF with regard to postnatal HIV transmission (104).  
In paper 1, we analysed survival and presented curves describing the feeding behaviour of the 
participants. The outcome was to stop EPBF practice before the end of the follow-up period 
that was set at week 22, since after this time-point, stopping EPBF would be most likely induced 
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by the trial requirement. The outcome was reached when the mother gave any food item out of 
the list of liquid-based food allowed in EPBF practice. The censoring date was the date the 
woman stopped EPBF whatever the reason (child’s death, discontinuation from the study, lost 
to follow-up) or at the end of the follow-up at 22 weeks. We also explored potentially 
modulating factors associated with early cessation of EPBF, as well as the early weaning before 
50 weeks. To this purpose, we ran a non-proportional hazard flexible parametric multiple 
regression analysis with duration of EPBF, or any breastfeeding as continuous variables using 
the “stpm2” command in Stata (121, 122). Variables with p ≤0.20 in the bivariate analysis were 
considered for the multivariate analysis in the pooled data analysis. Other covariates included 
the trial arm (lopinavir/ritonavir vs lamivudine), the trial country (Burkina Faso, South Africa, 
Uganda or Zambia) and the maternal age categorized into 3 age groups (<25 years, 25 to 30 or 
30+). The rest of the covariates were used as dichotomised variables (single vs. married or co-
habiting, primi- vs. multi-para, vaginal vs. caesarean section delivery, primary vs. secondary 
school level or higher and breastfeeding initiation in time within the first hour postpartum vs. 
later). We also presented a country-specific analysis catering for contextual variation in factors 
associated with the feeding behaviour of the neonates. Since South Africa has a different socio-
economic and cultural context, we stratified the data by creating 2 models - South Africa alone, 
and Uganda and Zambia together. Burkina Faso was excluded from these analyses due to the 
very small numbers of the events (women initiating mixed feeding in the study period before 
week 26). The same list of variables was used in the country-specific analysis regardless of the 
p-value in the bivariate analysis. 
In paper 2, we considered separately 2 dependent variables, the mothers’ BMI and hemoglobin 
concentration. Both were used as continuous variables and the main exposure variables for both 
was the exclusive/predominant breastfeeding or any breastfeeding duration. First, we 
implemented a bivariate analysis, using the Bonferroni-corrected paired t-test for multiple 
comparisons, comparing the baseline mean BMI (measured at day 7) with mean BMI measured 
at weeks 14, 26, 38 and 50. Baseline mean hemoglobin concentration (week 14) was also 
compared with the mean hemoglobin concentration at week 38. Then, in order to take into 
account the country as well as the inter-subject variability and the confounders, we fitted a 
linear mixed-effect model with BMI as the dependent variable and EPBF or any breastfeeding 
duration as the key explanatory variables. One important variable that was also considered in 
the multiple regression model was the socio-economic status. To build this index, 16 asset-
variables per country were used in the principal component analysis method. 
Similarly in paper 3, we ran linear mixed-effect models where we considered separately HIV-
1-positive mothers’ weight, CD4 cell count and HIV-1 viral load change in relation to EPBF 
duration. When the inter-country variability was not significant, we simply ran linear or logistic 
regression models. Then we used a multiple logistic regression model with HIV-1 disease 
progression as a composite variable, combining mothers’ weight, CD4 cell count and HIV-1 
staging as per WHO classification. HIV-1 disease progression was accelerated when CD4 cell 
count decreased to <350 cells/µl or the HIV-1 infection was assessed by the study physician at 
stage 3 or above or the mothers lost at least 10% in weight. Otherwise, HIV-1 disease 
progression was absent or slow. Regarding mothers’ weight loss, we generated a new variable 
called “weight loss”, which was calculated as the mothers’ weight at week 26 minus the baseline 
weight at day 7 post-partum which was compared to the baseline weight to assess if the loss 
reached 10%. In these risk factor analyses, participants were stratified into two strata: stratum 
1 with South Africa alone because the South African context was specific enough and different 
from the contexts of the stratum 2, which included Burkina Faso, Uganda and Zambia together. 
The socio-economic, cultural and demographic environments of these latter countries were 
deemed sufficiently similar to form the second stratum together. 
In papers 2 and 3, potential confounders and other covariates used to build the models included 
the mother’s viral load, CD4 count, hemoglobin concentration, BMI, HIV stage, mode of 
delivery (vaginal vs. C-section), parity, age, education level, marital status and occupation. The 
child’s characteristics included gender, birth weight, treatment group and breastfeeding 
initiation time.  
The data was collected by trained physicians, pharmacists, biologists and counsellors. We 
analysed the data using STATA/SE 13.1 (4905, Lakeway Drive College Station, Texas 77845 
USA) statistical software. 
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4.4 Methodological challenges  
The challenges for the completion of this study were mainly statistical. In paper 1, the issue 
related to executing a survival analysis with a time-varying phenomenon. We had to determine 
what was happening at different time-points in addition to the simple time-to-end of EBF 
analysis; a recurrent event as a repeated occurrence of EPBF cessation; and interval censored 
data, since the exact EBF cessation time was unknown. Survival curves were plotted using the 
Kaplan-Meier method to describe the practice of exclusive or predominant breastfeeding from 
birth to the introduction of complementary food, loss to follow-up or the end of the study 
follow-up. To solve the issue of recurrent events with some mothers showing periods of relapses 
of EPBF, we considered only the first event in our analysis. A mother who stopped EPBF even 
for one day was censored and had no possibility to return to the EPBF group. The same principle 
was applied to breastfeeding as a whole. For example, after cessation of breastfeeding, 62 
mothers (25, 20 and 17 in South Africa, Zambia and Uganda, respectively) resumed it. In total, 
54 mothers resumed breastfeeding once and stopped breastfeeding permanently and 8 resumed 
twice. The mean duration of all periods with resumed breastfeeding was 17.2 days. In the 
calculation of this mean, 5 women who had resumed breastfeeding of long duration and had 
been characterized as outliers were disregarded (80, 93, 97, 134 and 137 days). The mean 
duration of the periods with resumed breastfeeding for those who resumed once was 18.2 days 
(once again without the 5 women), 14.9 and 13.2 days for the first and second period, 
respectively, for those who resumed breastfeeding twice. In the analysis, we could see that the 
phenomenon of reversal of breastfeeding was not significant. Presenting the mothers’ 
breastfeeding practice at different time-points added no new information on the findings since 
in our data, the decline being almost steady.  
In plus of the Kaplan-Meier graph, we had to fit a model that allows the inclusion of adjusting 
covariates in the assessment of the factors influencing EPBF and breastfeeding practice. Since 
the proportional hazard assumption was invalid, we reverted to a non-proportional hazard 
flexible parametric multiple regression model using “stpm2” command in Stata. This model 
allows proportional hazard and proportional odd to be fit, and can be extended to model a time-
dependent effect, which we also had to deal with in our models.  
The analysis of risk factors stratified by site suffered from small sample size. Sparse cells 
explained some of the large discrepancies between adjusted and unadjusted hazard ratios in the 
tables. To cope with the small cells issue and also to make the data more heterogeneous, we 
stratified the countries into 2 groups (South Africa vs. Uganda and Zambia). The data from 
Burkina Faso was dropped from the analysis because it was considered too homogenous with 
regard to every few events of interest. 
In paper 2, the introduction of the socio-economic status variable implied an important 
challenge in the calculation of the SES index. Sixteen asset-variables were considered, 
including owning a bike, a fridge, a phone, a radio, a scooter, a television, or a washing machine; 
the material used for the dwelling roof, floor and wall, the source of drinking water, of heat 
used for cooking and having electricity or not, and the type of toilet. Two new assets (means of 
communication and house-keeping tools) resulting from the combination of owning a phone, a 
radio and a television, and owning a fridge and a washing machine, were created and added to 
these items. Since the countries involved in the study presented diverse socio-economic 
contexts, we stratified our SES index by country. The asset-variables were categorized and 
included in different ways in each analysis of a country, and were excluded each time when 
their distribution among the participants was too homogenous. The first component (explaining 
33, 39, 29 and 34% of the variation for Burkina Faso, South Africa, Uganda and Zambia, 
respectively) was used to reflect the socio-economic status, and thus it was divided into tertiles. 
To assess the impact of breastfeeding on mothers’ BMI, we were unable to consider the 
mothers’ calories (food) intake because of the lack of data on this variable. This was indeed an 
unresolved challenge that we mitigated as the consequences of our results by using the SES 
index in the country-stratified models. The linear mixed effect model implemented in paper 2 
contributed also to mitigating the consequences of the lack of data on food intake.  
This linear mixed effect model allows the inclusion of a maximum of subjects, regardless of 
the missing data; the differences in measurement times (although the study visits were well 
planned for all participants), women were counselled not to start the weaning process before 
eight months post-partum until a maximum of 50 weeks follow-up period); regardless of 
correlations resulting from different measurements in the same subject; regardless of major 
variabilities in the study incurred by different countries with relevant differences in socio-
economic contexts; regardless of the between-subject and within-subject variabilities. All these 
variabilities were controlled in the random-effect part of the model. 
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In paper 3, our outcome was a composite endpoint, which has a lot of advantages, including a 
higher frequency of the study events that allows a more precise grasp of an eventual intervention 
effect and a reduction in the necessary sample size. However, it has also some pitfalls, the main 
one being how to accurately include the component endpoints so that they are of more or less 
of equivalent importance from a clinical point of view, that they are of equal frequency, and 
finally that they are similarly impacted by the study intervention. Otherwise, the interpretation 
of the findings may be misleading. For example, the conclusion may be that the intervention is 
highly efficacious, when it has only greatly reduced a less important, but highly frequent, event 
while the main important one was less influenced or completely uninfluenced. An example of 
such a misleading interpretation may be, for example, a composite endpoint including death or 
chest pain as the component endpoint. The intervention may be deemed efficacious when it has 
only reduced the occurrence of chest pain. 
Our composite endpoint was set up to assess the participant progression from HIV-1 infection 
to AIDS disease. This disease is a syndrome and there is no test to diagnose a patient with AIDS 
as for malaria, meningitis or cancer. The clinician relies on a certain number of symptoms and 
biological markers to make a diagnosis. Therefore, our composite endpoint needed to include 
relevant AIDS-defining criteria. We chose as component endpoints a weight loss of >10% of 
the initial weight, a CD4 count <350 cells/µl, or a WHO-clinical stage of HIV infection >2. The 
component endpoints we used to build up our composite endpoint were coherent and 
sufficiently equivalent.  
4.5 Ethics 
For the ANRS 12174 trial, ethical clearances were obtained from the different sites, including 
the approval from the health research national ethic committee in Burkina Faso (n° 2008-039  
on 29 may 2008), the institutional review board of Stellenbosch University in South Africa 
(M09/11/043), Uganda (ref: HS470), Zambia (ref: 008-02-08) and Norway (200802523-
5/KST017/400). To obtain the informed consent, the participants were informed that the data 
may be used beyond the need of the clinical trial for further studies, and they agreed upon signed 





5.1 Study flow chart 
The trial considered 3,199 pregnant HIV-1 infected women for the antenatal screening. Some 
2,238 women were eligible for the post-natal screening, 1,274 eligible for the enrolment visit 
and 1,273 enrolled and randomized to the 2 arms of the trial. Of these, 6 randomizations were 
excluded afterwards because of protocol violations. Further, 42 participants were excluded from 
the analysis of our first paper due to a lack of breastfeeding data after the randomization. We 
therefore analysed a sample of 1,225 participants in paper 1, 204 from Burkina Faso, 213 from 
South Africa, 274 from Uganda and 534 from Zambia. 
In papers 2 and 3, 9 more participants were dropped because of missing data for the initial 
mother’s weight variable, leaving 1,216 participants’ data (Burkina Faso 203, South Africa: 
212, Uganda: 272 and Zambia: 529) for the analysis. The eligibility criteria were the same for 
all papers. 
5.2 Baseline characteristics 
The median (interquartile range) age, body mass index and gestational age of the mothers were 
27.0 (23.3; 31.0) years, 23.7 (21.3; 27.0) kg/m² and 38.0 (38.0; 40.0) weeks, respectively. The 
medians CD4+ cells count, HIV-1 viral load and hemoglobin concentration were 530 (432.5; 
668.5) cells/µl, 3.0 (0.8; 13.7)*103 copies/µl, and 12.2 (11.3; 13.1) g/dl respectively (Table 5a). 
The number (and percentage) of participants having completed secondary school or further was 
626 (51.1%) for a total literacy rate of 1,062 (86.7%). Employed, married or cohabiting, 
primiparous and vaginal-delivered mothers represented 296 (24.2%), 966 (78.9%), 276 (22.5%) 
and 1100 (89.8%), respectively. The infant median birth weight was 3.0 (2.8; 3.3) kg. Female 
infants represented 594 (48.5%) and 616 (50.3%) of the children were allocated to the 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3 Breastfeeding patterns and its determinants among HIV-1 
infected mothers (paper 1) 
5.3.1 Breastfeeding patterns 
In all 4 countries, 57.7% of mothers initiated breastfeeding within the first hour after delivery; 
25.1% between 2 and 5 h post-delivery. In total 93.9% of the women initiated breastfeeding 
within the first day after birth. During the first week post-delivery, 99.0 and 95.9% of the 
mothers initiated any or exclusive breastfeeding, respectively (Table 5b). The food items 
provided as prelacteal food to the infants in the first week included water and water-based items, 
such as water plus sugar or glucose, water plus salt, juice, infant formula, cow’s milk and liquids 
as part of traditional practices. 
The median duration of any breastfeeding and EBF was 40.6 (IQR; 32.3; 45.4) weeks and 20.9 
(IQR: 19.1; 21.1) weeks, respectively.  PBF was reported only during 59 monthly visits (4/1,000 
person-year). At week 22, 185 (90.7%), 104 (48.8%), 200 (73.5%) and 434 (83.1%) were 
exclusively or predominantly breastfeeding in Burkina Faso, South Africa, Uganda and 
Zambia, respectively (Figure 2, paper 1). At week 50, 24 (11.8%), 10 (4.7%), 7 (2.5%) and 17 
(3.2%) were continuing to breastfeed in the same countries, respectively (Figure 3, paper 1). 
There were 457 (37.3%) and 456 (37.2%) infants still on EPBF at week 22 in the lamivudine 
and lopinavir/ritonavir arms, respectively, whereas at week 50, there were 5.1 and 4.4% of 
breastfed children in the lamivudine and lopinavir/ritonavir arms, respectively (Figure 4). 
Figures 5 and 6 present the Kaplan Meier curves by country, and trial arms for any breastfeeding 
and EPBF practices. In these curves, South African women showed the fastest decline among 
all the breastfeeding and EPBF infants. 
Porridge or cereals were introduced at week 10 and 18 in Zambia and Uganda, respectively 
whereas in Burkina Faso they were used from week 26. Soup, meat, fish or eggs were 
introduced as early as week 18 in South Africa, Uganda and Zambia whereas these items were 







Figure 4: Infant’s feeding option by trial arm 
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Figure 6: Any form of breastfeeding by country and trial arm    
  
5.3.2 The determinants of breastfeeding patterns 
Risk factor analysis was restricted to South Africa, Uganda and Zambia. Burkina Faso was 
excluded because the feeding behaviour of the women from this country was homogeneous. 
Table 6 summarizes the objectives, main findings and risk factors of each sub-topic of our 
study.  
5.4 BMI changes and hemoglobin concentration (paper 2) 
Overall, the BMI of breastfeeding mothers decreased from baseline to week 26 before 
plateauing through to week 50 (Table 2, paper 2).  With the Bonferroni-corrected paired t-test 
for multiple comparisons regarding BMI of day 7 post-partum, overall we found a significant 
mean BMI (95% CI) decrease of -0.5 (-0.7; -0.4), -0.7 (-1.0; -0.3), -0.7 (-0.9; -0.4) and -0.7 (-
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67 
association between breastfeeding duration and BMI decrease was found in the country-specific 
analysis, except in Uganda, where there was no significant decrease. The largest mean BMI 
decrease was found in Burkina Faso, reaching 1.1 kg/m² at week 26. In South Africa and 
Zambia, the maximum mean BMI decreases were -0.9 (-1.8; -0.0) and-0.6 (-0.9; -0.2) kg/m², 
respectively at week 38. Regarding hemoglobin concentration, no significant change was found 
both in overall and country-specific analysis. 
Categorizing women into 3 BMI groups, we found that slimmer women (BMI <18.5 kg/m²) 
showed no statistically significant change in their BMI postpartum (p>0.05), whereas the other 
groups (BMI between 18.5 and 24.9 kg/m² and BMI≥25 kg/m²) showed a significant decrease 
over the breastfeeding period (Table 4, paper 2). The thinnest group of women had the steepest 
drop in hemoglobin concentration at week 38,but the difference was not significant -0.3 (-1.5; 
0.9) g/dl; Table 5, paper 2). Overall, the multivariate analysis found no association between 
EPBF duration and mothers’ BMI (Table 6, paper 2). 
5.5 HIV-1 disease progression among HIV-1-infected mothers in 
relation to their feeding patterns (paper 3) 
In all models, including mothers’ weights, CD4 count, HIV-1 viral load or HIV-1 disease 
progression as outcome variables, no association was found between these outcomes and EPBF 
duration (Table 6). However, an increase in HIV-1 viral load was associated with any 
breastfeeding duration in South Africa (7.7 (95% CI: 3.4; 12.1) *103 copies/µl) and at the pooled 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.1 The main findings 
In general, the mothers in the ANRS 12174 phase 3 clinical trial adhered to the breastfeeding 
recommendations. Considered separately, no variations in the mothers’ weight, CD4 cell count 
or HIV-1 viral load were related to EPBF or “any breastfeeding”. When these outcomes are 
combined in a composite endpoint representing HIV-1 disease progression, there was still no 
variation in relation to EPBF or “any breastfeeding”. Not surprisingly, the mothers’ baseline 
BMI was consistently associated with an increase in the mothers’ weight, in CD4 cell count, 
and a lower mean HIV-1 viral load for both EPBF, and any breastfeeding groups. At a bivariate 
analysis, there was a significant mean reduction of 0.7 kg/m² in mothers’ BMI from 26 to 50 
weeks after delivery.  This was also the case for changes that occurred mainly after 26 weeks 
in hemoglobin concentration. Associated with the study outcomes, but in an opposite 
direction, was also the allocation of the babies to the lopinavir/ritonavir arm, which seemingly 
was associated with an acceleration of the mother’s HIV-1 disease progression  (AOR : 1.3 
(95% CI: 1.0; 1.6)), a higher HIV-1 viral load (31.1 (95% CI: 7.1; 55.0)*103 copies/µl), and, 
though not significantly, a lower CD4 cell count (-19.2 (95% CI: -41.9; 3.6) cells/µl) and lower 
mothers’ weight (AOR: -0.1 (95% CI: -0.7; 0.4) kg). 
6.2 Discussion of findings 
6.2.1 The breastfeeding pattern and its determinants among HIV-1 
positive women 
In spite of clear breastfeeding recommendations, only 40-43% of infants were exclusively 
breastfed worldwide in 2017 and 2018, and ~36% over from 2007 to 2014 (123, 124). The 
global estimate of EBF ranges from 22 to 37% in Sub-Saharan Africa where breastfeeding is 
a traditional practice, although EBF is not (52, 58, 125-128). 
Recent studies conducted in the general population and among mothers living with HIV found 
that the proportion of women initiating breastfeeding within the first hour postpartum varied 
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from 40 to 70% (129-132). In our study, the country having the lowest percentage of women 
initiating breastfeeding within the first hour was Burkina Faso (only 6.9%).  
In our trial, <10% of the participants across all sites gave prelacteal feeds compared to 22 to 
57% in other studies (125, 130-132). The Burkina Faso site in our trial had the highest 
proportion of women giving prelacteal feeds (>16%). The same feeding patterns were found 
in the PROMISE-EBF trial promoting breastfeeding by peer-counsellors in the Burkina Faso 
rural site, with <4 and 11% of participants initiating breastfeeding within the first hour and 
giving prelacteal feeding, respectively, in the intervention clusters (133). In Burkina Faso, 
however, women breastfed longer compared to the other countries, for which we have no clear 
explanation. Our hypothesis is that the tradition through a cultural influence, better 
counselling sessions and a poorer economic context that could be accompanied with 
difficulties in affording quality complementary food for children, may have been important 
factors. More mothers in South Africa, and to some extent in Zambia, had to resume formal 
work after a few months, preventing them from continuing breastfeeding.  
The Kesho Bora study was another PMTCT trial in overlapping countries preceding the ANRS 
12174 trial, where the intervention assessed the efficacy and safety of a 3-drug ARV regimen 
compared with zidovudine plus single-dose nevirapine for PMTCT of HIV-1 during 
pregnancy, delivery and breastfeeding for women with CD4 counts of 200 and 500 cells per 
cubic millimetre (134).  The proportion of women initiating breastfeeding in the first week 
and the median duration of any breastfeeding were higher in our study than that in Kesho Bora 
(99% and 41 weeks vs. 70% and 20 weeks, respectively). In the Kesho Bora trial, there was a 
lower proportion of EBF (22% at 5 months) compared to our trial (75.3% at 5 months). Even 
comparing the countries that participated in both the Kesho Bora study and our own trial 
(Burkina Faso and South Africa), the exclusive breastfeeding rate was higher in our trial. In 
other breastfeeding studies among HIV-infected women, from contexts similar to this trial, the 
median duration of EBF varied from 1.8 (135) to 5 months (129, 135, 136) and the proportion 
of EBF at 6 months ranged from 0 to 84% (125, 132, 134, 135, 137). Therefore one has to 
acknowledge the high variability of infant feeding practices in sub-Saharan Africa among 
HIV-positive women.  
In general, the ANRS12174 participants adhered to a large extent to the WHO infant feeding 
recommendations. The trial setup and the frequent counselling sessions are the most likely 




for the promotion of safe infant feeding practices among HIV-1 positive women. However, 
we have some methodological concerns that will be discussed below.  
Interestingly, the trial allocation was a factor associated with breastfeeding behaviour, but in 
South Africa alone, the lopinavir/ritonavir group had a 3 times higher risk of shorter EPBF 
compared to the lamivudine group. It is possible that the poor palatability of lopinavir/ritonavir 
influenced South African participants to stop EPBF earlier than recommended. Why this 
happened only in South Africa is unclear, but formula-feeding is more common in South 
Africa, where it has a central role in infant feeding as it was provided to HIV-infected women 
by the health system for almost 10 years (138). It is also possible that, due to bad taste, women 
in South Africa mixed the drug with other foods than milk, unlike women in Uganda and 
Zambia who mixed it with breastmilk. Other risk factors limiting EBF practices included age 
between 25 and 30 years, living as a couple, being employed, multiparity or being from South 
Africa. Other authors have found that older age (35-49 years) (57) favoured EBF. With regards 
to any breastfeeding, better educated women (i.e. having completed secondary school or 
beyond) were more at risk to stop breastfeeding earlier.  
6.2.2 Breastfeeding and HIV-1 positive mothers’ health 
Mothers’ nutritional status and hemoglobin concentration 
The mean BMI decrease over time compared with baseline BMI at day 7 postpartum in our 
study (Table 2, paper 2) was generally small, and therefore is probably of limited clinical 
significance. The largest decrease (-1.1 kg/m²) was seen in Burkina Faso at week 26. The 
median BMI for this country was 23.0 (interquartile range: 21.2; 25.4) kg/m² and the mean 
BMI was 23.8 (95% CI: 23.2; 24.3) kg/m². Therefore, a mean decrease of 1.1 kg/m² did not 
push the participants into the underweight category. This finding was supported in a country-
pooled analysis where the greatest decrease was seen after 50 weeks and women who were 
underweight (<18.5 kg/m²) had a maximum weight loss of 0.5 kg/m² (95% CI: -2.1; 1.1), a 
statistically insignificant estimate with low precision (Table 4, paper 2).  
Our study tested a dose-response relationship by looking at the duration of EPBF and any 
breastfeeding, respectively, in relation to BMI change of HIV1-infected mothers. In addition, 
we also investigated this relationship where HIV-1 disease progression including maternal 
weight loss was the main outcome variable. These analyses showed no relationship between 
exposure and the nutritional outcomes in the women. This was also seen in a Tanzanian study 
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(139), which, despite its loss to follow-up, concluded that neither the modality of breastfeeding 
(exclusive or any), nor the duration of breastfeeding had any influence on the weight of 
mothers with HIV infection. 
Analysis of Zambian data (97) covering the first 2 years after birth, controlling for 
confounding variables, such as socio-economic status, obstetric history, season and food 
shortage, reported a net weight gain rather than a weight loss. This has also been found in 
undernourished lactating mothers (140-142). Hartmann (142) explained this weight gain by a 
homeorhetic theory of metabolic adjustment in favour of a dominant physiological state, such 
as lactation. This could explain why the thinnest mothers lost no weight during the EPBF 
period in our cohort (Table 4, paper 2).  
Some studies have compared breastfeeding and formula-feeding (99, 100), or HIV-positive 
with HIV-negative breastfeeding mothers (143). Unlike our findings, studies in Kenya (99, 
100) and South Africa (143) found that breastfeeding was a risk factor to a faster decrease in 
mothers’ BMI, CD4 cell count and more frequent deaths (99, 100) among HIV-positive 
mothers. 
The literature is extensive regarding breastfeeding influence on mothers’ body weight or BMI 
in the general population. It is assumed that when there is a decrease in lactating mothers’ 
body weight, this is caused by an imbalance between the energy needs of the lactating mothers 
(energy needs of lactation plus normal energy needs) and their energy intake. Breastfeeding 
mothers combine different adaptive strategies, including increased food intake, mobilization 
of tissue stores or reducing energy expenditure by reducing physical activity (144). 
Breastfeeding women undergo a mild progressive weight loss in the first 6 months postpartum. 
The mean rates of the weight loss in those first 6 months (ranging from 0.1 kg/m²/month in 
resource-limited settings to 0.8 kg/ m2/month in high income countries) is comparable to our 
findings as significant in the bivariate pooled analysis of the HIV-positive women (-0.7 
kg/m²/month). Weight gains have also been observed (145). Considering the mothers’ energy 
intake, usually breastfeeding mothers consume more than women who formula feed. 
Therefore, breastfeeding may play a role both in postpartum weight loss and even in weight 
gain if there is a high energy intake (145, 146).  
Except in extreme cases of malnutrition, milk production in quantity and quality is scarcely 




towards the baby’s need. Therefore, even if the mother is facing deficiencies, most nutrients, 
such as iron, zinc, calcium and copper, continue to be adequately supplied by the breastmilk 
at the expense of the mother’s stores. Duration and intensity of breastfeeding have a significant 
impact on maternal nutritional requirements, as has age, the baseline postpartum weight, and 
the level of activity (her metabolism). Some nutrients such as the water-soluble vitamin 
concentrations in breastmilk come from maternal intake, whereas the fat-soluble ones depend 
on maternal stores. The nutritional requirements in women through the reproductive cycle is 
highest during the breastfeeding period. Milk produced during the first 4 months of lactation 
constitutes an energy level that is equivalent to the total energy expenditure of gestation, since 
during the same period an infant will double the weight gained during the whole pregnancy 
period (107). 
During the first 6 months post-delivery, 750 ml of breastmilk would be produced every day, 
providing a daily energy of 525 kcal to the infant. This is equivalent to 700 kcal/litre of 
breastmilk produced by the mother. The women’s food requirement should not be 
mathematically balanced since a third of the energy needed to produce breastmilk comes from 
the mother’s stores, physiologically often gained during pregnancy. When a diet provides 
<1800 kcal/day, these stores may be depleted beyond a pre-pregnancy state. Furthermore, low 
energy intake of <1500 kcal/day may lead to decreased milk supply. The total daily energy 
intake recommended for breastfeeding mothers ranges from 2300 to 2500 kcal to feed a single 
child, and 2600 to 3000 kcal for twins, on average (107). Another study estimated that the total 
energy cost of breastmilk production over the first 6 month period would be 117000 kcal. This 
energy would represent the mobilization of 13 kg of the mother’s body fat if nothing changes 
in the energy metabolism, but in reality this is seldom observed. In the absence of other energy 
saving methods than physical activity, increased energy (food) intake remains the main 
explanation why lactating women do not lose a lot of body weight (147). Weight loss can 
occur in breastfeeding women when the energy intake is below the minimum requirement. 
This may be what we observed in Burkina Faso, probably the highest weight loss in our study. 
The Burkina Faso mothers breastfed more intensively than in the other countries, and their 
food intake may have probably been insufficient. Weight loss can be rapid when it is combined 
with excessive physical activity.  
A consistent weakness of the studies on weight change and lactation (148) is that the mean 
change in the mothers’ weight does not in fact convey the changes in individual participants. 
It has been suggested that differences in mean weight changes may be due to differences in 
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gestational weight gains, cultural practices, physical activity levels, seasonal food availability 
and desired weight loss. Other confounding factors associated with postpartum weight change 
include pre-pregnancy weight, age, parity, race, smoking and return to work outside the home. 
Gestational weight gain was by far the most consistent and strongest associated factor across 
these studies, whereas lactation was a minor contributor (144, 149). In a systematic review, 
whereas the majority of studies showed little or no association between lactation and weight 
change, 5 studies considered higher methodological quality reported that breastfeeding was 
positively associated with weight change (148). To sum up, our findings accord with the 
existing literature on weight change in the general population, confirming physiological 
weight change from lactation. There is limited evidence for other interpretations of relevance 
to HIV-positive women. 
Regarding hemoglobin concentration, lactation is protective against iron deficiency, as 
breastfeeding mothers usually are in amenorrhea during the first 6 months of exclusive 
breastfeeding. Therefore, a net decrease up to 50% in mothers’ daily iron requirement can be 
expected (147). In addition, iron secretion in breastmilk is very limited (147). These combined 
factors may be the reason why we found no decrease in hemoglobin concentration in our 
research.   
HIV disease progression  
Regarding HIV-1 disease progression in Durban, South Africa, a study found no deleterious 
effect of breastfeeding in HIV-1-infected mothers, in agreement with our own results (150). 
This study had as outcome variables CD4 and CD8 cells counts, the mothers’ illness and 
mortality, and the hemoglobin levels. Other studies in Malawi and South Africa also found 
that breastfeeding, regardless of the modality, exclusive or not, was not associated with higher 
risk of maternal morbidity or mortality (150, 151). A study in Zambia concluded much the 
same direction that at 12 months after delivery there was no difference in mortality between 
groups that were recommended to breastfeed short (4 months) versus prolonged (68). An 
individual patient data meta-analysis on mortality among HIV-infected women according to 
the infant’s feeding modality confirmed that the risk of dying within 18 months postpartum 
was not significantly different regarding infant’s feeding modality (breastfed vs. never 
breastfed) (152). In a randomized trial on prolonged breastfeeding and maternal mortality in 




Regarding the change in CD4 cell count, the above-mentioned South African study concluded 
that CD4 cell count did not differ significantly between women who breastfed and those who 
did not (150), which is contrary to the Kenyan where the rate of CD4 cell count decline was 
higher in breast-feeding mothers than in mothers who never breast-fed. However, in that 
Kenyan study, HIV-1 RNA levels did not differ significantly between breast-feeding mothers 
and women feeding their babies with formula (100). Even if the Kenyan study generated many 
questions, it also discussed issues related to the study design and implementation, including 
higher baseline HIV viral load (though statistically non-significant) in the breastfeeding group, 
the differential implementation of follow-up of the study groups (the formula feeding group 
having had more interaction with the clinical team), the smaller number of events of interest, 
and a higher rate of loss to follow-up of up to 18% (99, 100). Given our comparable results to 
other HIV studies, we likewise have to discuss the specific methodological challenges of this 
thesis. 
6.3 Discussion of the research methods  
The design of the 3 papers in this thesis was a cohort-design; however, the cohort was 
established as a phase 3 randomized control trial (RCT), namely the ANRS 12174 trial. An 
RCT is in nature a cohort study with an allocation of an intervention randomly assigned to the 
study population. Thus, using an RCT as a cohort population requires consideration as to the 
success of the trial criteria specific for trials and criteria common for trials and cohort studies.  
The aim of the trial has been to prevent mother-to-child transmission of HIV, thus an HIV-1 
positive population of pregnant women were included. This makes any comparison of 
practices or non-HIV related health outcome, such as BMI, with a HIV-negative population 
of women impossible. HIV-positive women also had a CD4 cell count of >350 cells/µl due to 
the health policies of the countries at the time of intervention. The intervention was not given 
when the mothers were on ART for their own health, which was provided below a threshold 
of 350 cells/µl. Therefore the study population was a selected group of HIV-positive women 
enrolled into the trial cohort from antenatal care screening. Other constraints were a 
willingness to breastfeed, physical characteristics of the baby and informed consent to trial 
participation. One could argue that, given a classical cohort design including HIV-positive 
pregnant women, there would have been a larger variation in population characteristics, such 
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as health status. In that respect, the cohort study of this thesis must acknowledge its restrictive 
selection of participants in its final interpretation.  
On the other hand, the clinical RCT design facilitated rigorous follow-up of the trial cohort, 
given its frequently scheduled events and tracing system in place, which are often not 
affordable in cohort studies. The loss of follow-up was 3.3% in the first paper and 4% in the 
last 2 papers over a period of 50 weeks, which makes the differential loss to follow-up bias 
between participation and non-participation no major concern for interpretation of the 
outcomes. In addition, we used statistical methods (survival analyses, non-proportional hazard 
flexible parametric multiple regression and linear mixed effect models) that coped with the 
issues of missing data, as well as the loss to follow-up.  
Even if the trial intervention was not the exposure of interest in the cohort analysis, a classical 
RCT presentation is interested in whether the intervention is randomly allocated to the study 
population. In the ANRS 12174 trial, randomisation was considered successful, meaning that 
baseline characteristics, such as biomarkers and socio-economic characteristics, were evenly 
distributed between the arms. Therefore, it was unexpected that the lopinavir/ritonavir infant 
prophylaxis was associated with a faster HIV-1 disease progression and increased HIV-1 viral 
load in mothers compared to lamivudine given to the babies. We have no clear explanation for 
this finding at this time.  
The sample size was estimated based on the trial’s outcome of interest, and not for secondary 
outcomes or any cohort study. For the descriptive paper on breastfeeding practices, we are 
confident that the sample size was sufficient as we could estimate the population 
characteristics with high precision. Even if this was the case for the 2 analytical papers where 
we looked at feeding practices as exposure, and nutritional status and elements of HIV 
progression as an outcome, there are concerns over suboptimal sample size as to drawing any 
confident conclusion. There is the possibility of a type 2 error being present. In epidemiology, 
this is the failure to reject the H0 hypothesis when H0 is not true, where H0 indicates no 
association between exposure and outcome. The reason for this concern was that there was 
limited variation in the exposure variable; most women were practicing EPBF and any 
breastfeeding with limited variation, and furthermore the outcome variable also showed 
limited variation. Regression coefficients generally indicated no association. In paper 2, no 
association was seen between feeding practices and women’s BMI, which may be due to non-




practices and mothers’ health, the composite variable as an endpoint was constructed in paper 
3, which reconfirmed the findings in paper 2. Thus, one can be confident from this trial cohort 
that no association existed between feeding practices and the investigated mothers’ health 
outcome; however, type 2 error cannot be ruled out, as mentioned on a more important 
research question on the relationship between the feeding practices and HIV-1 positive 
mothers’ health. 
In addition to design issues, any study has to consider information bias. In this trial cohort, in 
some sites such as Burkina Faso, the nutritional counsellors were also collecting feeding data. 
Therefore, there was a risk of a “Hawthorne effect” or social desirability bias, which is a bias 
occurring when the mothers under-report non-recommended practices while emphasizing the 
recommended ones mainly because they know they are being “observed” (147). However, the 
counsellors were senior staff with considerable experience in research and knew the 
techniques needed to probe participants in obtaining accurate data. Furthermore, the Burkina 
Faso participants had the highest proportion of prelacteal feeding and delayed initiation of 
breastfeeding, which suggests that information bias was limited. Moreover, our findings 
regarding prelacteal feeding practices and breastfeeding initiation time in Burkina Faso are 
comparable with the PROMISE-EBF findings (48), where peer counsellors were not the same 
as the data collectors.  
It is recommended that one considers postpartum weight change, the energy intake, the 
physical activity level and the intentional restriction of energy intake when studying 
breastfeeding and mothers’ health (147). The ideal design for reliable assessment of the 
outcome variable would be a longitudinal study considering a baseline weight measured within 
the first few weeks postpartum, i.e. not too early to allow the evacuation of fluids usually 
retained during the early postpartum period and not too late to catch up the early changes 
associated with the feeding method. Subsequent weights should be measured during a follow-
up period of at least one year. Our trial cohort considered weight separately and BMI only, 
and did not consider energy intake and physical activity. Our baseline BMI was measured on 
day 7 postpartum, which may not have been sufficient time for the women to stabilize their 
weight. The next measurement at 14 weeks was considered too late to provide baseline 
information. The anthropometric data were collected by trained personnel using validated 
equipment which has minimized information and classification bias for nutritional status. The 
validity of the biochemical outcome was very high as the lab procedure were certified.  
 82
As mentioned in discussing the design, there are restrictions to generalisation of the study 
findings. Another challenge with the trial cohort was the fixed time of 50 weeks for provision 
of the infant prophylaxis. This limited the generalisation of the data in particular on ‘any 
breastfeeding’. 
The international multicentre design included participants from countries in West Africa 
(Burkina Faso), East Africa (Uganda) and Southern Africa (Zambia and South Africa). 
Though the study sites inside the participating countries were mostly urban or semi-urban, the 
participants were deemed representative of the target population in Sub-Saharan Africa. One 
could argue that largely rural areas, with a poor infrastructure dominating a large part of 
Africa, are under-represented in this trial cohort. We introduced a socio-economic status (SES) 
variable that was challenging because the study environments in the 4 countries were diverse. 
For this reason we built a country-specific SES variable, since a pooled 4-country index was 
not meaningful. The clinical trial context may have also distorted the SES effect on BMI 
change. However, these issues were less likely to influence the association between EPBF 
duration and BMI change. To deal with the large differences between South Africa and the 
other countries, we stratified the participants into 2 strata, viz. South Africa vs. Burkina Faso, 
Uganda and Zambia. This stratification reduced the sample size in South Africa. Some models 
for South Africa could not converge well enough and the findings regarding the risk factors in 
this country may not reflect the reality. Furthermore, the nutritional, financial (transport costs) 
and technical support provided to all participants in the trial, combined with the relative 
homogeneity in our study population, tended to minimize the effect of disparities in general, 
as also those that were eventually related to food intake and physical activities. The 
participants generally had a good nutritional status (only 50 participants had a BMI of <18.5 
kg/m²), making it representative for that group of women. Therefore we suggest that our results 
can be generalized to all breastfeeding HIV-1 infected and immune-competent mothers in 
similar settings. 
6.4 Implications and recommendations 
Even if the incidence of HIV transmission is reduced, MTCT continues to constitute the major 
reason (90% of all pediatric HIV infection) for the 1.8 million pediatric infections seen 
globally (154). One of the main contributing factors to the HIV incidence decline has been the 




suboptimal coverage and adherence remain challenges to the successful elimination of MTCT 
(76-78). Postnatal transmission still constitutes a large proportion of MTCT, disproportionally 
high in LMICs. Even if postnatal transmission is a major problem, breastfeeding promotion is 
held as one of the most important strategies to increase neonatal and infant survival (136, 156, 
157). 
This thesis supports the interpretation that EBF for 6 months and breastfeeding for a year does 
not harm HIV-1 positive women’s nutritional status or accelerate their HIV-1 disease 
progression. In addition, recommended feeding practices are achievable given sufficient 
support and motivation. One important finding of a systematic review on the association 
between breastfeeding and postpartum weight change has been that the difficulty in assessing 
such a relationship using observational research. “Although the available evidence challenges 
the widely held belief that breastfeeding promotes weight loss”, the authors recommended that 
“more robust studies are needed to reliably assess the impact of breastfeeding on postpartum 
weight management” (148). It is not clear what type of design that can be, because one cannot 
randomize for ethical reasons pregnant women into feeding options not including 
breastfeeding, given today’s knowledge about its benefits. 
Even if there is a progress, there is still a clinical and implementation research needs. The 
ultimate aim is viral suppression in women. The universal treatment program was 
implemented for its programmatic efficiency; however, other strategies may still lead towards 
e-MTCT, but have not yet been operationally tested. One such example is the integration of 
the infant PrEP within existing public health program. This could mitigate the gap in infant 
protection where coverage or adherence to universal treatment program is weak. Other 
opportunities exist with new drug regimens, administration and indication methods, and 
preventive options, all of which would need clinical and implementation research (28, 86, 
158). Even if opportunities exist in HIV research, there is still a need to identify and tackle 
existing bottlenecks in the universal treatment program particularly related to adherence to 
ART regimen and current feeding recommendations. For instance, working women may quit 
breastfeeding too early as they do not manage EBF in the initial phase and fear transmission 
due to earlier messages (159). Other groups that are in need of specific attention are women 
with comorbidities, hard-to-reach groups and child and adolescent parents (160-162). Multi-
disciplinary research is needed to understand and tackle the bottlenecks.  
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Nutritional counselling and monitoring has been on the global agenda since the Alma Ata 
declaration (163). Key strategies have been the baby-friendly hospital initiative in resource-
limited settings. This initiative with its correlated 10 steps to successful breastfeeding is a very 
useful tool to achieve good breastfeeding practices (124). Promotion of breastfeeding and 
improved complementary feeding are 2 main nutritional specific interventions that need full 
implementation. Strategies to successfully deliver these interventions need contextual 
scientific implementation. For example, it is not clear why late initiation of breastfeeding and 
use of prelacteal feeding in Burkina Faso is more frequent both in rural and urban sites (134, 
164). Even if evidence exists that EBF is safe, questions remain about breast milk production 
and composition. This is of particular relevance in situations of undernutrition such as in 
mothers with a BMI < 18.5. To improve breastfeeding practices and achieve the 2025 goal of 
50% of EBF prevalence (165), there remains a need for clinical and implementation science 
in the field of infant feeding. 
High-level policy commitment and broad societal support, national law and social security 
systems need to improve for successful achievement of safe infant feeding practices.  WHO 
recommends 6 months of mandatory paid maternity leave as well as policies that encourage 
women to breastfeed in the workplace and in public (166). This could be equally recommended 
as policies focusing solely on behavioural aspects in the women. 
Finally, a holistic approach is needed in policy adjustment in favour of breastfeeding, to 
embrace the nutritional issue as a whole. As stated by Webb in his publication entitled “Why 
nutrition must feature prominently in the post-2015 Sustainable Development Goals” (167): 
“Poor nutrition doesn’t just represent a lack of nutritious and safe food; it derives from a host 
of interacting processes that link healthcare, education, sanitation and hygiene, access to 
resources, women’s empowerment and more. We know that good nutrition leads to higher 
individual earnings and mental acuity, which in turn support macroeconomic and societal 
growth… good nutrition needs to be understood and positioned as both an input to, and an 
outcome of the success of the SDGs as a whole.” This thesis looked at the breastfeeding 
situation and mothers’ health in the context of HIV in Sub-Saharan Africa; it recommends 






7. Conclusion  
Improved breastfeeding practices as per WHO’s recommendations have been achieved in the 
ANRS12174 clinical trial for the majority of the children. However, late initiation of 
breastfeeding and prelacteal feeding remains important issues that need to be addressed 
specifically during the nutritional counselling to the mothers. In our study, these practices were 
more pronounced in Burkina Faso.  
Breastfeeding did not affect the BMI in HIV-1 infected Sub-Saharan African mothers when 
their CD4 counts were >350 cells/μl. However, a higher baseline BMI and a CD4 cell count 
>500 cells/μl led to an increase in BMI during the EPBF period. Our study showed that 
breastfeeding (exclusive or not) was not a risk factor for the CD4 cell count or HIV-1 viral 
load change, nor for the HIV-1 disease progression. Higher weight and hemoglobin 
concentration at baseline were important factors consistently associated with an improvement 
of the outcome variables at stake including the changes in the mothers’ weight, CD4 cell count, 
HIV-1 viral load or HIV-1 disease progression. A higher education level (secondary school or 
further) was also a factor associated with a better HIV-1 infection status (higher weight, lower 
HIV-1 viral load and slower HIV-1 disease progression). 
There is a need to improve breastfeeding and complementary feeding practices of children, 
particularly those exposed to HIV and anti-retrovirals, taking into account context and socio-
demographic factors. Considering the benefits of breast milk for infants, and the recurrent 
results from different studies elsewhere that breastfeeding does not harm HIV-1-infected 
mothers, this study also supports the WHO 2016 guidelines on infant feeding, which indicates 
that mothers living with HIV should behave like mothers in the general population with regard 
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7.1 Appendix 1. ANRS 12174 schematic trial design  
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7.2 Appendix 2. Flow chart of the study outlining follow-up visits 


























































































Acceptable time shift (days)  1-6 ± 2 ± 4 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 4 ± 4 ± 7 ± 7 ± 7 
Mother visits                 
- Informed consent X X X              
- Eligibility of mother X X X              
- Follow up visits 
Interview (mother )    X X X X X X X X X X X X X 
- Clinical assessment  X  X    X      X   X 
- Infant feeding counselling X X X X X X X X X X X X X X X X 
Lab tests on mother:                 
- HIV-1 serology X                
FBC       X      X    
- CD4 X      X      X    
- Plasma HIV-1 RNA   X    X      X    
- Stored plasma (HIV-1 
genotyping) 
  X  X  X   X   X    
- Breast milk (storage)   X  X  X   X   X    
Infant                 
- Eligibility of infant  X X              
- Randomization   X              
- Clinical assessment,  
AE, SAE & anthropometry  
  X X X X X X X X X X X X X X 
Lab tests on infant:                 
- HIV-1 DNA PCR and stored 
DBS 
 X *  X  X   X   X   X 
 - ALT, FBC**, creat, natremia, 
kalemia,  stored blood 
 X   X     X   X  ** ** 
- Cholesterol, HDL cholesterol, 
LDL cholesterol, triglycerides 
    X        X    
 - Plasma 3TC and LPV/r  X   X        X    
*  Collect 5 spots on DBS card for storage. Only perform HIV DNA PCR if HIV DNA PCR is positive at W6 
 
FBC =  Full blood count 
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Abstract
Background: HIV-1 transmission rates have been reduced over the last decade, an estimated 2 million
new infections per year arise, including 220,000 paediatric cases. The main post-natal HIV exposure is
through breastfeeding, where both its duration and modality (exclusive or not) are associated with
postnatal transmission. The ANRS 12174 trial compared HIV-1 postnatal transmission of 2 prophylaxis drugs
for infants during lactation (lamivudine and lopinavir-ritonavir). Our objective has been to examine the
feeding practices and the determinants of exclusive/ predominant (EPBF) or any breastfeeding among the
participants of this trial in Burkina Faso, South Africa, Uganda and Zambia.
Methods: Mothers infected with HIV-1 and their uninfected offspring were followed from day 7 after
birth for 50 weeks, keeping monthly records of their feeding patterns. Feeding was classified into 3
categories: 1) exclusive breastfeeding during the first six months, only breast-milk being given to infant
for 6 months, 2) predominant breastfeeding, breast-milk with liquid-based items being given, and 3)
mixed feeding, other non-breast milk or solid food being given in addition to breast milk with or without
liquid-based items. The categories were merged into 2 groups: EPBF applying to infants aged <6 months
and mixed feeding applying to infants of any age. The feeding patterns have been given as Kaplan-Meier
curves. A flexible parametric multiple regression model was used to identify the determinants of the
mothers’ feeding behaviour.
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Results: A total of 1,225 mother-infant pairs provided feeding data from Burkina Faso (N = 204), South
Africa (N = 213), Uganda (N = 274) and Zambia (N = 534) between November 2009 and March 2013. The
mean maternal age was 27.4 years and the mean BMI was 24.5. 57.7 and 93.9% of mothers initiated
breastfeeding within the first hour and first day, respectively. Overall, the median durations of any form of
breastfeeding and EPBF were 40.6, and 20.9 weeks, respectively. Babies randomized to the lopinavir/
ritonavir group in South Africa tended to do less EPBF than those in the lamivudine group.
Overall the group of mothers aged between 25 and 30 years, those married, employed or multiparous
tended to stop early EPBF. Mothers living in Uganda or Zambia, those aged between 25 -30 years, better
educated (at least secondary school level), employed or having undergone C-section stopped any
breastfeeding early.
Conclusions: There is a need to improve breastfeeding and complementary feeding practices of children, particularly
those exposed to HIV and anti-retrovirals, taking into account context and socio-demographic factors.
Trial registration: Clinical trial registration: NCT00640263.
Keywords: HIV infection, Exclusive breastfeeding, Vertical transmission, Prevention, Sub Saharan Africa, Risk factors,
Cohort study
Background
Worldwide, there are 2.6 million children <15 years
old living with the Human Immuno-deficiency Virus
(HIV). Mother-to-child transmission of HIV-1
(MTCT) through pregnancy, childbirth and breast-
feeding are the main routes of transmission accord-
ing to estimates made in 2015 through the United
Nations programme on HIV/AIDS (UNAIDS) [1].
Even if transmission rates have been reduced over
the last decade, an estimated 2 million new HIV-1
infections occur per year including 220,000 paediat-
ric cases [1]. Improved prevention of mother-to-child
transmission of HIV-1 (PMTCT) strategies and
programme implementation strengthening are there-
fore needed. Postnatal HIV-1 exposure can be
avoided by replacement feeding, but this has been
detrimental in settings with a high child mortality
[2–4]. Non-breastfed children will also be deprived
of the many known benefits of breastfeeding - better
survival rates, and immunological and nutritional
status [5–9]. Developmental [10] benefits include
bonding of the mother-infant dyad, natural spacing
of pregnancies [11] and cultural acceptability [12].
Mixed feeding seems to be the most risky option
during the first 6 months of life regarding HIV
transmission for infants born to mothers living with
HIV-1 where there is no antiretroviral therapy (ART)
[13–15]. Reasons for mixed feeding include social,
cultural, tradition and individual factors of the
mother [16–19]. Breastfeeding is traditional in Sub-
Saharan Africa, but exclusive breastfeeding (EBF) is
not [16, 19–24]. The prevalence of EBF ranges from
22 to 37% in this region, whereas it is estimated glo-
bally to be 35% [25, 26]. Factors known to negatively
influence the practice of EBF are a) late initiation of
breastfeeding (after one h postnatally), b) not giving
colostrum, and c) provision of pre-lacteal feeds [25, 27, 28].
By giving ART to pregnant or breastfeeding women, post-
natal HIV-transmission can be substantially reduced [29].
For these reasons, the World Health Organization
(WHO) currently recommends HIV-infected pregnant
women to breastfeed when formula is unsafe, i.e. as in
most of Sub-Saharan Africa. At the time of the trial, ex-
clusive breastfeeding for 6 months was recommended
and thereafter, to introduce complementary food while
continuing breastfeeding up to a year or until safe re-
placement feeding could be provided [30]. Potential
strategies included the infant’s protection during the
breastfeeding period, either by ART to the mother (op-
tion B or B+) or peri-exposure prophylaxis to the child
(option A) [29–31]. However, maternal ART does not
entirely eliminate postnatal MTCT, probably because of
the persistence of a residual stable CD4+ T cell-
associated reservoir of HIV-1 in breast milk [32]. Thus
prolonged infant prophylaxis covering the entire rec-
ommended breastfeeding period was tested in the
ANRS 12174 trial [33]. The trial aimed to compare the
efficacy of lopinavir/ritonavir versus lamivudine to pre-
vent the mother to child transmission of HIV-1 during
breastfeeding period. The postnatal transmission rates
were 1.4% (95% confidence interval [CI]; 0.4;2.5) and 1.5%
(CI 0.7;2.5), respectively, in the lopinavir/ritonavir and
lamivudine arms [34]. However, as breastfeeding is the
main post-natal HIV exposure, and because its duration
and modality (exclusive or not) are associated with post-
natal transmission, we examined feeding practices and the
determinants of exclusive and predominant breastfeeding
practices of all participants in this trial.
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Methods
Study design
The ANRS 12174 clinical trial in Ouagadougou (Burkina
Faso), East London (South Africa), Mbale (Uganda) and
Lusaka (Zambia) was conducted from 2009 to 2013. The
protocol and the main outcome have been published
[33, 34]. Briefly, HIV-1 infected pregnant women at the
time ineligible for highly active antiretroviral therapy
(HAART) because their CD4 count was >350 cells/
mm3, aged 18 or above, planning to breastfeed and with
between 28 and 40 weeks of amenorrhea, were identified
from antenatal clinics. They received a pre-test counsel-
ling session before being tested for HIV infection. As
part of the post-test session, they were informed of the
different feeding options available for their babies. Only
women wanting to breastfeed were referred to the re-
search clinic for further assessment of the inclusion cri-
teria during the antenatal period, and again with their
child within 6 days after birth, for an enrolment and
site-stratified randomisation at day 7 postpartum. From
28 weeks of pregnancy to day 7 after birth, program-
matic mother to child transmission prophylaxis was im-
plemented according to national guidelines, but mainly
with antenatal zidovudine, an intrapartum single dose
nevirapine and zidovudine-lamivudine for mothers and
nevirapine for infants for 7 days postpartum. We ex-
cluded twins and triplets, infants positive in the HIV-1
DNA PCR test result at day 7 (±2 days) postpartum, low
birth-weight or ill babies (ranked grade II or above of
the DAIDS classification for adverse events) on the day
of enrolment [35].
The intervention was infant prophylaxis in the breast-
feeding period plus one week from day 7 to 50 weeks of
age with either lopinavir/ritonavir or lamivudine. Lami-
vudine is generally well tolerated and accepted; it has
been widely used in research and programs. Lopinavir/
ritonavir paediatric formulation has been a promising
prophylactic drug with low risks for resistance, high
antiviral potency and a good safety profile [33]. However,
it has poor palatability, which mattered less when intro-
duced very early. Breastfeeding recalls of 24-h and one
week were collected during the enrolment visit at day 7
± 2 days after birth, and the 13 monthly scheduled
follow-up visits starting at week 2. Prelacteal feeding
data (which we defined as any food items except
mothers’ milk given to infants before mothers initiated
breastfeeding) were also collected at enrolment.
Data management and analysis
Data were collected on case report forms or directly en-
tered online using the Electronic Data capture system,
viz. OpenClinica® (https://www.openclinica.com). Based
on the data collected at each visit, we categorized
mothers into one of the following groups: 1) exclusive
breastfeeding (EBF - only breast milk being given to the
infant without any other kind of food or liquid except
medically prescribed drugs or vitamins); 2) predominant
breastfeeding (PBF - breast milk with some liquid-based
food such as juice, tea, sugar-water and salt-water, includ-
ing glucose without any kind of formula or animal milk);
and 3) mixed feeding (MF - breast milk with other solid
or other kind of milks with or without liquid-based food).
We thereafter combined EBF and PBF into one group
called “exclusive and predominant breastfeeding” (EPBF)
as PBF presented few cases and was assessed to present
the same risk than EBF at least with regard to postnatal
HIV transmission [15]. The entire cohort was in this EPBF
group at the beginning of the study and were followed up
to detect any change to mixed feeding or non-
breastfeeding by week 26 post-partum, the time when it is
recommended to change from exclusive breastfeeding to
complementary feeding. Any breastfeeding was defined as
women breastfeeding whatever the pattern (exclusive, pre-
dominant or mixed feeding). Any breastfeeding applied
during the whole duration of the study from day 7 to week
50 and was opposed to non-breastfeeding. We have also
included women who stopped breastfeeding and eventu-
ally resumed it. We determined the number and mean
duration of the periods with resumed breastfeeding be-
tween day 7 and week 50 postpartum.
For continuous variables, the median with inter-
quartile range (IQR) were reported, and percentages for
categorical variables. Comparison across categorical vari-
ables was done using the Chi-squared test. We described
the participants’ feeding patterns using Kaplan-Meier
survival curves for each country. The censoring date was
the date of the child’s death, discontinuation, the last
EPBF date or 22 weeks for those who completed the
study without reporting any mixed feeding. The exit date
for survival analysis was set at week 22, since prior to
this time-point any stopping of EPBF was assumed to be
participant-driven whereas at week 26 or later, it was
induced by the trial requirements.
We also explored potentially modulating factors asso-
ciated with early cessation of EPBF, as well as the early
weaning before 50 weeks in a non-proportional hazard
flexible parametric multiple regression analysis with dur-
ation of EPBF, or any breastfeeding as continuous vari-
ables using the “stpm2” command in Stata [36, 37].
Variables with a p ≤ 0.20 in the bivariate analysis were
considered for the multivariate analysis in the pooled-
data analysis of all the countries. Other covariates
included the trial arm, trial country and the maternal
age in 3 age groups (<25 years, 25 to 30 and 30+). The
rest of the covariates were used as dichotomised vari-
ables (single vs. married or co-habiting, primi- vs. mul-
tipara, vaginal vs. caesarean section delivery, primary vs.
secondary school or higher, breastfeeding initiation in
Somé et al. International Breastfeeding Journal  (2017) 12:22 Page 3 of 12
time within the first hour postpartum vs. later. We also
presented a country-specific analysis catering for con-
textual variation in factors associated with the feeding
behaviour of the neonates. Since South Africa has a dif-
ferent socio-economic and cultural context, we stratified
the data by creating 2 models - South Africa alone, and
Uganda and Zambia together. Burkina Faso was ex-
cluded from these analyses due to the very small num-
bers of observations (women initiating mixed feeding in
the study period before week 26). The same list of vari-
ables was used in the country-specific analysis regardless
of the p-value in the bivariate analysis. Statistical analysis
was done using STATA/SE 13.1 (4905 Lakeway Drive
College Station, Texas 77845 USA).
Ethics consent and permissions
Prior to enrolment, the mothers signed a written in-
formed consent and assent form for themselves and
their children, respectively. The trial was conducted ac-
cording to the sponsor (ANRS) ethic charter, Good Clin-
ical Practices and the principles of the Helsinki
declaration. The protocol was approved by the relevant
ethics committees in the four participating countries and
the Medicines Control Council in South Africa.
Results
Baseline characteristics and feeding patterns
In the ANRS 12174 trial, 1,273 mother-infant pairs were
randomized, of which 6 were excluded due to protocol
violation. Of the remaining 1,267 participants, 204 were
from Ouagadougou, 222 from East London, 278 from
Mbale and 563 from Lusaka. Another 42 were excluded
from analysis due to lack of breastfeeding data after in-
clusion (Fig. 1). Trial profile.
The mothers excluded from analysis tended to be
younger (mean age 25 vs. 27 years), have better educa-
tion and fewer children. Regarding baseline characteris-
tics, South African mothers had the highest body mass
index (BMI), and Ugandan mothers the highest number
of children (Table 1).
Breastfeeding was initiated within 1 h and on the first
day postpartum by 57.7% and 93.9% of mothers, respect-
ively (Table 2), and 99% had started any breastfeeding
within the first week (Table 3). The main reason for de-
layed initiation of breastfeeding was reported as a lack of
breast milk. EBF, PBF and MF were practiced by 95.9, 1.6
and 1.5%, respectively, in the first week (Table 3). Water-
based liquids were the most common prelacteal items
(6.2% of the participants) during this week (Table 4).
The median duration of any breastfeeding was
40.6 weeks (interquartile range (IQR; 32.3; 45.4; Table 5).
Burkina Faso had the longest median duration and
South Africa the shortest. The median duration of EBF
was 20.9 (IQR: 19.1; 21.1) weeks. PBF was reported only
during 59 monthly visits (4/1000 person-year). When
PBF was combined with EBF, the overall median dur-
ation remained the same (20.9; IQR: 19.7; 21.1).
At week 22, EPBF was practiced by 90.7, 48.8, 79.6 and
83.1% in Burkina Faso, South Africa, Uganda and Zambia,
respectively (Fig. 2 and Additional file 1). Nevertheless at
week 22 there was no significant difference between the
trial arms (p = 0.05, log rank test; in the lopinavir/ritonavir
arm, 70.3% practiced EBF vs. 69.1% in the lamivudine arm).
At week 50, 11.8, 4.7, 2.5 and 3.2% of the mothers
were continuing to breastfeed in Burkina Faso, South
Africa, Uganda and Zambia, respectively (Fig. 3).
The details of the food items that the infants received
are set out in detail in Table 4 (first week) and in the
Additional files 2, 3 (first year). There were major coun-
try differences in prelacteal feeds (Table 4). In the first
3 days of life, water-based items (including water, water
and sugar or glucose, water and salt, cow’s milk, infant
formula and traditional beverages) were given to 24,
12.5, 4.7 and 1% of the children in Burkina Faso,
Uganda, South Africa and Zambia, respectively. After
the first week of life (Additional file 2, 3), milk items
were mainly used in South Africa, Uganda and Zambia.
Porridge or cereals were were introduced at week 10 and
18 in Zambia and Uganda, respectively while in Burkina
Faso they were used from week 26. Soup, meat, fish or
egg were introduced as early as week 18 in South Africa,
Uganda and Zambia while these items were first seen in
infant’s food only at week 26 (0.5% for meat, fish or egg)
in Burkina Faso (additional file 2c). After cessation of
breastfeeding, 62 (5.1%) of 1225 mothers (25 (11.7%), 20
(7.3%) and 17 (3.2%) in South Africa, Zambia and
Uganda, respectively) resumed breastfeeding. In total, 54
(4.4%) mothers resumed breastfeeding once and stopped
breastfeeding permanently, and 8 (0.6%) resumed it
twice. The mean duration of all periods with resumed
breastfeeding was 17.2 days, and in calculating this mean,
we disregarded 5 women who had resumed breastfeeding
of long duration (mean duration of 108.2 days) and were
characterized as outliers. The mean duration of these
periods with resumed breastfeeding for mothers who
resumed once was 18.2 days (i.e. without these 5 women),
14.9 and 13.2 days for the first and second period,
respectively, for those who resumed twice. We did not
find any difference between the women who stopped
breastfeeding earlier (before 26 weeks) and resumed it
and those who stopped it later (after 26 weeks).
Risk factors analysis
Almost all the Burkina Faso mothers continued EPBF be-
yond 22 weeks after birth. We therefore removed them
from the pooled multivariable analysis on risk factors for
stopping EPBF (Additional file 2: Table S6). The groups of
mothers significantly more at risk to stop EPBF before
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Fig. 1 Study flow-chart
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26 weeks in the remaining 3 countries were the 25-30
year-old married, employed, and multiparous mothers, or
those in the lopinavir/ritonavir arm. On the other hand,
Ugandan and Zambian women were more likely to con-
tinue EPBF until 26 weeks than South African women.
The behaviour of South African women to stop EPBF
early affected the overall analysis, showing that the lopina-
vir/ritonavir arm was a risk factor in this situation.
With regard to any breastfeeding, Burkina Faso was
once again dropped from the multivariate analysis of the
determinants. The survival curve (Fig. 3) of any breast-
feeding by country shows a dramatic drop of the South
African curve from the beginning until around week 40.
From week 40, the remaining South African mothers
tended to breastfeed longer than those mothers in the
other countries. Having completed secondary school or
beyond was an independent risk factor for early cessa-
tion of any breastfeeding (Additional file 2: Table S6).
In the country-specific analyses (Additional file 2:
Table S7a), there were in general no large differences in
the infant feeding behavior, except for South Africa
where there was an interaction with trial allocation.
Children in the lopinavir/ritonavir group were 3 times
more likely to stop EPBF early than children from the
lamivudine group. In Uganda and Zambia, the trial drug
had no significant influence on infant feeding behavior.
Table 1 Study participants’ baseline characteristics
Burkina Faso South Africa Uganda Zambia All sites
N = 204 N = 213 N = 274 N = 534 N = 1225
n (%) n (%) n (%) n (%) n (%)
Age group
<25 years 54 (26.5) 73 (34.3) 107 (39.0) 200 (37.8) 434 (35.6)
25 – 30 years 75 (36.8) 67 (31.5) 97 (36.1) 175 (33.1) 414 (34.1)
30 and above 75 (36.8) 73 (34.3) 68 (24.8) 154 (29.0) 370 (30.3)
Literacy rate 103 (50.5) 211 (99.1) 261 (95.3) 487 (91.2) 1062 (86.7)
Education level (%)
Primary school 155 (76.0) 19 (0.5) 176 (15.7) 249 (18.7) 599 (13.0)
Secondary school and higher 49 (24.0) 194 (91.1) 98 (35.7) 285 (53.4) 626 (51.1)
Occupation: employed 18 (8.8) 89 (41.8) 97 (35.4) 92 (17.2) 296 (24.2)
Married/co-habiting 185 (90.7) 83 (38.0) 225 (82.1) 473 (88.6) 966 (78.9)
Primiparous 44 (21.6) 71 (33.3) 49 (17.9) 112 (21.0) 276 (22.5)
Surgical breast history 8 (3.9) 1 (0.5) 8 (2.9) 1 (0.2) 18 (1.5)
Mother’s HIV stage 1 190 (93.1) 210 (98.6) 253 (92.3) 533 (99.8) 1184 (96.6)
Facility delivery 200 (98.0) 211 (99.1) 212 (77.4) 518 (97.0) 1141 (93.1)
Vaginal delivery 191 (93.6) 139 (65.3) 256 (93.4) 514 (96.2) 1100 (89.8)
Female infant 86 (42.2) 105 (49.3) 144 (52.5) 259 (48.5) 594 (48.5)
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Mean BMI 23.8 (23.2; 24.3) 28.3 (27.5; 29.0) 23.0 (22.6; 23.4) 24.1 (23.7; 24.4) 24.5 (24.3; 24.8)
Mean number of children 2.8 (2.6; 3.0) 2.0 (1.9; 2.2) 3.5 (3.3; 3.7) 2.6 (2.5; 2.7) 2.7 (2.7; 2.8)
Table 2 Time to initiation of breastfeeding after birth
Hours Burkina Faso South Africa Uganda Zambia All sites
N = 204 N = 213 N = 274 N = 534 N = 1225
n (%) n (%) n (%) n (%) n (%)
0-1 14 (6.9) 109 (51.2) 152 (55.5) 432 (80.9) 707 (57.7)
2-5 73 (35.8) 85 (39.9) 76 (27.7) 74 (13.9) 308 (25.1)
6-12 54 (26.5) 10 (4.7) 32 (11.7) 22 (4.1) 118 (9.6)
12-24 4 (2.0) 3 (1.4) 6 (2.2) 4 (0.7) 17 (1.4)
Total initiated 1st day 145 (71.1) 207 (97.2) 266 (97.1) 532 (99.6) 1150 (93.9)
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Contrary to any breastfeeding, having a secondary
school or higher education level was beneficial for EPBF
practice, allowing up to 40, 60 and 40 of babies to bene-
fit from EPBF in South Africa, Uganda and Zambia, re-
spectively. However, this association was significant only
for Zambian children. Being married or living as a
couple was a risk factor for shorter EPBF, with a signifi-
cant adjusted hazard ratio (AHR) of 1.6 (95% CI: 1.2;
2.1) and 2.6 (95% CI: 1.9; 3.6) in South Africa and
Zambia, respectively. A similar pattern was observed
with employed mothers and multiparous mothers. Late
initiation of breastfeeding (after 1 h) was associated with
shorter EPBF in Uganda and Zambia.
Discussion
In general, the mothers in this trial adhered to the breast-
feeding recommendations: 58% initiated breastfeeding
within the first hour and 94% within the first day. EPBF
was practiced at a high rate in all countries throughout
the 22-week period. This performance can probably be
Table 3 Feeding pattern during the first week of life by country
Breast feeding pattern Burkina Faso South Africa Uganda Zambia All sites
N = 204 N = 213 N = 274 N = 534 N = 1225
n (%) n (%) n (%) n (%) n (%)
Any breastfeeding first 3 days 200 (98.0) 206 (96.7) 272 (99.3) 532 (99.6) 1210 (98.8)
Any breastfeeding day 4-7 202 (99.0) 205(96.2) 273 (99.6) 533 (99.8) 1213 (99.0)
Exclusive breastfeeding throughout first 3 days 156 (76.5) 199 (93.4) 250 (91.2) 528 (98.9) 1133 (92.5)
Exclusive breastfeeding throughout days 4-7 177 (86.8) 200 (93.9) 266 (97.1) 532 (99.6) 1175 (95.9)
Predominant breastfeeding throughout first 3 days 34 (16.7) 2 (0.9) 18 (6.6) 1 (0.2) 55 (4.5)
Predominant breastfeeding throughout days 4-7 15 (7.3) 4 (1.9) 1 (0.4) 0 (0.0) 20 (1.6)
Mixed feeding first 3 days 10 (4.9) 5 (2.3) 4 (1.5) 3 (0.6) 22 (1.8)
Mixed feeding day 4-7 10 (4.9) 1 (0.5) 6 (2.2) 1 (0.2) 18 (1.5)
Table 4 Proportion of infants receiving different food items during the first week of life by country
Nutrient or other intake Burkina Faso South Africa Uganda Zambia All sites
N = 204 N = 213 N = 274 N = 534 N = 1225
n (%) n (%) n (%) n (%) n (%)
Days 1 to 3
Breast milk 200 (98.0) 206 (96.7) 272 (99.3) 532 (99.6) 1210 (98.8)
Water 34 (16.7) 5 (2.3) 12 (4.4) 0 (0.0) 51 (4.2)
Water + sugar or glucose 6 (2.9) 0 (0.0) 15 (5.5) 0 (0.0) 21 (1.7)
Water + salt 0 (0.0) 0 (0.0) 4 (1.5) 0 (0.0) 4 (0.3)
Juice 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.2) 2 (0.2)
Cow’s milk 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 1 (0.1)
Infant formula 2 (1.0) 4 (1.9) 0 (0.0) 3 (0.6) 9 (0.7)
Liquid as part of traditional practice 6 (2.9) 1 (0.5) 3 (1.1) 0 (0.0) 10 (0.8)
Other 2 (1.0) 0 (0.0) 2 (0.4) 0 (0.0) 3 (0.2)
Days 4 to 7
Breast milk 20 2(99.0) 205 (96.2) 273 (99.6) 533 (99.8) 1213 (99.0)
Water 19 (9.3) 4 (1.9) 1 (0.4) 0(0.0) 24 (2.0)
Water + sugar or glucose 1 (0.5) 1 (0.5) 1 (0.4) 0 (0.0) 3 (0.2)
Tea 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
Juice 3 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.2)
Infant formula 1 (0.5) 0 (0.0) 1 (0.4) 1 (0.2) 3 (0.2)
Powdered milk 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
Liquid as part of traditional practice 6 (2.9) 1 (0.5) 3 (1.1) 0 (0.0) 10 (0.8)
Other 3 (1.5) 0 (0.0) 1 (0.4) 0 (0.0) 4 (0.3)
Somé et al. International Breastfeeding Journal  (2017) 12:22 Page 7 of 12
attributed to the study design, including close tracking
of the mothers during the antenatal period and fre-
quent follow-up visits with infant feeding counselling.
The median durations of any and exclusive breastfeed-
ing were 40.6 and 20.9 weeks, respectively. At week 22,
>75% of the children were on EPBF. Only 4.7% were
breastfed at week 50.
In other recent studies of both the general population
and mothers living with HIV, findings showed that the
proportion of women initiating breastfeeding within the
first hour postpartum was between less than half and
76% [18, 38–40]. However, with respect to our study, the
country having the lowest percentage of women initiat-
ing breastfeeding within the first hour was Burkina Faso
(only 6.9%).
Under 10% of the participants in this trial gave pre-
lacteal feeds compared to 22 to 57% in other studies
[18, 20, 39, 40]. Burkina Faso had the highest propor-
tion of women giving prelacteal feeds (>16%). The same
feeding patterns were found in the PROMISE-EBF
study in Burkina Faso site with <4 and 11% of partici-
pants initiating breastfeeding within the first hour and
giving prelacteal feeding, respectively [41]. In Burkina
Faso, however, women breastfed longer compared to
the other countries, for which we have no clear explan-
ation. Our hypotheses are that the tradition through a
cultural influence, better counselling sessions and a
poorer economic context that could be accompanied
with difficulties in affording quality complementary
food for children, may have been important factors.
More mothers in South Africa (and to some extent in
Zambia) had to resume formal work after a few months,
preventing them from continuing breastfeeding.
In the Kesho Bora study [42], the participants from
Burkina Faso had a considerably lower level of educa-
tion, than in our study. In contrast to our study, South
Africa had the longest median duration of any breast-
feeding compared with Burkina Faso and Kenya. The
proportion of women initiating breastfeeding in the first
week and the median duration of any breastfeeding were
higher in our study (99% and 41 weeks vs. 70% and
20 weeks, respectively). Likewise, the Kesho Bora study
had a lower proportion of EBF (22% at 5 months) com-
pared to our study (75.3% at 5 months). Even comparing
the countries that participated in both the Kesho Bora
and our trial (Burkina Faso and South Africa), the exclu-
sive breastfeeding rate was higher in our study. In other
EBF studies with contexts similar to this trial, the
Table 5 Median duration of “any breastfeeding”, “exclusive breastfeeding” and “exclusive and predominant breastfeeding” in weeks
Feeding patterns Burkina Faso South Africa Uganda Zambia All sites
N = 204 N = 213 N = 274 N = 534 N = 1225
Median (p25; p75) Median (p25; p75) Median (p25; p75) Median (p25; p75) Median (p25; p75)
Any breastfeeding 46.5 (45.0; 48.7) 29.1 (13.0; 46.3) 39.9 (34.1; 43.0) 39.0 (33.0; 43.6) 40.6 (32.3; 45.4)
Exclusive breastfeeding 20.7 (18.9; 21.3) 19.5 (12.4; 21.0) 20.9 (19.6; 21.0) 21.0 (20.4; 21.1) 20.9 (19.1; 21.1)
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Fig. 2 Kaplan-Meier survival curve by country for exclusive and predominant breastfeeding until week 26 post-partum
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median durations of EBF varied from 1.8 [43] to
5 months [38, 43, 44] and the proportion of EBF at
6 months ranged from zero percent to 84% [18, 20, 42,
43, 45, 46]. Therefore one has to acknowledge the high
variability of infant feeding practices in sub-Saharan Af-
rica among HIV-positive women. In general, the
ANRS12174 participants adhered to a large extent to the
WHO HIV and infant feeding recommendations. The
trial setup and the frequent counselling is the most likely
explanation for that; thus, it is possible that frequent
quality counselling is required for the promotion of the
safe infant feeding practices among HIV-1 positive
women.
Interestingly, the trial allocation was a factor associ-
ated with breastfeeding behaviour, but only in South
Africa where the lopinavir/ritonavir group had a 3 times
higher risk of shorter EPBF compared to the lamivudine
group. It is possible that the poor palatability of lopina-
vir/ritonavir influenced the South African participants to
stop EPBF earlier than recommended. Why this hap-
pened only in South Africa is unclear, but formula-
feeding is more common in South Africa, which may be
one explanation. It is also possible that, due to the bad
taste, women in South Africa mixed the drug with other
foods than milk, unlike women in Uganda and Zambia
where they mixed it with breastmilk.
Our findings together with the ANRS 12174 trial
results [34] demonstrated enough that breastfeeding
in HIV-1 infected women could be almost as safer as
in HIV-1 uninfected mothers for the infants, provided
it is practised according to the international recom-
mendations. However, it is currently commonly ac-
cepted to breastfeed babies born to HIV-1 infected
mothers while the peri-exposure prophylaxis is as-
sured by the mothers taking lifelong anti-retroviral
medicines (option B+). Nonetheless, the efficacy dem-
onstrated for the option A in our studies required
some reflections on how to combine all these options
for an improved PMTCT strategy as we know that
some HIV reservoirs (including in breastmilk) [32]
are not fully controlled by the mother’s HAART. In
the other hands, some mothers may not be able to
afford or to take HAART.
There are certain limitations to our study. In some
sites, including Burkina Faso, the nutritional counsellors
were also collecting feeding data; therefore, there was a
risk for the mothers to under-report non-recommended
practices while emphasizing the recommended ones.
However, the counsellors were senior staff with consid-
erable experience in research and knew the techniques
needed to probe participants to obtain accurate data.
Furthermore, the Burkina Faso participants had the
highest proportion of prelacteal feeding, delayed initi-
ation of breastfeeding, among other items, which sug-
gests that information bias was limited. Moreover, our
findings regarding prelacteal feeding practices and
breastfeeding initiation time in Burkina Faso are com-
parable with PROMISE-EBF findings [41], where peer
counsellors were not the same as the investigators who
collected the data.
Other potential limitations are the trial context with a
fixed time of 50 weeks for provision of the infant
prophylaxis, which limits the generalisability of our data
particularly on ‘any breastfeeding’, and the selection
criteria that may not allow any extrapolation of the re-
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Fig. 3 Kaplan-Meier survival curve by country for any breastfeeding until week 50 post-partum
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sample size, the long duration of our follow-up, the
international multicentre design, as well as the stringent
randomised clinical trial context and the cohort design,
added value and accuracy to our findings.
Conclusion
ANRS 12174 trial participants were relatively more
successful in practicing EPBF than has been seen in sev-
eral previous studies. However, in Burkina Faso, late initi-
ation of breastfeeding postpartum and the extensive use
of prelacteal feeds remain prevalent. Why women in the
lopinavir/ritonavir arm were more likely to stop EPBF in
South Africa is a question requiring further investigation.
There is a need to improve breastfeeding and complemen-
tary feeding practices of children, particularly those ex-
posed to HIV and anti-retrovirals, taking into account
context and socio-demographic factors.
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Breastfeeding is recommended for infants born to HIV-infected women in low-income set-
tings. Both breastfeeding and HIV-infection are energy demanding. Our objective was to
explore how exclusive and predominant breastfeeding changes body mass index (BMI)
among breastfeeding HIV1-positive women participating in the ANRS12174 trial (clinical
trial no NCT0064026).
Methods
HIV-positive women (n = 1 267) with CD4 count >350, intending to breastfeed HIV-negative
infants were enrolled from Burkina Faso, South Africa, Uganda and Zambia and counselled
on breastfeeding. N = 1 216 were included in the analysis. The trial compared Lamivudine
and Lopinavir/Ritonavir as a peri-exposure prophylaxis. We ran a linear mixed-effect model
with BMI as the dependent variable and exclusive or predominant breastfeeding duration as
the key explanatory variable.
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Results
Any breastfeeding or exclusive/predominant) breastfeeding was initiated by 99.6% and
98.6% of the mothers respectively in the first week after birth. The median (interquartile
range: IQR) duration of the group that did any breastfeeding or the group that did exclusive
/predominant breastfeeding were 9.5 (7.5; 10.6) and 5.8 (5.6; 5.9)) months, respectively.
The median (IQR) age, BMI, CD4 count, and HIV viral load at baseline (day 7) were 27
(23.3; 31) years, 23.7 (21.3; 27.0) kg/m2, 530 (432.5; 668.5) cells/μl and 0.1 (0.8; 13.7)1000
copies/mL, respectively. No major change in mean BMI was seen in this cohort over a 50-
week period during lactation. The mean change between 26 and 50 weeks after birth was
0.7 kg/m2. Baseline mean BMI (measured on day 7 postpartum) and CD4 count were posi-
tively associated with maternal BMI change, with a mean increase of 1.0 kg/m2 (0.9; 1.0) per
each additional baseline-BMI kilogram and 0.3 kg/m2 (0.2; 0.5) for each additional CD4 cell/
μl, respectively.
Conclusion
Breastfeeding was not negatively correlated with the BMI of HIV-1 infected Sub-Saharan
African mothers. However, a higher baseline BMI and a CD4 count >500 cells/μl were asso-
ciated with maternal BMI during the exclusive/ predominant breastfeeding period. Consider-
ing the benefits of breast milk for the infants and the recurrent results from different studies
that breastfeeding is not harmful to the HIV-1-infected mothers, this study also supports the
WHO 2016 guidelines on infant feeding that mothers living with HIV should breastfeed
where formula is not safe for at least 12 months and up to 24 months, given that the right
treatment or prophylaxis for the infection is administered. These findings and conclusions
cannot be extrapolated to women who are immune-compromised or have AIDS.
Introduction
HIV infection is among the leading causes of mortality among women of childbearing age [1].
It will be associated with an increased risk of infections from non-obstetric and direct obstetric
causes, making HIV-infected mothers more vulnerable than uninfected mothers [2,3]. HIV in
pregnancy contributed to high maternal mortality rates with a 9% contribution in Sub-Saharan
Africa (SSA) between 1990 and 2008. It is the leading cause of death during pregnancy and the
postpartum period in countries with a high prevalence of HIV [4,5]. A recent meta-analysis
pointed out clearly the significance of HIV infection in global maternal mortality rates, with
an estimated 5% pregnancy-related deaths worldwide and 25% in SSA [6]. The reasons of this
high mortality in HIV-infected women are unclear. The risk of obstetric complications may be
increased in HIV-infected women or pregnancy might accelerate HIV progression [6–8].
Weight loss and low body mass index (BMI) can serve as markers of HIV disease progres-
sion. Weight has been used to diagnose clinical AIDS disease; a 10% weight loss in the absence
of any other evident cause was one of the early WHO clinical criteria in areas without laborato-
ries [9–13]. Individuals with asymptomatic HIV need an extra 10% energy intake to maintain
body weight, which increases to 20–30% among those who have symptomatic HIV [14,15].
Moreover during pregnancy and lactation, the woman’s body in a normal physiological state
undergoes massive energy trade-off seen through weight changes, typically an increase during
pregnancy and a loss to pre-pregnancy weight during lactation [16,17].
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There has been a dilemma during the last 20 years in choosing between exclusive breast-
feeding (EBF) and replacement feeding [18], which was only considered on the basis of the
best nutritional and survival outcome for the infant. Specifically, in the pre-ART period the
focus was on ensuring the HIV-free survival of infants exposed to HIV.However, in socio-eco-
nomically deprived settings, breastfeeding has proven to be a key survival strategy for infants
born to women living with HIV because increased morbidity and mortality have been associ-
ated with replacement feeding [19]. After 2010, availability of, and accessibility to, antiretrovi-
ral drugs during pregnancy and lactation have increased. The programs of prevention of
mother-to-child transmission (PMTCT) of HIV yielded 2 antiretroviral (ARV) prophylaxis
options, including regimen A (prophylactic ARV drugs are given to the mothers and children
during the risk period); and regimen B (antiretroviral therapy is given to the mothers during
the risk period), or regimen B+ (extending regimen B to lifelong treatment) [20]. In the
WHO’s 2010 recommendations, women living with HIV who opted to breastfeed were recom-
mended to practice exclusive breastfeeding (EBF) until the infant was 6 months old, introduce
appropriate complementary foods thereafter, and continue breastfeeding for the first 12
months of the infant’s life. The 2016 recommendations recommend mothers living with HIV
to prolong the breastfeeding period to up to 24 months, as advised for the general population
(i.e. HIV-uninfected women). The importance of having a nutritionally adequate and safe diet
for the child, a lifelong ARV therapy, with adherence counselling and support for breastfeed-
ing for the mothers, is stressed as a prerequisite before breastfeeding can be gradually stopped.
Thus, option B+ has made it easier for countries to opt for exclusive breastfeeding for 6
months as the preferred early child feeding option [21–23].
Regarding the mother’s health, studies have reached inconsistent conclusions as to the
effect of breastfeeding on the weight of those infected with HIV [14,24,25]. The South African
Vertical Transmission Study that compared women practicing EBF compared to those opting
for replacement feeding or mixed feeding concluded that a) HIV-infected and uninfected
mothers experienced similar weight loss over 24 months; and b) postpartum weight change
was not associated with feeding practices for the first 5 months of the baby’s life. [14]. In this
study, the mothers received a single-dose of nevirapine as PMTCT treatment. The Kesho Bora
study, a combination of a randomized clinical trial and a prospective cohort study, comprised
3 parts: part IA included women with CD4 count <200 cells/mm3, receiving Zidovudine
(AZT), lamivudine and nevirapine (NVP) twice daily; part IB included women with CD4
count>500 cells/mm3, receiving AZT 300 mg taken by the mother twice daily starting from
34 to 36 weeks of pregnancy until the onset of labor, plus one 600 mg dose of AZT and one
200 mg dose of NVP at the onset of labor; and part II or the RCT part, included women with a
CD4 count between 200 and 500 cells/mm3, randomized to receive the same prophylaxis as
part IB or triple-ARV prophylaxis (AZT [300 mg], 3TC [150 mg] and lopinavir/ritonavir
[LPV/r, 400 mg/100 mg]) twice daily from 34 to 36 weeks of pregnancy, through delivery and
during breastfeeding to a maximum of 6 months postpartum [26]. It showed that 6 months of
breastfeeding was not detrimental to the weight of well-nourished HIV-infected mothers [24].
A study in Zambia randomized women into a short-duration (4 months EBF and abrupt
weaning) and a long-duration (mean duration of 16 months including 6 months EBF) breast-
feeding period; it showed a net weight gain in HIV-infected women breastfeeding from 4 up to
24 months postpartum [27]. All mothers in the Zambian study were categorized into low
(350 cells/μl) and high (>350 cells/ μl) CD4 count groups. The subjects had received a sin-
gle-dose nevirapine as MTCT prophylaxis. When antiretroviral treatment became available in
May 2004, 26 women were started on the first-line regimen. CD4 count was associated with
lower weight. Effects of lactation in women with low CD4 counts were similar to the effects in
women with higher CD4 counts. In contrast, two Kenyan studies [28,29] found weight loss
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among HIV-infected breastfeeding mothers compared to mothers using formula feeding.
Though the design of these studies made a comparison difficult with the precedent studies.
they were worse in showing adverse outcomes due to breastfeeding, which included more
maternal deaths. These studies in Nairobi, representing two different analyses of the same
data, compared mothers who breastfed from delivery until 2 years of age to formula-feeding in
a cohort study where all the pregnant women received a short course of zidovudine prophy-
laxis. When antiretroviral treatment became available, women were referred to highly active
antiretroviral treatment programs.
HIV infection also seems to be detrimental to maternal hemogloblin concentration [30,31],
which could be worsened by the use of some antiretroviral substances [32–34]. Our aim was
therefore to explore within the ANRS12174 trial population how breastfeeding might change
BMI and hemoglobin concentration. We also assessed other factors that might have influenced
weight changes of HIV-infected mothers during lactation.
Methods
Study design
The ANRS 12174 clinical trial in Ouagadougou (Burkina Faso), East London (South Africa),
Mbale (Uganda) and Lusaka (Zambia) was conducted from 2009 to 2013, the protocol and the
primary analysis having been published [35,36]. Briefly, pregnant women who tested positive
for HIV-1 infection in the context of routine antenatal clinic service making them ineligible
for highly active antiretroviral therapy because their CD4+ count was>350 cells/ml, who had
to be at least 18 years old and who were planning to breastfeed, were identified at antenatal
clinics between 28 and 40 weeks of pregnancy. They received a pre-test counselling session
before testing for HIV infection. As part of the post-test session, they were informed of the dif-
ferent feeding options for their babies. Only women intending to breastfeed were referred to
the research clinic for further assessment of the inclusion criteria during the antenatal period,
and again with their child within 6 days after birth, for enrolment and randomisation at day 7
postpartum. From 28 weeks of pregnancy to day 7 after birth, programmatic mother-to-child
transmission prophylaxis was followed with antepartum zidovudine, intrapartum single dose
nevirapine, and zidovudine-lamivudine for mothers and nevirapine for infants for 7 days post-
partum. The intervention implemented during the trial was infant prophylaxis in the breast-
feeding period starting from 7 days to 50 weeks of age with either lopinavir/ritonavir or
lamivudine. Twins and triplets, infants with a positive HIV-1 DNA PCR test result at day 7
(+/- 2) postpartum, and low birth-weight or ill babies (ranked grade II or above of the ANRS
classification for adverse events) on the day of enrolment were excluded [37].
Lamivudine, generally well tolerated and accepted, has been widely used in research and
clinical trials. The lopinavir/ritonavir paediatric formulation has been a very promising pro-
phylactic combination with low risks for resistance, high antiviral potency and a good safety
profile [35]. However, it is known to be distasteful (https://www.medicines.org.uk/emc/
medicine/4602; https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf),
which was thought to matter less when introduced very early.
Data management and analysis
Data were collected on a paper case-report form or directly entered online using the Electronic
Data capture system OpenClinica™ (www.openclinica.com). Twenty-four hours and one week
breastfeeding recalls were collected during the enrolment visit on day 7 (±2) after birth and
during the 13 monthly-scheduled follow-up visits that started at week 2. During these visits,
mothers were particularly asked if they gave their infants other foods/liquids in addition to
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breastmilk. Pre-lacteal feeding data which was defined as any food item except mothers’ milk
given to infants before initial breastfeeding) were also collected at the enrolment visit. The data
were collected by trained physicians, pharmacists, biologists and counsellors. Seca-brand scales
and stadiometers were used to measure the mother’s height and weight. Weights were rounded
to the nearest 10 grams and the height at the nearest millimetre. Weight and height were mea-
sured twice based on the WHO guidelines (http://www.who.int/childgrowth/training/en/).
We categorized mothers at each visit into the following groups: 1) exclusive breastfeeding,
EBF (only breastmilk being given to the infant without any other kind of food or liquid, except
medically prescribed drugs or vitamins); 2) predominant breastfeeding, PBF (breastmilk with
some liquid-based food, such as juice, tea, sugar-water and salt-water including glucose with-
out any kind of formula or animal milk); and 3) mixed feeding, MF (breastmilk with other
solid or liquid-based food, including other kinds of milk). We thereafter combined EBF and
PBF into one group called “exclusive and predominant breastfeeding” (EPBF) because the
number of women who practised PBF was too small and the practice was occasional. The
entire cohort was in this latter group at the beginning of the study, which was followed up to
detect any change in EPBF status, i.e. change to mixed feeding by week 26 post-partum, which
is the time when exclusive breastfeeding is supposed to be changed to complementary feeding.
Data on maternal dietary intake were not collected
In a bivariate analysis, we compared the mean BMI at weeks 14, 26, 38 and 50 with the
mean BMI at day 7 (baseline) post-delivery using Bonferroni-corrected paired t-tests for multi-
ple comparisons. Data were presented for all 4 sites, by country and baseline BMI groups.
Group 1 included women with BMI<18.5 kg/m2 (underweight), Group 2 included those with
a BMI between 18.5 and 24.9 kg/m2 (normal range), and Group 3 were those with a BMI25
kg/m2 (overweight) according to the WHO classification system (http://apps.who.int/bmi/
index.jsp?introPage=intro_3.html) [38]. We also compared the mean hemoglobin concentra-
tion at week 38 with week 14 (because this data was available only for these visits) in the same
way. To take into account the inter-country and inter-subject variability, we ran a further lin-
ear mixed-effect model with BMI as the dependent variable and EPBF duration as the key
explanatory variable adjusted for baseline BMI and other covariates, including the mother’s
viral load, CD4 count, hemoglobin concentration, HIV stage, mode of delivery (vaginal versus
C-section), parity, age, education level, marital status and occupation. The child’s characteris-
tics included its gender, birth weight, treatment group and the breastfeeding initiation time.
We checked that the total variance due to country effect was always >10% by running a vari-
ance component analysis and a likelihood ratio test to confirm that the differences related to
countries were significant. Variables with p0.20 in the bivariate analysis were considered for
the multivariate analysis in the pooled-data analysis for all the countries. We also stratified by
country and ran the same multivariate analysis, introducing a country-specific socio-economic
status (SES) index.
The principal component methods was used to construct the SES index, [39]. Sixteen asset
variables were variously included in the principal component analysis, considering country
specificities. The first components (explaining 33, 39, 29 and 34% of the variation for Burkina
Faso, South Africa, Uganda and Zambia, respectively) were retained to weigh the variables and
calculate the index at the household level. This was the sum of the different variables’ weight/
score per subject, which was divided into tertiles.
For continuous variables, the mean values with 95% confidence interval (CI) were esti-
mated, and for categorical variables, percentages were used. Medians (IQR) were also reported.
Associations between variables were tested using the Chi-square test for categorical variables.
STATA/SE 13.1 (4905 Lakeway Drive College Station, Texas 77845 USA) was the statistical
software used.
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Ethics
Prior to enrolment, the mothers signed written informed consent and assent forms for them-
selves and their children, respectively. The trial was conducted according to the sponsor
(ANRS) ethic charter, Good Clinical Practices and the principles of the Helsinki declaration.
The protocol had obtained approval from the relevant ethical committees, including the Ethi-
cal Committee for Health Research in Burkina Faso, the Biomedical Research Ethics Commit-
tee in Zambia, the Uganda National Council for Science and Technology, the Stellenbosch
University ethical committees, the Medicines Control Council in South Africa and the
Regional Committee for Medical Research Ethics of Norway.
Results
In the ANRS 12174 trial, 1,273 mother-infant pairs were randomized and 6 were excluded due
to protocol violations. Of the remaining 1,267 participants, 204 were from Ouagadougou, 222
from East London, 278 from Mbale and 563 from Lusaka. In all, 42 were excluded from analy-
sis due to lack of breastfeeding data after inclusion, 7 due to inaccurate feeding duration data
and 2 women had no data on weights. Thus 1,216 subjects were included in the analysis.
At baseline (Table 1), South Africa had the largest mean BMI, and the highest frequency of
single women and C-section delivery. Burkina Faso participants had the lowest HIV viral load,
the lowest hemoglobin concentration, and the lowest literacy and formal occupation fre-
quency. Breastfeeding was initiated later in Burkina Faso where EPBF frequency was also the
lowest the first week.
During pregnancy antiretroviral prophylaxis was given 100% of women in all 4 countries
Breastfeeding duration and BMI changes
The median (Interquartile Range (IQR)) durations of EPBF and any breastfeeding were 5.8
(5.6; 5.9) and 9.5 (7.5; 10.6) months, respectively. The median (IQR) durations of EPBF were
20.9 (20.0; 21.5), 19.8 (12.9; 21.0), 20.9 (19.9; 21.0), 21.0 (20.6; 21.1) for Burkina Faso, South
Africa, Uganda and Zambia, respectively
The BMI of breastfeeding mothers decreased from baseline to week 26 before plateauing
until week 50 (Table 2). The same linear trend in the association between breastfeeding dura-
tion and BMI decrease was found in the country-specific analysis except in Uganda where we
did not find any significant decrease. The maximum weight loss was at week 26 (p<0.001) in
Burkina Faso and Zambia, whereas it was at week 38 for South Africa and Uganda.
Comparing the hemoglobin concentration at weeks 14 and 38, there was no overall change,
as also in the country-stratified analysis (p>0.05; see Table 3).
Categorizing women into 3 BMI groups, we found that slimmer women (BMI<18.5 kg/
m2) had no statistically significant change in their BMI postpartum (p>0.05), while the others
had significant decrease over the breastfeeding period (Table 4). The thinnest group of women
(BMI<18.5) had the steepest drop in hemoglobin at week 38; however, the difference was not
significant (-0.3 (-0.8; 0–3); see Table 5).
Factors associated with BMI changes in mothers
Overall, the univariate analysis showed that EPBF duration and all other controlled variables
were significantly associated with the BMI change, but not with the CD4 count, possibly
because the most vulnerable group, i.e. those with CD4 counts <350, were excluded from the
analysis. However, this variable was kept in the final model because of the known association
between CD4 count and HIV disease progression, usually leading to weight loss (Table 6). In
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the multivariate analysis shown in Table 6, no association between EPBF duration and moth-
ers’ BMI was found. Only baseline BMI, CD4 counts, education level, marital status and child
Table 1. Baseline characteristics.
A Burkina Faso South Africa Uganda Zambia All sites
N = 203 N = 212 N = 272 N = 529 N = 1216
% (95% CIa) % (95% CIa) % (95% CIa) % (95% CIa) % (95% CIa)
CD4>500 57.1 (50.2; 63.8) 51.4 (44.7; 58.1) 57.3 (51.4; 63.1) 59.9 (55.7; 64.0) 57.4 (54.6; 60.2)
Education level
Incomplete primary 68.5 (61.7; 74.5) 8.5 (5.4; 13.1) 48.5 (42.6; 54.5) 28.2 (24.5; 32.2) 36.0 (33.4; 38.8)
Completed primary 7.4 (4.5; 11.9) 0.5 (0.1; 3.3) 15.8 (11.9; 20.6) 18.5 (15.4; 22.1) 12.9 (11.1; 14.9)
Secondary and more 24.1 (18.7; 30.5) 91.0 (86.4; 94.2) 35.7 (30.2; 41.5) 53.3 (49.0; 57.5) 51.1 (48.2; 53.9)
Occupation (employed) 8.9 (5.6; 13.6) 41.5 (35.0; 48.3) 35.3 (29.8; 41.2) 17.0 (14.0; 20.5) 24.0 (21.7; 26.5)
Married/co-habiting 90.6 (85.8; 93.0) 39.1 (32.8; 45.9) 82.0 (76.9; 86.1) 88.7 (85.7; 91.1) 78.9 (76.5; 81.1)
Mode of delivery (vaginal) 93.6 (89.3; 96.2) 65.1 (58.4; 71.2) 93.4 (89.7; 95.8) 96.2 (94.2; 97.5) 89.7 (87.9; 91.3)
Parity (primiparous) 21.7 (16.5; 27.9) 33.5 (27.4; 40.1) 18.0 (13.9; 23.0) 20.6 (17.4; 24.3) 22.4 (20.2; 24.9)
Trial arm (lamivudine) 49.7 (42.9; 56.6) 51.9 (45.1; 58.6) 49.6 (43.7; 55.6) 50.3 (46.0; 54.5) 50.3 (47.5; 53.1)
HIV stage 1 93.1 (88.7; 95.9) 98.6 (95.7; 99.5) 92.3 (88.4; 94.9) 99.8 (98.7; 100.0) 96.8 (95.6; 97.6)
Child sex (male) 41.9 (35.2; 48.8) 49.1 (42.4; 55.8) 52.9 (47.0; 58.8) 48.4 (44.1; 52.7) 48.4 (45.6; 51.2)
ART prophylaxis postpartum 100.0 7.1 (4.3; 11.4) 71.0 (65.3; 76.1) 100.0 77.3 (74.9; 79.6)
Breastfeeding initiation time
Within 1st hour 6.9 (4.1; 11.3) 51.4 (44.7; 58.1) 55.9 (49.9; 61.7) 80.7 (77.1; 83.9) 57.7 (54.9; 60.5)
After 1st hour and within 1st day 64.0 (57.2; 70.4) 45.7 (39.1; 52.5) 41.2 (35.5; 47.1) 18.9 (15.8; 22.5) 36.1 (33.4; 38.8)
After 1st day 29.1 (23.2; 35.7) 2.8 (1.3; 6.2) 2.9 (1.5; 5.8) 0.4 (0.1; 1.5) 6.2 (4.9; 7.7)
EPBFb 1st 3 days 93.1 (88.7; 95.9) 94.3 (90.3; 96.8) 97.8 (95.2; 99.0) 99.0 (97.7; 99.6) 97.0 (95.8; 97.8)
EPBFb last 4 days 94.1 (89.8; 96.6) 95.7 (92.1; 97.8) 97.4 (94.7; 98.8) 99.6 (98.5; 99.9) 97.5 (96.5; 98.3)
Any BF 1st week 100.0 97.6 (94.4; 99.0) 100.0 100.0 99.6 (99.0; 99.8)
EPBFb 1st week 96.5 (92.9; 98.3) 97.2 (93.8; 98.7) 98.9 (96.6; 99.6) 99.8 (98.7;100.0) 98.6 (97.8; 99.1)
SESc tertiles
Highest tertile 31.5 (30.3 32.8) 19.8 (18.8 20.9) 38.2 (37.1 39.3) 42.3 (41.5 43.1)
Middle tertile 39.4 (38.1 40.7) 73.6 (72.4 74.7) 27.9 (26.9 29.0) 17.4 (16.8 18.0)
Lowest tertile 29.1 (27.9 30.3) 6.6 (6.0 7.3) 33.8 (32.7 34.9) 40.3 (39.5 41.1)
B
N = 203 N = 212 N = 272 N = 529 N = 1216
Median (IQRd) Median (IQRd) Median (IQRd) Median (IQRd) Median (IQRd)
Maternal age (years) 28.0 (24.3; 32.0) 27.3 (23.5; 32.8) 26.9 (23.0; 29.9) 26.8 (23.3; 31.0) 27.0 (23.3; 31.0)
BMI (kg/m2) 23.0 (21.2; 25.4) 27.8 (24.2; 31.8) 22.8 (20.8; 24.6) 23.2 (21.2; 26.5) 23.7 (21.3; 27.0)
CD4+ cells/μL 526 (428; 653) 505 (426; 648.5) 524.5 (429.5; 624) 548 (445; 705) 530 (432.5; 668.5)
Gestational age (weeks) 39.0 (37.0; 40.0) 38.0 (38.0; 38.0) 40.0 (39.0; 40.0) 38.0 (37.0; 40.0) 38.0 (38.0; 40.0)
HIV viral loade (x1000 /mL) 1.8 (0.7; 7.2) 2.1 (0.8; 7.9) 4.1 (0.6; 17.5) 3.8 (1.2; 20.6) 3.0 (0.8; 13.7)
Haemoglobin (g/dL) 11.2 (10.5; 12.1) 12.0 (11.3; 12.9) 12.4(11.7; 13.2) 12.5 (11.6; 13.3) 12.2 (11.3; 13.1)
Birth weight (kg) 2.9 (2.7; 3.2) 3.2 (2.8; 3.5) 3.0 (2.8; 3.3) 3.0 (2.8; 3.3) 3.0 (2.8; 3.3)
a Confidence Interval
b Exclusive and predominant breastfeeding
c Socio-economic status
d Interquartile range
e N = 173, 167, 180, 477 and 997 for Burkina Faso, South Africa, Uganda, Zambia and overall, respectively
f N = 175, 161, 218, 454 and 1008 for Burkina Faso, South Africa, Uganda, Zambia and overall, respectively
https://doi.org/10.1371/journal.pone.0177259.t001
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birth weight remained significant risk factors for BMI changes. Each additional kilogram of
mother’s baseline weight increased BMI by 1.0 kg/m2 during the lactation period.
Compared to mothers with a CD4 count of 350–500 cells/μl, the group with the higher
count had an increase in their BMI of 0.3 kg/m2. Regarding education level, the group that
completed primary and secondary or further education had a reduced BMI of 0.3 and 0.1 kg/
m2, respectively, over the lactation period. Eighty per cent of women in the last 2 categories
were employed compared to 18.8% among those who had zero or some years of primary
schooling. Living with a partner also conveyed a mean decrease in BMI of 0.3 kg/m2 compared
to being single. Finally, mothers of babies born with a birth weight of>3,500 g had a mean
BMI increase of 0.2 kg/m2 compared to mothers of babies with<2,500 g.
The multivariate analysis stratified by country (Table 7) shows EPBF had a significantly
decreased BMI of 0.1 kg/m2/month for Zambian participants. South Africa had exactly oppo-
site (of borderline significance) outcome of EPBF on mothers’ BMI. No effect from EPBF was
seen in the other countries. This relationship may be partially explained by the median dura-
tion of EPBF and the proportion of women still on EPBF at week 26 at the different study sites.
The median duration of EPBF was highest in Burkina Faso, Uganda and Zambia (5.8 months)
and lowest in South Africa (4.9 months). At weeks 26, 27 (13.2%), 4 (0.02%), 12 (0.04%) and
33 (0.06%) were still practicing EPBF in Burkina Faso, South Africa, Uganda and Zambia,
respectively. Conversely, baseline BMI was consistently and significantly associated with an
increase in mothers’ subsequent BMI measures in all countries throughout the lactation
period. A higher CD4 count increased BMI in Burkina Faso and Zambia, whereas an HIV
stage greater than one decreased BMI in Zambia. In the 4 countries, delivering by C-section or
delivering a girl was associated with mean BMI changes in different ways. In Burkina Faso, sin-
gle mothers had lowered BMI, whereas in South Africa it increased, these participants being in
the highest socio-economic tertile. The trial arm was not associated with any BMI change.
Table 2. Country-stratified paired t-test comparing mean BMI at different endpoints with baseline mean BMI.











BMI at week 14 minus
BMI at baseline (D7)
-0.8 (-1.1; -0.4) § -0.8 (-1.4; -0.3) § -0.2 (-0.5; 0.1) -0.5(-0.8; -0.2) § -0.5(-0.7; -0.4)§
BMI at week 26 minus
BMI at baseline (D7)
-1.1 (-2.4; 0.2) -0.8 (-1.5; -0.1) § -0.6(-0.9; -0.2) § -0.7 (-1.0; -0.3)§
BMI at week 38 minus
BMI at baseline (D7)
-0.9 (-1.5; -0.4) § -0.9 (-1.8; -0.0) § -0.4 (-0.9; 0.1) -0.6(-1.0; -0.2) § -0.7 (-0.9; -0.4)§
BMI at week 50 minus
BMI at baseline (D7)
-1.0 (-1.7; -0.2) § -0.8 (-1.7; 0.1) -0.6(-1.0; -0.2) § -0.7 (-1.0; -0.3)§
* data on mothers’ weight were missing on weeks 26 and 50 in Uganda
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t002
Table 3. Country-stratified paired t-test comparing mean hemoglobin at week 14 and week 38 (hemoglobin at week 14 > hemoglobin at week 38).
Burkina Faso South Africa Uganda Zambia All sites
Mean hemoglobin (g/dl) at W14 (95% CI) 11.2 (10.8; 11.7) 12.0 (11.5; 12.5) 12.4 (12.1; 12.8) 12.4 (12.1; 12.7) 12.1 (11.9; 12.3)
Mean hemoglobin (g/dl) at W38 (95% CI) 11.2 (10.7; 11.6) 12.1 (11.6; 12.6) 12.5 (12.2; 12.9) 12.6 (12.3; 12.8) 12.3 (12.1; 12.5)
Mean difference (g/dl) (95% CI) -0.1 (-0.5; 0.3) 0.1 (-0.3; 0.5) 0.1 (-0.2; 0.4) 0.2 (-0.1; 0.5) 0.1 (-0.1; 0.3)
https://doi.org/10.1371/journal.pone.0177259.t003
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Discussion
Considering our results, no marked change in BMI was seen in this cohort over a 26-week
period of lactation covering the EPBF period neither in the pooled analysis (Table 6) nor in the
country-stratified analysis.The mean change from 26 to 50 weeks after birth was 0.7 kg/m2 at
the paired t-test. This was also the case for changes in hemoglobin concentration. However,
the thinnest mothers had the largest change, although not statistically significant. The major
factor contributing to the biggest change in BMI was the mother’s own BMI after birth. The
heaviest mothers gained most weight during lactation. Higher birth weights and CD4 counts
correlated with some increase in BMI. Education level showed the opposite pattern, with a
higher educational status being associated with a slight reduction in BMI. In the country-strat-
ified analysis, socio-economic status was not a risk factor for BMI change, except in South
Africa where high SES was associated with an increase in BMI. However, a HIV stage above 1
correlated with a small decrease in BMI in Zambia.
The magnitude of the mean BMI decrease observed in Table 2 does not seem enough
important to have a clinical significance. The most important decrease (minus 1.1 kg/m2) was
seen in Burkina Faso at week 26. The mean BMI for this country was 23.8 (95% CI: 23.2; 24.3)
kg/m2 [data not shown]. Therefore, a decrease of 1.1 kg/m2 did not put a participant of this
site in an underweight category. This analysis was confirmed by the findings in Table 4A
where the underweight women group (<18.5 kg/m2) had a maximum non statistically-signifi-
cant weight loss of 0.5 kg/m2 smaller than the overall maximum of 1.1 kg/m2.
To the best of our knowledge, only one study [40] has tested the dose-response relationship
between breastfeeding and HIV disease progression including maternal weight loss. We also
tested whether the duration of EPBF was detrimental to the BMI of HIV-infected mothers.
Table 4. Women stratified in 3 BMI-categories: Paired t-test comparing mean BMI at different endpoints with baseline mean BMI.
BMI<18.5 N = 50 BMI between 18.5 and 24.9
N = 715









BMI at week 14<BMI at
baseline (D7)
-0.0 (-1.1; 1.0) -0.4 (-0.6; -0.2)§ -0.8 (-1.1; -0.4)§ -0.5 (-0.7; -0.4)§
BMI at week 26<BMI at
baseline (D7)
-0.2 (-1.6; 1.2) -0.6 (-1.0; -0.2)§ -0.8 (-1.3, -0.2)§ -0.7 (-1.0; -0.3)§
BMI at week 38<BMI at
baseline (D7)
-0.1 (-1.2; 0.9) -0.7 (-0.9; -0.4)§ -0.8 (-1.3; -0.2)§ -0.7 (-0.9; -0.4)§
BMI at week 50<BMI at
baseline (D7)
-0.5 (-2.1; 1.1) -0.7 (-1.2; -0.3)§ -0.6 (-1.2; -0.0)§ -0.7 (-1.0; -0.3)§
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t004
Table 5. BMI-categories-stratified paired t-test comparing mean hemoglobin at weeks 14 and 38 (hemoglobin at week 14> hemoglobin at week 38).
Number of
observations
Mean hemoglobin (g/dl) at W14
(95% CI)




BMI<18.5 36 12.1 (10.9; 13.3) 11.8 (10.7; 13.0) -0.3(-1.5; 0.9)
BMI between 18.5 and
24.9
502 12.2 (11.9; 12.5) 12.3 (12.0; 12.6) 0.1 (-0.2; 0.3)
BMI25 kg 295 12.1 (11.8; 12.42) 12.3 (12.0; 12.6) 0.2 (-0.1; 0.5)
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t005
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Other studies [28,29] compared any breastfeeding group with a formula-feeding group. A Tan-
zanian study [40], despite its loss to follow-up, concluded that neither the modality of breast-
feeding (exclusive or any), nor the duration of breastfeeding had an influence on the of
mothers with HIV infection. However, this research was focused on HIV disease progression,
and considered parameters that included maternal HIV viral load, CD4 count and weight loss.





EPBF duration -0.1 (-0.1; -0.0) -0 (0; 0)
Baseline BMI 1.0 (0.9; 1.0) § 1.0 (0.9; 1.0) §
Mother’s age 0.2 (0.1; 0.2) § 0 (0; 0)
CD4 count
<500 1 1
> = 500 0 (0; 0) 0.3 (0.2; 0.5) §
Number of children 0.4 (0.3; 0.5) § -
Number of child death -1.0 (-1.5; -0.5) § -
BF initiation time 0 (0; 0)
Within 1 hour 1 -
After 1 hour and within 1st day -0.1 (-0.4; 0.1) -
After 1st day 0.9 (0.3; 1.5) § -
Child gender
Male 1 -
Female 0.2 (0.0; 0.5) -
HIV stage
1 1 1
>1 -1.1 (-1.8; -0.3) § -0.1 (-0.4; 0.2)
Education level 0.3 (0.1; 0.5) §
No education or some primary 1 1
Complete primary 1.0 (0.6; 1.5) § -0.3 (-0.4; -0.1) §
Secondary and more 0.6 (0.3; 1.0) § -0.1 (-0.3; -0.0)
Marital status
Single 1 1
Married/cohabiting -0.9 (-1.2; -0.6) § -0.3 (-0.4; -0.2) §
Mode of delivery
Vaginal 1 -
C-section 1.8 (1.4; 2.1) § -
Parity
Primiparous 1 -
Multiparous 1.8 (1.5; 2.0) § -
Trial arm
lamivudine 1 1
lopinavir/ritonavir 0.2 (0.0; 0.4) -0.0 (-0.1; 0.0)
Child birth weight 0 (0; 0)
<2.5 kg 1 1
2.5 to 3.4 kg 1.0 (0.5; 1.4) § -0.0 (-0.2; 0.2)
> = 3.5 kg 3.2 (2.8; 3.7) § 0.2 (0.0; 0.4)
Gestational age 0.5 (0.4; 0.6) § -
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t006
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It recorded relative risks as association measures, making it difficult to compare with our
study in terms of absolute numbers. In a randomized trial on prolonged breastfeeding and
maternal mortality in Zambia [41], there seemed to be no harmful effect of breastfeeding. The
study was well designed, but its main defect lies in the failure toadhere fully to random assign-
ment by the participants, although the investigators deemed this had no significant effect on
the findings. Another analysis of the same Zambian data [27] over 2 years, in which there was
control for confounding, such as SES, obstetric history, season and food shortage, reported net
weight gain rather than weight loss, which has also been found in undernourished lactating
mothers [25,42,43]. Hartmann [43] explained this weight gain by a “homeorhetic theory of
metabolic adjustment” in favor of a dominant physiological state such as lactation. This may
also explain why the thinnest mothers did not lose weight during EPBF period in our cohort.
However, we do not have sufficient data to address issues such as food shortages, or other prac-
tical or mental issues, that could have led to the underweight status in the first place.
Table 7. Multivariate country-stratified analysis testing BMI change in breastfeeding mothers over the duration of extended EBF.
Adjusted Coefficient (95% CI)
Burkina Faso South Africa Uganda Zambia
EPBF duration 0.0 (-0.1; 0.2) 0.1 (-0.0; 0.1) -0.0 (-0.1; 0.1) -0.1 (-0.1; -0.0)
Baseline BMI 0.9 (0.9; 1.0) § 1.0 (0.9; 1.0) § 1.0 (0.9; 1.0) § 1.0 (0.9; 1.0) §
Mothers’ age -0.0 (-0.0; 0.0) 0.0 (-0.0; 0.1) -0.00 (-0.0; 0.0) -0.0 (-0.0; 0.0)
CD4 count
<500 1 1 1 1
> = 500 0.5 (0.2; 0.8) § 0.2 (-0.1; 0.4) 0.1 (-0.1; 0.4) 0.2 (0.0; 0.4)
Child sex
Male 1 1 1 1
Female -0.4(-0.6;-0.1) § 0.5 (0.1; 0.9) § -0.5 (-0.8; -0.2) § -0.8 (-1.8; 0.1)
HIV stage
1 1 1 1 1
>1 0.4 (-0.1; 0.8) 0.6 (-0.4; 1.6) -0.0 (-0.1; 0.1) -0.1 (-0.1; -0.0)
Marital status
Single 1 1 1 1
Married/cohabiting -1.0 (-1.5; -0.5) § - - -
Mode of delivery
Vaginal 1 1 1 1
C-section -0.5 (-1.0; -0.1) § 0.6 (0.0; 1.2)
Trial arm
lamivudine 1 1 1 1
lopinavir/ritonavir -0.0 (-0.3; 0.3) 0.2 (-0.2; 0.6) -0.16 (-0.3; 0.0) -0.2 (-0.4; 0.0)
Child birth weight
<2.5 kg 1 1
> = 2.5 to 3.4 kg 0.1 (-0.4; 0.6) -0.5 (-1.2; 0.2) -0.1 (-0.6; 0.3) 0.3 (-0.1; 0.8)
> = 3.5 kg 0.3 (-0.3; 0.9) 0.0 (-0.7; 0.8) 0.2 (-0.7; 0.2) 0.4 (-0.2; 0.9)
SES (tertiles)
Highest tertile 1
Middle tertile -0.3 (-0.6; 0.0) 0.0 (-0.5; 0.5) 0.2 (-0.4; 0.1) -0.1 (-0.4; 0.1)
Lowest tertile 0.0 (-0.3; 0.4) 0.6 (0.1; 1.1) § 0.2 (-0.0; 0.5) 0.2 (-0.1; 0.6)
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t007
Changes in BMI and heamoglobin in HIV-1 breastfeeding mothers
PLOS ONE | https://doi.org/10.1371/journal.pone.0177259 May 9, 2017 11 / 16
Our study did not have a non-breastfeding group for comparison, and therefore cannot
confirm or refute the findings from Kenya [28,29], where breastfeeding women were found
that lose more weight than non-breastfeeding ones. Another study in South Africa [44] showed
that breastfeeding HIV-positive mothers lost more weight than breastfeeding HIV-negative
mothers. In addition to the limitations of the study (including the lack of power of the study),
the design did not truly allow attribution of the weight change to the breastfeeding factor,
since it did not compare breastfeeding and formula groups, nor assess a dose-response by con-
sidering the duration of breastfeeding; instead, the study compared cross-sectional data at dif-
ferent time points.
The different studies referred to above were not directly comparable, mainly because of dif-
ferences in follow-up time. It was 24 months in the Vertical Transmission Study [14]; 20
months in the Zambian study with follow-up starting at 4 months post-partum [27]; and 6
months in the Kesho Bora trial [24]. The Kenyan studies had a number of methodological
issues [45].
In an analysis of 2 sets of data from Honduras [46], EBF did not affect maternal weight loss
in one study regarding 119 full-term low birth-weight infants. In the second study of 141
infants of low-income primiparous women, the EBF group lost more weight than mothers
feeding their children with solid foods between 4 and 6 months of age. Being of a low income
group could contribute to poor dietary intake, thereby contributing to the weight loss. The
study design may not have controlled properly all potential confounders.
Validity of our findings
This analysis was done on data collected from a large sample of HIV-positive mothers from 4
different countries in a clinical trial setting. However, the rigorous selection criteria may have
resulted in a recruited a study population that was not strictly representative of the general
population. Hence, the association between the HIV stage and BMI change may not reflect
that in the general population of HIV-positive mothers, since only patients with CD4 counts
above 350 and at stage 1 or 2 were included, and almost all of them remained at the same
asymptomatic stage until the end of the study. The SES index calculation proved challenging
because the study environments in the 4 countries were diverse; for this reason we built a
country-specific SES since a pooled 4-country index was not meaningful. Moreover, the clini-
cal trial context was not the routine or standard care environments for most women, which
may have distorted the SES effect on BMI change. However, these issues were less likely to
influence the association between EPBF duration and BMI change.
It is also possible that some reporting bias regarding our variable of interest was involved,
since in some sites (e.g. Burkina Faso), the study team in charge of nutritional counseling also
collected the breastfeeding data. No data was collected to validate the mothers’ reports of their
own feeding practices. We dropped all subjects without breastfeeding data or with obvious
inaccurate data to partially mitigate this issue.
We also failed to consider the mothers’ daily food intake and physical activities as important
factors in our assessment of BMI change. Nevertheless, we believe that the nutritional, finan-
cial (transport costs) and technical support provided to all participants in the trial, combined
with the relative homogeneity of our study population tended to minimize the effect of dispari-
ties in general and also those that were eventually related to food intake and physical activities.
Conclusion
Breastfeeding did not affect the BMI in HIV-1 infected Sub-Saharan African mothers when
their CD4 counts were >350 cells/μl. However, a higher baseline BMI and a CD4 count >500
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cells/μl led to an increase in BMI during the EPBF period. Considering the benefits of breast
milk for infants, and the recurrent results from different studies elsewhere that breastfeeding
does not harm HIV-1-infected mothers, this study also supports the WHO 2016 guidelines on
infant feeding, which indicates that mothers living with HIV should breastfeed for at least 12
months and up to 24 months, provided that the right treatment or prophylaxis for the infection
is given where formula feeding is unsafe.
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Research
AbstrACt
Objective We have assessed HIV-1 disease progression 
among HIV-1-positive mothers in relation to duration of 
any or exclusive breast feeding in the context of ANRS 
12174 trial.
Methods The analysis was completed on 203, 212, 272 
and 529 HIV-1-positive and lactating mothers with CD4 
count >350 cells/µL from Burkina Faso, South Africa, 
Uganda and Zambia, respectively. The trial compared 
lamivudine and lopinavir/ritonavir as a peri-exposure 
prophylaxis during a 50-week follow-up time. A multiple 
logistic regression model was run with the mothers’ 
weight, CD4 count and HIV-1 viral load as separate 
dependent variables, then combined into a dependent 
composite endpoint called HIV-1 disease progression 
where HIV-1 viral load was replaced by the HIV-1 clinical 
stage. Exclusive or predominant breast feeding (EPBF) 
and any breastfeeding duration were the key explanatory 
variables.
results In the adjusted model, the associations 
between EPBF duration and weight change, CD4 
cell count and the HIV-1 viral load were consistently 
insignificant. The CD4 cell count was associated with 
a significantly higher mothers’ body mass index (BMI; 
a mean increase of 4.9 (95% CI 2.1 to 7.7) CD4 cells/
µL per each additional kilogram per square metre of 
BMI) and haemoglobin concentration (19.4 (95% CI 
11.4 to 27.4) CD4 cells/µL per each additional gram 
per decilitre of haemoglobin concentration). There was 
no significant association between EPBF duration and 
HIV-1 disease progression. A higher education level 
was a factor associated with a slower HIV-1 disease 
progression.
Conclusion Breast feeding was not a risk factor for a 
faster progression of HIV-1 disease in mothers of this 
cohort with a baseline CD4 cell count >350 cells/µL.
trial registration number NCT0064026; Post-results.
IntrOduCtIOn 
In 2015, 36.7 (34.0–39.8) million people were 
infected with HIV. Among them, 17.4 (16.1–
20.0) million were women of childbearing 
age.1 2 HIV-1 prevalence was estimated 
between 5.3% and 6.5% among pregnant 
women in sub-Saharan Africa.3 Because of 
the almost irreversible immune activation 
involved, HIV-1 infection creates a condition 
of metabolic stress that may result in wasting 
and immune depression.4–7 Ten per cent 
weight loss and a CD4 count of <350 cells/µL 
in the context of HIV-1 infection have been 
recognised as major criteria of the diagnosis 
of AIDS.8 This weight loss is also associated 
strengths and limitations of this study
 ► Our study has been implemented in four countries 
in Africa, namely Burkina Faso (West), South Africa 
and Zambia (South), and Uganda (East), which made 
our sample representative of the wider sub-Sahara 
African population.
 ► The data were collected in the context of a rigorous 
clinical trial, which minimised the loss to follow-up, 
the missing data as well as other data collection er-
rors, and therefore improved the quality of our data.
 ► However, the selection associated with the environ-
ment of a clinical trial, usually quite different from a 
routine environment, may have biased our findings.
 ► Nonetheless, the variables analysed separately as 
dependent variables or as part of our composite 
endpoints (mother’s weight, CD4 cell count, HIV-1 
viral load or HIV-1 clinical stage) were sufficiently 
robust and had a high validity.
group.bmj.com on April 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Somé EN, et al. BMJ Open 2018;8:e019239. doi:10.1136/bmjopen-2017-019239
Open Access 
with a higher risk of mortality in HIV-1-infected breast-
feeding mothers.9 Furthermore, HIV-1 is a major cause 
of maternal mortality in affected countries in Southern 
Africa. About 25% of pregnancy-related deaths in sub-Sa-
haran Africa are attributable to HIV,10 and 88% of deaths 
among pregnant and postpartum women with HIV infec-
tion are attributable to the virus.11 
In women, pregnancy is, though a physiological condi-
tion, a period of increased metabolic activities and 
synthesis requiring a supplement of energy and nutri-
ents. After delivery, breast feeding prolongs the increased 
metabolic demands. Despite this, WHO still recommends 
HIV-1-infected women to breast feed as the best choice 
for the infant and the mother12 in contexts where replace-
ment feeding does not meet AFASS (affordable, feasible, 
available, safe and sustainable) criteria.
There have been conflicting results on assessment of 
the impact of breast feeding in HIV-1-infected mothers. 
Some studies found that breast feeding was harmful to 
HIV-positive mothers by either accelerating HIV disease 
progression as assessed by the mother’s weight loss, a 
decrease in CD4 cell count or even an increased risk 
of maternal mortality, suggesting that metabolic, immu-
nological or hormonal changes associated with breast 
feeding may accelerate HIV-1 disease progression in 
postpartum mothers.13–15 Others found no effect on 
the mothers’ health assessed by death, development 
of a low CD4 cell count, anaemia or excessive weight 
loss.16 17 Some studies have found breast feeding protec-
tive, allowing weight gain in HIV-1-infected breast-
feeding mothers.15 18–22
In the ANRS 12174 trial, we assessed mothers’ HIV-1 
disease progression (measured by the change in weight, 
CD4 cell count and HIV-1 disease stage as per WHO clas-
sification) in relation to exclusive breast feeding or dura-
tion of any breast feeding during the infant first 6 months 
of life and until week 50 post partum.
MethOds
study design
The ANRS 12174 clinical trial in Ouagadougou (Burkina 
Faso), East London (South Africa), Mbale (Uganda) and 
Lusaka (Zambia) was conducted from 2009 to 2013. The 
protocol and the main outcome have been published.23 24 
Briefly, a cohort of HIV-1-infected, pregnant women, at 
the time not eligible for highly active antiretroviral therapy 
because CD4 count was >350 cells/µL, aged 18 or 
above and planning to breast feed were identified from 
antenatal clinics between 28 and 40 weeks of amenor-
rhoea. As part of the HIV post-test counselling session, 
they were informed on the different feeding options for 
their babies. Only women intending to breast feed were 
referred to the research clinic for further assessment of 
the inclusion criteria during the antenatal period and 
again with their child within 6 days after birth, for an 
enrolment and randomisation at day 7 post partum. From 
28 weeks of pregnancy to day 7 after birth, programmatic 
mother-to-child transmission prophylaxis was imple-
mented with antepartum zidovudine, intrapartum single-
dose nevirapine and zidovudine–lamivudine for mothers 
and nevirapine for infants for 7 days postpartum. Twins 
and triplets, infants with positive HIV-1 DNA PCR test 
result at day 7 (±2 days) post partum, low birthweight or 
ill babies (ranked grade II or above of the ANRS classifi-
cation for adverse events) were excluded.25 The interven-
tion provided an infant prophylaxis in the breastfeeding 
period plus 1 week from day 7 to 50 weeks of age with 
either lopinavir/ritonavir or lamivudine.
data management and analysis
Data were collected on a paper case-report form or 
directly entered online using the Electronic Data capture 
system: OpenClinica (http://www. openclinica. com). 
Twenty-four-hour and 1-week breastfeeding recalls were 
collected during the enrolment visit at day 7±2 days after 
birth and the 13 monthly scheduled follow-up visits that 
started at week 2. During these visits, mothers were asked 
in particular if they gave their infants other foods/liquids 
as well as breast milk. Prelacteal feeding data—
defined as any food item except mothers’ milk given to 
infants before initial breast feeding—were also collected 
at the enrolment visit.
The mothers at each visit were categorised into the 
following groups: (1) exclusive breast feeding, EBF (only 
breast milk being given to the infant without any other 
food or liquid, except medically prescribed drugs or vita-
mins); (2) predominant breastfeeding, PBF (breast milk 
with some liquid-based food, such as juice, tea, sugar water 
and salt water, including glucose without any kind of 
formula, or animal milk); and (3) mixed feeding, MF 
(breast milk with other solid-based or liquid-based food, 
including other kinds of milk). We thereafter combined 
EBF and PBF into one group called ‘exclusive or predom-
inant breastfeeding’ (EPBF) as PBF presented few cases 
and was assessed as having much the same risk as EBF, at 
least with regard to postnatal HIV transmission.26
During the follow-up visits, the mothers underwent a 
clinical assessment, including weight measurement and 
HIV-1 infection staging at the first screening visit or 
screening one (between 28 and 40 weeks of gestation), 
day 7 post partum, weeks 26 and 50; CD4 cell count anal-
ysis at screening one, weeks 26 and 50; and HIV-1 viral 
load at screening one, day 7, weeks 6, 14, 26, 38 and 50. 
The dependent variables were mothers’ weight, CD4 cell 
count and HIV-1 viral load considered separately and 
measured at the same time points as per above. We gener-
ated a new variable called ‘weight loss’, which was calcu-
lated as the mothers’ weight at W26 (because of missing 
data, mothers’ weights were not available for week 50) 
minus the baseline weight at day 7 post partum, which was 
compared with the baseline weight to assess if the loss had 
reached 10%. Furthermore, we combined CD4 cell count, 
mothers’ weight loss and HIV-1 disease stage as per WHO 
classification to create the composite endpoint called 
‘HIV-1 disease progression’. HIV-1 disease progression was 
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accelerated when CD4 cell count decreased to <350 cells/
µL, or the HIV-1 infection was assessed by the trial physi-
cian at stage 3 or above, or the mothers lost >10% of their 
weight; otherwise, HIV-1 disease progression was deemed 
absent or slow. Our main independent variable was EPBF 
(until week 26 post partum) or any breastfeeding (until 
week 50 post partum) duration. The data were collected 
by trained physicians, pharmacists, biologists and coun-
sellors. Seca-brand scales and stadiometers were used to 
measure the mother’s height and weight. Weights were 
rounded to the nearest 10 g and the height to the nearest 
millimetre. Weight and height were measured twice 
based on the WHO guidelines (http://www. who. int/ 
childgrowth/ training/ en/).
We first ran linear mixed-effect models that considered 
separately the mothers’ weight, CD4 cell count and HIV-1 
viral load changes as dependent variables, and EPBF or 
any breast feeding as key independent variables. The loss 
to follow-up were censored in a survival analysis completed 
to build the EPBF and any breastfeeding variables.27 When 
the inter-country variability was not significant, a linear 
multivariate regression analysis was run. We ran a logistic 
regression regarding the composite endpoint. Adjust-
ment covariates included baseline variables measured at 
the screening one visit (body mass index (BMI), educa-
tion level, marital status, haemoglobin concentration) or 
on day 7 post partum (mode of delivery, breastfeeding 
initiation time, the baby’s gender and the trial arm). 
These multivariate analyses were run taking all partici-
pants together and also as two strata comprising South 
African mothers (stratum 1) and Burkina Faso, Uganda 
and Zambia together (stratum 2) because South Africa 
presented important socioeconomic, cultural and demo-
graphic differences compared with the other countries. 
For continuous variables, the mean values with 95% CI 
were estimated, and for categorical variables, percentages 
were used. Associations between variables were tested 
using the χ2 test for categorical variables. STATA/SE 
V.13.1 statistical software has been used for the analyses.
ethics
Prior to enrolment, the mothers signed a written informed 
consent and assent forms for themselves and their chil-
dren, respectively. The trial was conducted according to the 
sponsor (ANRS) ethic charter, Good Clinical Practices and 
the principles of the Helsinki declaration.
results
In the ANRS 12174 trial, 1273 mother–infant pairs were 
randomised and six were excluded due to protocol viola-
tions. Of the remaining 1267 participants, 204 were from 
Ouagadougou, 222 from East London, 278 from Mbale 
and 563 from Lusaka. In all, 42 were excluded from anal-
ysis due to lack of breastfeeding data after inclusion, 7 
due to inaccurate feeding duration data and 2 women had 
no data on weights. The analysis included 1216 subjects. 
The complete flow chart has been published elsewhere.27 
The mean baseline weight, the percentage of educated 
and employed women was highest, and the mean EPBF 
Table 1a Baseline characteristics collected at screening one or on day 7 post partum and breastfeeding duration data 
(continuous variables)
Burkina Faso South Africa Uganda Zambia All sites
n=203 n=212 n=272 n=529 n=1216
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Mean duration of 
zidovudineregimen 
post-delivery (days)*




6.6 (6.5 to 6.8) Data not available 6.7 (6.6 to 6.8) 7.0 (6.9 to 7.0) 6.8 (6.8 to 6.9)
Mean baseline CD4 
count×102 cells/µL
5.6 (5.4 to 5.8) 5.5 (5.3 to5.7) 5.6 (5.4 to 5.8) 6.0 (5.8 to 6.2) 5.8 (5.7 to 5.9)
Mean baseline viral 
load×103 copies/µL
23.0 (7.3 to 38.7) 13.5 (7.5 to 19.6) 34.9 (19.7 to 50.0) 29.1 (21.5 to 36.6) 26.4 (21.1 to 31.8)
Baseline mothers’ 
weight (kg)
62.9 (61.4 to 64.5) 72.1 (70.0 to 74.1) 58.1 (57.0 to 59.2) 62.0 (61.0 to 62.9) 63.0 (62.3 to 63.7)
Mean EPBF duration 
(months)
6.3 (6.2 to 6.4) 4.8 (4.7 to 4.9) 5.6 (5.5 to 5.7) 6.0 (5.9 to 6.1) 5.8 (5.7 to 5.9)
Mean breastfeeding 
duration (months)
10.5 (10.4 to 10.6) 6.7 (6.6 to 6.8) 8.4 (8.3 to 8.5) 8.4 (8.3 to 8.5) 8.4 (8.3 to 8.5)
*AZT and 3TC (zidovudine and lamivudine) are usually administered together. However, in our data collection tool (the questionnaire), the 
investigators had to ask specifically and separately the question for AZT and 3TC. We suspect that they may have been some reporting 
errors, creating slight differences in the percentages of women who complied with the prophylaxis requirements.
EPBF, exclusive or predominant breast feeding.
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and any breastfeeding durations shortest in South Africa 
where the HIV-1 viral load was also the lowest (table 1a 
and b).
Overall, in the adjusted model, the association between 
EPBF duration and weight change was negative and 
non-significant. Mothers who completed secondary school 
had a significant mean increase of 1.1 kg compared with 
those who did not complete primary school (table 2a).
The association between CD4 cell count and EPBF 
duration was non-significant (5.4 (95% CI −0.1 to 10.9) 
and 4.5 (95% CI −6.2 to 15.1) CD4 cells/µL increase per 
month of EPBF duration at univariate and multivariate 
analyses, respectively). The association was significantly 
positive between the mothers’ baseline BMI, haemo-
globin concentration and CD4 cell count yielding a mean 
increase of 4.9 (95% CI 2.1 to 7.7) CD4 cells/µL per addi-
tional BMI unit and 19.4 (95% CI 11.4 to 27.4) CD4 cells/
µL per additional unit of haemoglobin throughout the 
EPBF period (table 2b).
There was no significant association between HIV-1 
viral load and EPBF duration. The heavier and older 
mothers, those who delivered female babies and the 
best educated women group had a significantly lower 
mean viral load in the multivariate analysis. The 
mothers allocated to the lopinavir/ritonavir group had 
a significantly higher mean viral load than the ones in 
the lamivudine arm (table 2c).
We found no significant association between EPBF 
duration and HIV-1 disease progression. However, 
randomisation to the lopinavir/ritonavir arm or being 
a single mother led to a significantly adjusted OR of 
1.3 (95% CI 1.0 to 1.6; P=0.04) and 1.6 (95% CI 1.3 to 
2.1), respectively (table 2d).
Considering any breastfeeding duration, there was no 
weight change at univariate and multivariate analyses 
overall (table 3a). Still regarding any breast feeding, overall, 
there was a significant mean increase of 5.7 (95% CI 0.4 to 
10.9) CD4 cells/µL per month of any breast feeding. We 
found also that being a single mother was associated with a 
mean decrease of −43.3 (95% CI −72.8 to −13.7) CD4 cells/
µL as compared with married ones (table 3b). Any breast-
feeding duration was also associated with a significantly 
higher mean viral load (table 3c). Analysis with any breast-
feeding pattern and HIV-1 disease progression showed the 
same associations as EPBF and HIV-1 disease progression 
(table 3d).
Table 1b Baseline characteristics collected at screening one or on day 7 post partum and breastfeeding duration data 
(categorical variables)
Burkina Faso South Africa Uganda Zambia All sites
n=203 n=212 n=272 n=529 n=1216
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Mother’s age group (years)
  Below 25 26.2 (20.5 to 32.6) 34.4 (28.3 to 41.1) 39.3 (33.7 to 45.3) 37.8 (33.8 to 42.0) 35.6 (33.0 to 38.3)
  25–30 36.9 (30.6 to 43.8) 31.2 (25.2 to 37.7) 35.7 (30.2 to 41.5) 33.1 (29.2 to 37.2) 34.0 (31.3 to 36.7)
  30 and above 36.9 (30.6 to 43.8) 34.4 (28.3 to 41.1) 25.0 (20.2 to 30.5) 29.1 (25.4 to 33.1) 30.4 (27.9 to 33.1)
HIV stage 1 93.1 (88.7 to 95.9) 98.6 (95.7 to 99.5) 92.3 (88.4 to 94.9) 99.8 (98.7 to 100.0) 96.8 (95.6 to 97.6)
Education
  Did not 
complete 
primary school
68.5 (61.7 to 74.5) 8.5 (5.4 to 13.1) 48.5 (42.6 to 54.5) 28.2 (24.5 to 32.2) 36.0 (33.4 to 0.38.8)
  Completed 
primary school
7.4 (4.5 to 11.9) 0.5 (0.1 to 3.3) 15.8 (11.9 to 20.6) 18.5 (15.4 to 22.1) 12.9 (11.1 to 14.9)
  Secondary 
school and 
more
24.1 (18.7 to 30.5) 91.0 (86.4 to 94.2) 35.7 (0.30.2 to 41.5) 53.3 (49.0 to 57.5) 51.1 (48.2 to 53.9)
Marital status 
(married)
90.6 (85.8 to 94.0) 39.1 (32.8 to 45.9) 82.0 (76.9 to 86.1) 88.7 (85.7 to 91.1) 78.9 (76.5 to 81.1)
Occupation 
(employed)
8.9 (5.6 to 13.6) 41.5 (35.0 to 48.3) 35.3 (29.8 to 41.2) 17.0 (14.0 to 20.5) 24.0 (21.7 to 26.5)
Primipara 21.7 (16.5 to 27.9) 33.5 (27.4 to 40.1) 18.0 (13.9 to 23.0) 20.6 (17.4 to 24.3) 22.4 (20.2 to 24.9)




6.9 (4.1 to 11.3) 51.4 (44.7 to 58.1) 55.9 (49.9 to 61.7) 80.7 (77.1 to 83.9) 57.7 (54.9 to 60.5)
Lamivudine arm 49.7 (42.9 to 56.6) 51.9 (45.1 to 58.6) 49.6 (43.7 to 55.6) 50.3 (46.0 to 54.5) 50.3 (47.5 to 53.1)
Female baby 41.9 (35.2 to 48.8) 49.1 (42.4 to 55.8) 52.9 (46.0 to 58.8) 48.4 (44.1 to 52.7) 48.4 (45.6 to 51.2)
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In the stratified analysis, we found that EPBF duration had 
no influence on mothers’ weight, CD4 count or HIV-1 viral 
load, whatever the stratum. HIV-1 disease progression was 
not associated either with EPBF duration (table 2a, b, c and 
d). In stratum 2, C-section delivery was associated with an 
increase in CD4 cell count (table 2b), whereas delivering a 
female baby and being educated beyond secondary school 
were associated with a decrease in HIV-1 viral load (table 2c).
In South Africa, initiating breast feeding 1 hour 
post-delivery and being a single mother were related to 
an increase in HIV-1 viral load. In both strata, C-section 
delivery and multiparity were also related to an increase 
in HIV-1 viral load. There was no association between 
any breast feeding and the mothers’ weight, CD4 cell 
count and HIV-1 disease progression in any of the 
strata (table 3a, b and d). However, any breastfeeding 
duration was associated with an increase of the HIV-1 
viral load in South African women (table 3c).
dIsCussIOn
Considered separately, there appeared to be no variations 
in the mothers’ weight, CD4 cell count and HIV-1 viral 
Table 2a Mothers’ weight change according to EPBF duration adjusted to different covariates: stratification presenting South 
Africa versus the other sites and pooled analysis
South Africa
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BMI, body mass index; EPBF, exclusive or predominant breast feeding.
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load related to EPBF or any breast feeding. The same 
conclusion applied to these outcomes was combined in a 
composite endpoint representing HIV-1 disease progres-
sion. Unsurprisingly, mothers’ baseline BMIs were consis-
tently associated with an increase in the mothers’ weight 
and CD4 cell count, and with a lower mean HIV-1 viral 
load for both EPBF and any breastfeeding groups.
In a review of the literature on weight change in the 
postpartum period, there appeared to be no association 
between breast feeding or generally between the mode 
Table 2b Mothers’ CD4 cell count change according to EPBF duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis
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of infant feeding, and postpartum weight loss. However, 
C-section delivery was a risk factor for postpartum weight 
loss,28 similar to our findings. South Africa had mark-
edly lower rates of vaginal deliveries versus other coun-
tries (table 1b). In the year 2000, studies were published 
demonstrating that elective C-section before the labour 
and before the rupture of membranes added protection 
against HIV transmission to the newborn.29 30 The lower 
rates of vaginal deliveries in South Africa were likely 
due to the country policies (influenced by the scientific 
Table 2c Mothers’ HIV-1 viral load change according to EPBF duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis
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evidence) that supported HIV-infected women towards 
delivering HIV-free babies. This support included free 
formulas and probably scheduled C-section for the HIV-in-
fected pregnant women and mothers. Why the rest of the 
countries did not implement the same policy is certainly 
a matter of affordability and availability of local resources. 
Another reason is that C-section rate is ‘recklessly high’ in 
South Africa where up to 90% of pregnant women deliver 
through this method in private hospitals (The Guardian, 
https://www. theguardian. com/ world/ 2014/ sep/ 24/ 
caesarean- section- south- africa (accessed on 27 October 
2017)). This practice may have spilled over but at a lesser 
extent into public health facilities. We believe this prac-
tice has not skewed our results since these C-section deliv-
eries were not medically indicated at first hand, at least 
not based on a vaginal delivery risk; therefore, they are 
not done on women with poorer health status. Actually, 
South African women had the lowest mean HIV-1 viral 
load and the highest mean BMI.
Yet, this review of literature28 found that less educated 
mothers (<12 years of schooling) were at risk of post-
partum weight retention; we found that higher educated 
women (secondary school or further) were at risk of that 
weight retention. This difference in our finding may be 
explained by the difference in our categorisation of the 
education variable. In our study, less educated partici-
pants included only women with primary school level, 
meaning around 6 years of schooling. Therefore, the 
results of the two studies are not really comparable. A 
higher education level was also a factor associated with a 
slower HIV-1 disease progression. This finding is consis-
tent with our result that higher educated women retained 
more weight.
In a further review of literature on the effects of lacta-
tion on the mother’s body weight, it is clear that the 
assumption that the postpartum weight loss is due to the 
high energy demand associated with lactation has been 
challenged by many studies.31 Some reports conflict with 
our own findings, such as the one in KwaZulu Natal, 
where HIV-1-infected mothers at between 8 and 24 weeks 
had a mean weight loss of 1.4 kg in contrast to a 0.4 kg 
weight gain in HIV-1-uninfected mothers (P=0.01) during 
breast feeding.15
Regarding the change in CD4 cell count, the South 
African data support the conclusion that CD4 cell count 
did not differ significantly between women who breast 
fed and those who did not.32 This finding contradicts the 
Kenyan study that found that the rate of CD4 cell count 
decline was higher in breastfeeding than in non-breast-
feeding mothers.13 However, in that Kenyan study, HIV-1 
RNA levels did not differ significantly between breast-
feeding and formula-feeding mothers.
Regarding HIV-1 disease progression, the same 
data showed no deleterious effect of breast feeding in 
HIV-1-infected mothers, similar to our study findings. 
The outcome variables were the CD4 and CD8 cell count, 
the mothers’ illness and mortality, and their haemo-
globin levels.32 Another study from Malawi reached the 
Table 2d Mothers’ HIV-1 disease progression according to EPBF duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis
South Africa

















EPBF duration (months) 1.0 (0.9 to 1.1) 1.1 (1.0 1.2) 1.0 (0.9 to1.1) 1.1 (1.0 to 1.1) 1.1 (1.0 to 1.2)
Mother’s age (years) 1.0 (1.0 to 1.1) 1.0 (1.0 to 1.1) 1.0 (1.0 to 1.0)
Child’s gender
  Male babies 1 1 1
  Female babies 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.0)
HIV disease stage
  HIV stage 1 1 1
  HIV stage >1 4.0 (2.5 to 6.2) 4.2 (2.6 to 6.5)
Marital status
  Married/cohabiting 
mothers
1 1 1 1
  Single mothers 1.6 (1.1 to 2.2) 1.8 (1.3 to 2.6) 1.5 (1.2 to 1.9) 1.6 (1.3 to 2.1)
Trial arm
  Lamivudine arm 1 1 1 1
  Lopinavir/ritonavir arm 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.7) 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.6)
Birth weight (g) 0.9 (0.8 to 1.0)
EPBF, exclusive or predominant breast feeding.
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same conclusion that breast feeding was not associated 
with higher risk of maternal morbidity or mortality.33 A 
study in Zambia concluded in the same direction that 
at 12 months after delivery, there was no difference in 
mortality between women who breast fed for a short dura-
tion (4 months) versus those who breast fed for a dura-
tion of their own choice.17 An individual patient data 
meta-analysis on mortality among HIV-1-infected mothers 
according to children’s feeding modality confirmed that 
the risk of dying within 18 months post partum was not 
significantly affected by the infants’ feeding modality (ie, 
ever vs never breast fed).34
In healthy breastfeeding mothers, the postpartum 
weight loss would be around 0.5 kg per month among 
population with relatively high mean of BMI. The 
mechanism of the weight loss would be burning of 
483–538 kcal per day.35 36 Therefore, losing weight after 
birth is likely when the mother’s calorie intake does not 
cover the calorie expense related to breast-milk produc-
tion. Considering these findings, we think that energy 
Table 3a Mothers’ weight change according to any breastfeeding duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis 
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requirement and thus the metabolic stress related 
to breast feeding would be quite bearable. This may 
explain why in our study HIV-1-infected, immune-com-
petent and breastfeeding mothers’ health status was not 
deteriorated by breast feeding. This evidence inspires 
the idea that option A peri-exposure antiretroviral 
prophylaxis might still have pertinent indications since 
breast feeding remained the most frequent feeding 
Table 3b Mothers’ CD4 cell count change according to any breastfeeding duration adjusted to different covariates: 
stratification presenting South Africa versus the other sites and pooled analysis
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option in sub-Saharan Africa and since breast milk 
might still host HIV-1 reservoirs that mothers’ prophy-
laxis could not always 100% suppress.37
strengths and limitations
Our study has been implemented in four countries in Africa, 
including Burkina Faso (West), South Africa and Zambia 
(South) and Uganda (East). Therefore, we consider our 
study population representative of the sub-Sahara African 
population. The data were also collected in the rigorous 
context of a clinical trial, which minimised the loss to 
follow-up, the missing data as well as other data collection 
errors, and therefore improved the quality of our data.
However, the selection associated with the environment 
of a clinical trial—usually quite different from a routine 
environment—may have biased our findings. Nonethe-
less, our endpoints (mother’s weight, CD4 cell count and 
HIV-1 viral load) were sufficiently robust for us to vouch 
for their validity. Another point of note is the stratification 
of the participants into two strata, that is, South Africa 
versus Burkina Faso, Uganda and Zambia. This stratifica-
tion reduced the sample size in South Africa. Thus, some 
Table 3c Mothers’ HIV-1 viral load change according to any breastfeeding duration adjusted to different covariates: 
stratification presenting South Africa versus the other sites and pooled analysis
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of the modelling for South Africa could be less rigorous, 
and the findings regarding the risk factors there may not 
truly reflect the reality.
COnClusIOn
Breast feeding, whatever the type (exclusive or any) as 
far as this study can conclude, was not a risk factor for 
the HIV-1-infected mothers’ weight, CD4 cell count and 
HIV-1 viral load change, or HIV-1 disease progression, 
keeping in mind that all the participants had a baseline 
CD4 cell count >350 cells/µL. The mothers’ baseline 
high weight and high haemoglobin concentration were 
important factors in being consistently associated with an 
improvement of the outcome variables at stake. A higher 
education level was also a factor associated with a slower 
HIV-1 disease progression. Considering the benefits of 
breast milk for infants, and the consensus results from 
different studies elsewhere that breast feeding does not 
harm HIV-1-infected mothers, this study also supports the 
WHO 2016 guidelines on infant feeding, which indicate 
that mothers living with HIV should breast feed for at 
least 12 months and up to 24 months, provided that the 
right treatment or prophylaxis for the infection is given 
where formula feeding is unsafe.12
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HIV stage
  HIV stage 1 1 1 1 1
  HIV stage >1 4.0 (2.5 to 6.2) 4.2 (2.6 to 6.6) 4.4 (2.8 to 6.7) 4.6 (2.9 to 7.3)
Education
  Did not complete primary 
school
1 1
  Completed primary school 1.4 (0.9 to 2.0)
Secondary school and 
further
0.7 (0.5 to 0.9)
Marital status
  Married/cohabiting 
mothers
1 1
  Single mothers 1.6 (1.1 to 2.2) 1.8 (1.2 to 2.6) 1.5 (1.2 to 1.9)
Trial arm
  Lamivudine arm 1 1 1 1
  Lopinavir/ritonavir arm 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.7) 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.6)
BMI, body mass index.
group.bmj.com on April 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
13Somé EN, et al. BMJ Open 2018;8:e019239. doi:10.1136/bmjopen-2017-019239
Open Access
5Department of Paediatrics and Child Health, School of Medicine, University of 
Zambia, Lusaka, Zambia
6University Teaching Hospital, Lusaka, Zambia
7Department of Paediatrics and Child Health, School of Medicine, College of Health 
Sciences, Makerere University, Kampala, Uganda
8Effective Care Research Unit, University of Fort Hare, Alice, South Africa
Acknowledgements We would like to thank all the mothers who agreed to be 
part of the trial together with their children. Our acknowledgements also go to the 
different ANRS 12174 site staff for their dedicated effort in this research. We are 
also very grateful to the University of Bergen and the Centre for International Health 
for providing the infrastructure, and the needed supervision and training. We also 
thank the UMR 1058, pathogenesis and control of chronic infections, Montpellier, 
France, from which we received invaluable support regarding data management. 
The final typescript has been improved through the help of BioMedES Ltd, UK 
(http://www. biomedes. co. uk).
Contributors Conceptualisation: ENS, IMSE, NN, NYM, PVdP, TT. Data curation: 
ENS, RV. Formal analysis: ENS, IMSE. Investigation: ENS, MS-M, NYM, JKT, CK, GJH. 
Methodology: ENS, IMSE, TT. Project administration: NN, PVdP, TT, NYM. Resources: 
TT, IMSE. Supervision: TT, IMSE, NYM, NN. Validation: TT, IMSE, NYM, NN. Writing the 
original draft: ENS, IMSE. Writing and review and editing: ENS, IMSE, NN, NYM, TT, 
RV, CK, JKT, GJH, MS-M, KH.
Funding This study used data collected in the context of the ANRS 12174 clinical 
trial funded by the French National Institute of Health and Medical Research–
National Agency for Research on AIDS and Viral Hepatitis (INSERM–ANRS), the 
European and Developing Countries Clinical Trials Partnership (EDCTP; grant no. 
CT.2006.33020.004), the Research Council of Norway (GlobVac grant no. 183600) 
and the Total Foundation. ENS benefited from a PhD grant from the Norwegian 
Quota Scheme. 
disclaimer The funders had no role in study design, data collection and analysis, 
decision to publish or preparation of the manuscript.
Competing interests None declared.
Patient consent Not required.
ethics approval The Ethical Committee for Health Research in Burkina Faso 
(EC no. 2008-039), the Biomedical Research Ethics Committee in Zambia (EC 
no. 008-02-08), the Uganda National Council for Science and Technology (EC no. 
HS470), the Stellenbosch University ethical committees, the Medicines Control 
Council in South Africa (EC no. 20090938) and the Regional Committee for Medical 
Research Ethics of Norway.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement The study sponsor (the French agency for research on 
HIV and viral hepatitis: ANRS) offers data sharing upon request. ANRS will be the 
contact organisation ( direction@ anrs. fr). The shared data will be those presented in 
the article.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
reFerenCes
 1. UNAIDS. Core epidemiology. 2015  htt p://www.un aids.org/e n/res 
ources/do cume nts/ 2015 /201 50714_ coree pidemio logyslides_ ppt; 
(accessed 11 Nov 2015).
 2. UNAIDS. Global AIDS update 2016. http://www. unaids. org/ en/ 
resources/ documents/ 2016/ Global- AIDS- update- 2016 (accessed 17 
Oct 2016).
 3. Eaton JW, Rehle TM, Jooste S, et al. Recent HIV prevalence trends 
among pregnant women and all women in sub-Saharan Africa: 
implications for HIV estimates. AIDS 2014;28(suppl 4):8.
 4. Younas M, Psomas C, Reynes J, et al. Immune activation in the 
course of HIV-1 infection: causes, phenotypes and persistence under 
therapy. HIV Med 2016;17:89–105.
 5. Jacob JA. Men with HIV age faster according to DNA methylation 
study. JAMA 2016;316:135.
 6. Zevin AS, McKinnon L, Burgener A, et al. Microbial translocation and 
microbiome dysbiosis in HIV-associated immune activation. Curr 
Opin HIV AIDS 2016;11:182–90.
 7. DeVaughn S, Müller-Oehring EM, Markey B, et al. Aging with HIV-1 
Infection: motor functions, cognition, and attention—a comparison 
with Parkinson's disease. Neuropsychol Rev 2015;25:424–38.
 8. World Health Organization. Antiretroviral therapy for HIV infection 
in adults and adolescents: recommendations for a public health 
approach [2006 revision]134: World Health Organization, 2006.
 9. Koyanagi A, Humphrey JH, Moulton LH, et al. Predictive value of 
weight loss on mortality of HIV-positive mothers in a prolonged 
breastfeeding setting. AIDS Res Hum Retroviruses 2011;27:1141–8.
 10. Zaba B, Calvert C, Marston M, et al. Effect of HIV infection on 
pregnancy-related mortality in sub-Saharan Africa: secondary 
analyses of pooled community-based data from the network for 
Analysing Longitudinal Population-based HIV/AIDS data on Africa 
(ALPHA). Lancet 2013;381:1763–71.
 11. Guttmacher Institute. HIV linked to many pregnancy-related deaths 
in sub-Saharan Africa. International perspective on sexual and 
reproductive health 2013;39:4.
 12. World Health Organization, United Nations Children’s Fund. 
Guideline: updates on HIV and infant feeding: the duration of 
breastfeeding, and support from health services to improve feeding 
practices among mothers living with HIV. Geneva: World Health 
Organization, 2016.
 13. Otieno PA, Brown ER, Mbori-Ngacha DA, et al. HIV-1 disease 
progression in breast-feeding and formula-feeding mothers: a 
prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, 
and mortality. J Infect Dis 2007;195:220–9.
 14. Nduati R, Richardson BA, John G, et al. Effect of breastfeeding on 
mortality among HIV-1 infected women: a randomised trial. Lancet 
2001;357:1651–5.
 15. Papathakis PC, Van Loan MD, Rollins NC, et al. Body composition 
changes during lactation in HIV-infected and HIV-uninfected South 
African women. J Acquir Immune Defic Syndr 2006;43:467–74.
 16. Sedgh G, Spiegelman D, Larsen U, et al. Breastfeeding and maternal 
HIV-1 disease progression and mortality. AIDS 2004;18:1043–9.
 17. Kuhn L, Kasonde P, Sinkala M, et al. Prolonged breast-feeding and 
mortality up to two years post-partum among HIV-positive women in 
Zambia. AIDS 2005;19:1677–81.
 18. Winkvist A, Rasmussen KM, Lissner L. Associations between 
reproduction and maternal body weight: examining the component 
parts of a full reproductive cycle. Eur J Clin Nutr 2003;57:114–27.
 19. Murnane PM, Arpadi SM, Sinkala M, et al. Lactation-associated 
postpartum weight changes among HIV-infected women in Zambia. 
Int J Epidemiol 2010;39:1299–310.
 20. Ladner J, Castetbon K, Leroy V, et al. Pregnancy, body weight 
and human immunodeficiency virus infection in African women: 
a prospective cohort study in Kigali (Rwanda), 1992–1994. 
Pregnancy and HIV Study Group (EGE). Int J Epidemiol 
1998;27:1072–7.
 21. Hartmann PE, Sherriff JL, Mitoulas LR. Homeostatic mechanisms 
that regulate lactation during energetic stress. J Nutr 
1998;128:394S–9.
 22. Somé E, Engebretsen I, Nagot N, et al.  R_ BreastfeedingandBMI_ 
Main_ ENSOME_ WithoutTrackChange. pdf. PloS One 2017.
 23. Nagot N, Kankasa C, Meda N, et al. Lopinavir/ritonavir versus 
Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission 
by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174. 
BMC Infect Dis 2012;12:246.
 24. Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure 
prophylaxis with lopinavir-ritonavir versus lamivudine to prevent 
HIV-1 transmission through breastfeeding up to 50 weeks in infants 
in Africa (ANRS 12174): a randomised controlled trial. Lancet 
2016;387:566–73.
 25. ANRS. ANRS scale to grade the severity of adverse events in adults; 
version n° 1.0 4 November 2008. file:///C:/Users/install/Downloads/ 
ANRS- GradeEI- V1- En- 2008. pdf (accessed 14 Jan 2016).
 26. Becquet R, Bland R, Leroy V, et al. Duration, pattern of breastfeeding 
and postnatal transmission of HIV: pooled analysis of individual data 
from West and South African cohorts. PLoS One 2009;4:e7397.
 27. Somé EN, Engebretsen IMS, Nagot N, et al. Breastfeeding patterns 
and its determinants among mothers living with Human Immuno-
deficiency Virus-1 in four African countries participating in the ANRS 
12174 trial. Int Breastfeed J 2016;12.
 28. Crowell DT. Weight change in the postpartum period. A review of the 
literature. J Nurse Midwifery 1995;40:418–23.
 29. Maguire A, Sánchez E, Fortuny C, et al. Potential risk factors for 
vertical HIV-1 transmission in Catalonia, Spain: the protective role of 
group.bmj.com on April 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
14 Somé EN, et al. BMJ Open 2018;8:e019239. doi:10.1136/bmjopen-2017-019239
Open Access 
cesarean section. The Working Group on HIV-1 Vertical Transmission 
in Catalonia. AIDS 1997;11:1851–7.
 30. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV 
transmission: additive protective effect of elective Cesarean section 
and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS 
1998;12:205–10.
 31. Rogers IS, Golding J, Emmett PM. The effects of lactation on the 
mother. Early Hum Dev 1997;49:S191–S203.
 32. Coutsoudis A, Coovadia H, Pillay K, et al. Are HIV-infected women 
who breastfeed at increased risk of mortality? AIDS  
2001;15:653–5.
 33. Taha TE, Kumwenda NI, Hoover DR, et al. The impact of 
breastfeeding on the health of HIV-positive mothers and their 
children in sub-Saharan Africa. Bull World Health Organ  
2006;84:546–54.
 34. Breastfeeding and HIV International Transmission Study Group. 
Mortality among HIV-1-infected women according to children's 
feeding modality: an individual patient data meta-analysis. J Acquir 
Immune Defic Syndr 2005;39:9.
 35. Trumbo P, Schlicker S, Yates AA, et al. Dietary reference intakes for 
energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and 
amino acids. J Am Diet Assoc 2002;102:1621–30.
 36. Lovelady C. Balancing exercise and food intake with lactation to 
promote post-partum weight loss. Proc Nutr Soc 2011;70:181–4.
 37. Van de Perre P, Rubbo PA, Viljoen J, et al. HIV-1 reservoirs in breast 
milk and challenges to elimination of breast-feeding transmission of 
HIV-1. Sci Transl Med 2012;4:143sr3.
group.bmj.com on April 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
study
South Africa, Uganda and Zambia: a cohort
ANRS 12174 clinical trial in Burkina Faso, 
breastfeeding mothers participating in the
immune-competent HIV-1-infected and 
HIV-1 disease progression in
Perre and Thorkild Tylleskär
deMandisa Singata-Madliki, Kim Harper, G Justus Hofmeyr, Philippe Van 
Tumwine,Yelbomkan Meda, Roselyne Vallo, Chipepo Kankasa, James K 
Eric Nagaonle Somé, Ingunn M S Engebretsen, Nicolas Nagot, Nicolas
doi: 10.1136/bmjopen-2017-019239
2018 8: BMJ Open
 http://bmjopen.bmj.com/content/8/4/e019239




This article cites 30 articles, 1 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:




unication Division, UiB  /  Print: Skipnes Kom
m
unikasjon AS
uib.no
ISBN: 978-82-308-3521-0
